10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

  FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED September 30, 2020

or 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission file number: 001-35670

Regulus Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware	26-4738379
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
10628 Science Center Drive, Suite 225	92121
San Diego
CA
(Address of Principal Executive Offices)	(Zip Code)

858-202-6300

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	RGLS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ý

As of October 30, 2020, the registrant had 39,163,096 shares of Common Stock ($0.001 par value) outstanding.

REGULUS THERAPEUTICS INC.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements	3
Condensed Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019	3
Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019 (Unaudited)	4
Condensed Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2020 and 2019 (Unaudited)	5
Condensed Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (Unaudited)	7
Notes to Condensed Financial Statements (Unaudited)	8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3. Quantitative and Qualitative Disclosures about Market Risk	30
Item 4. Controls and Procedures	30
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	31
Item 1A. Risk Factors	31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	61
Item 3. Defaults Upon Senior Securities	61
Item 4. Mine Safety Disclosures	61
Item 5. Other Information	61
Item 6. Exhibits	62

PART I. FINANCIAL INFORMATION

ITEM 1.     FINANCIAL STATEMENTS

Regulus Therapeutics Inc.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share data)

	September 30, 2020		December 31, 2019
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	17,843	$	34,121
Contract and other receivables	4,000		1,141
Prepaid materials, net	3,388		3,924
Prepaid expenses and other current assets	1,076		1,221
Total current assets	26,307		40,407
Property and equipment, net	574		921
Intangibles, net	129		266
Other assets	333		487
Total assets	$	27,343	$	42,081
Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$	1,102	$	1,321
Accrued liabilities	1,089		917
Accrued compensation	1,260		1,676
Current portion of term loan, less debt issuance costs	13,647		14,631
Current portion of contract liabilities	—		6
Other current liabilities	2,381		3,047
Total current liabilities	19,479		21,598
Other long-term liabilities	110		468
Total liabilities	19,589		22,066
Stockholders’ equity:
Class A-1 convertible preferred stock, $0.001 par value; 256,700 and 415,898 shares authorized, issued, and outstanding at September 30, 2020 (unaudited) and December 31, 2019, respectively	—		1
Class A-2 convertible preferred stock, $0.001 par value; 1,639,515 and 3,288,390 shares authorized, issued, and outstanding at September 30, 2020 (unaudited) and December 31, 2019, respectively	2		3
Common stock, $0.001 par value; 200,000,000 shares authorized, 39,163,096 and 21,018,663 shares issued and outstanding at September 30, 2020 (unaudited) and December 31, 2019, respectively	39		21
Additional paid-in capital	433,436		431,305
Accumulated deficit	(425,723)		(411,315)
Total stockholders’ equity	7,754		20,015
Total liabilities and stockholders’ equity	$	27,343	$	42,081

See accompanying notes to these condensed financial statements.

3

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
	(Unaudited)
Revenues:
Revenue under collaborations	$	5,000	$	18	$	5,006	$	6,814
Total revenues	5,000		18		5,006		6,814
Operating expenses:
Research and development	4,036		2,440		11,396		10,259
General and administrative	2,059		2,571		6,736		8,954
Total operating expenses	6,095		5,011		18,132		19,213
Loss from operations	(1,095)		(4,993)		(13,126)		(12,399)
Other income (expense):
Interest and other income	38		87		127		332
Interest and other expense	(466)		(517)		(1,416)		(1,631)
Loss before income taxes	(1,523)		(5,423)		(14,415)		(13,698)
Income tax (expense) benefit	(1)		—		7		(1)
Net loss and comprehensive loss	$	(1,524)	$	(5,423)	$	(14,408)	$	(13,699)
Net loss per share, basic and diluted	$	(0.04)	$	(0.26)	$	(0.47)	$	(0.86)
Weighted average shares used to compute basic and diluted net loss per share	38,137,281		20,849,083		30,695,137		16,016,515

See accompanying notes to these condensed financial statements.

4

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

(In thousands, except share data)

	Convertible preferred stock			Common stock			Additional paid-in capital		Accumulated deficit		Total stockholders’ equity (deficit)
	Shares	Amount		Shares	Amount
Balance at December 31, 2019	3,704,288	$	4	21,018,663	$	21	$	431,305	$	(411,315)	$	20,015
Issuance of common stock upon vesting of restricted stock units	—	—		21,166	—		—		—		—
Issuance of common stock upon exercise of options	—	—		468	—		—		—		—
Issuance of common stock under Employee Stock Purchase Plan	—	—		1,666	—		1		—		1
Conversions of convertible preferred stock	(656,682)	(1)		6,566,820	7		(6)		—		—
Stock-based compensation expense	—	—		—	—		823		—		823
Net loss	—	—		—	—		—		(5,937)		(5,937)
Balance at March 31, 2020	3,047,606	$	3	27,608,783	$	28	$	432,123	$	(417,252)	$	14,902
Stock-based compensation expense	—	—		—	—		629		—		629
Issuance of common stock upon vesting of restricted stock units	—	—		17,703	—		—		—		—
Conversions of convertible preferred stock	(829,643)	(1)		8,296,430	8		(7)		—		—
Net loss	—	—		—	—		—		(6,947)		(6,947)
Balance at June 30, 2020	2,217,963	$	2	35,922,916	$	36	$	432,745	$	(424,199)	$	8,584
Stock-based compensation expense	—	—		—	—		692		—		692
Issuance of common stock upon vesting of restricted stock units	—	—		19,368	—		—		—		—
Issuance of common stock under Employee Stock Purchase Plan	—	—		3,332	—		2		—		2
Conversions of convertible preferred stock	(321,748)	—		3,217,480	3		(3)		—		—
Net loss	—	—		—	—		—		(1,524)		(1,524)
Balance at September 30, 2020	1,896,215	$	2	39,163,096	$	39	$	433,436	$	(425,723)	$	7,754

5

	Convertible preferred stock			Common stock			Additional paid-in capital		Accumulated deficit		Total stockholders’ equity (deficit)
	Shares	Amount		Shares	Amount
Balance at December 31, 2018	—	$	—	8,818,019	$	9	$	386,860	$	(392,723)	$	(5,854)
Issuance of common stock upon vesting of restricted stock units	—	—		93,648	—		—		—		—
Issuance of common stock through ATM	—	—		1,903,880	2		2,082		—		2,084
Stock-based compensation expense	—	—		—	—		959		—		959
Issuance of common stock under Employee Stock Purchase Plan	—	—		2,369	—		2		—		2
Net loss	—	—		—	—		—		(3,260)		(3,260)
Balance at March 31, 2019	—	$	—	10,817,916	$	11	$	389,903	$	(395,983)	$	(6,069)
Issuance of common stock upon exercise of stock options	—	—		2,500	—		2		—		2
Issuance of common stock, preferred stock and warrants from private placement, net of offering costs	415,898	—		9,730,534	10		15,495		—		15,505
Issuance of common stock upon vesting of restricted stock units	—	—		273,438	—		—		—		—
Stock-based compensation expense	—	—		—	—		321		—		321
Net loss	—	—		—	—		—		(5,016)		(5,016)
Balance at June 30, 2019	415,898	$	—	20,824,388	$	21	$	405,721	$	(400,999)	$	4,743
Issuance of common stock upon exercise of stock options	—	—		250	—		—		—		—
Issuance of common stock upon vesting of restricted stock units	—	—		100,749	—		—		—		—
Stock-based compensation expense	—	—		—	—		536		—		536
Issuance of common stock under Employee Stock Purchase Plan	—	—		1,666	—		1		—		1
Net loss	—	—		—	—		—		(5,423)		(5,423)
Balance at September 30, 2019	415,898	$	—	20,927,053	$	21	$	406,258	$	(406,422)	$	(143)

6

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

	Nine months ended September 30,
	2020		2019
	(Unaudited)
Operating activities
Net loss	$	(14,408)	$	(13,699)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	362		800
Stock-based compensation	2,144		1,816
Gain on reduction of lease liability	—		1,839
Other	148		262
Change in operating assets and liabilities:
Contracts and other receivables	(2,859)		(673)
Prepaid materials	536		368
Prepaid expenses and other assets	299		572
Accounts payable	(219)		(193)
Accrued liabilities	172		(473)
Accrued compensation	(416)		(676)
Contract liabilities	(6)		(2,554)
Other liabilities	(1,478)		(2,233)
Net cash used in operating activities	(15,725)		(14,844)
Investing activities
Purchases of property and equipment	—		(162)
Sales of property and equipment	—		318
Acquisition of intangibles	(11)		(23)
Net cash (used in) provided by investing activities	(11)		133
Financing activities
Proceeds from borrowing under Paycheck Protection Program	662		—
Proceeds from issuance of securities through private placement, net of issuance costs	—		15,505
Proceeds from issuance of common stock, net	3		2,087
Proceeds from exercise of common stock options	—		3
Principal payments on term loan	(1,000)		(1,977)
Payments on financing leases	(207)		(196)
Net cash (used in) provided by financing activities	(542)		15,422
Net (decrease) increase in cash and cash equivalents	(16,278)		711
Cash and cash equivalents at beginning of period	34,121		13,935
Cash and cash equivalents at end of period	$	17,843	$	14,646
Supplemental disclosure of cash flow information
Interest paid	$	(1,066)	$	(1,263)
Income taxes paid	$	(1)	$	(1)
Supplemental disclosure of non-cash investing and financing activities
Non-cash acquisition of property and equipment	$	—	$	61

See accompanying notes to these condensed financial statements.

7

Regulus Therapeutics Inc.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2019, from which the balance sheet information herein was derived.

Liquidity

The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements, totaling $455.1 million. As of September 30, 2020, we had approximately $17.8 million of cash and cash equivalents. Based on our operating plans, we believe our cash and cash equivalents may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amounts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2020 and December 31, 2019, due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified, by the Lender, of an event of default as of the date of the filing of this Form 10-Q.

We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. In addition, the COVID-19 pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could negatively affect our liquidity. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.

If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.

Use of Estimates

Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.

Revenue Recognition

8

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements.

We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Collaborative Arrangements

We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.

As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

License Fees

If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments

At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.

9

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.

Clinical Trial and Preclinical Study Accruals

We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.

Prepaid Materials

We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements, which clarifies the interaction between Topic 808, Collaborative Arrangements and Topic 606, including clarification around certain transactions between

10

collaborative arrangement participants and adding unit-of-account guidance to Topic 808. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The adoption of this guidance on January 1, 2020 had no impact on our financial statements.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on its financial statements and disclosures.

2. Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options outstanding under our stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.

Dilutive common stock equivalents were 25,813,032 for the three and nine months ended September 30, 2020, consisting of convertible preferred stock, stock options and restricted stock units, and 4,908,289 and 2,973,525 for the three and nine months ended September 30, 2019, respectively, consisting of convertible preferred stock, stock options and restricted stock units.

3. Investments

We have historically invested our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis. As of September 30, 2020 and December 31, 2019, our cash balance was comprised entirely of cash and cash equivalents and there was no unrealized gain or loss in either period.

4. Fair Value Measurements

We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:

•Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

11

•Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

•Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

Financial Assets Measured at Fair Value

The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands):

	Fair value as of September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	14,900	$	14,900	$	—	$	—
	$	14,900	$	14,900	$	—	$	—

	Fair value as of December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,909	$	8,909	$	—	$	—
	$	8,909	$	8,909	$	—	$	—

We obtain pricing information from quoted market prices or quotes from brokers/dealers. We have historically determined the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.

5. Debt

Term Loan

On June 17, 2016, we entered into a loan and security agreement ("Loan Agreement") with Oxford Finance, LLC, ("Oxford", or sometimes referred to as the “Lender”), pursuant to which we received $20.0 million in proceeds, net of debt issuance costs, on June 22, 2016 (the "Term Loan").

The outstanding Term Loan will mature on May 1, 2022 (the “Maturity Date”) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.

In August 2018, we and Oxford entered into an amendment to our Loan Agreement, providing for a modification of the loan amortization period. Under the terms of the amendment, principal amortization and repayment was deferred between August 2018 through October 2018, and during this period, we were required to make payments of interest-only. Amortization payments recommenced in November 2018. Pursuant to the amendment, we granted the Lender a security interest in our intellectual property as additional collateral for the repayment of the Term Loan.

In November 2018, and in connection with the 2018 Sanofi Amendment, we entered into a fourth amendment to the Loan Agreement with the Lender (the "Fourth Amendment"). Under the terms of the Fourth Amendment, the Lender consented to the 2018 Sanofi Amendment and our license, assignment and transfer to Sanofi of certain of our intellectual property, as required to be delivered to Sanofi under the 2018 Sanofi Amendment (the “Assigned Assets”), which previously served as collateral under the Loan Agreement, and released its liens in the Assigned Assets, provided that the Lender will continue to have liens on all proceeds received by us pursuant to our collaboration and license agreement with Sanofi dated February 4, 2014 (the “Sanofi License Agreement”). Under the terms of the Fourth Amendment, we have the option to prepay part of the Term Loan at any

12

time and in any amount after 10 days’ prior written notice. We are also required to prepay a portion of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. In accordance with this term, we prepaid $0.6 million pursuant to our receipt of $2.5 million in Upfront Amendment Payments in November 2018. Additionally, we prepaid $0.4 million pursuant to our receipt of $1.8 million in Upfront Amendment Payments in March 2019. We are required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment.

On January 31, 2019, we entered into a fifth amendment to the Loan Agreement with the Lender (the "Fifth Amendment"). Under the terms of the Fifth Amendment, our required monthly payment to the Lender for the month of February 2019 was comprised of interest only. On March 7, 2019, we entered into a sixth amendment to the Loan Agreement with the Lender (the "Sixth Amendment"). Under the terms of the Sixth Amendment, our required monthly payment to the Lender for the month of March 2019 was comprised of interest only.

On April 9, 2019 we entered into a seventh amendment to the Loan Agreement with the Lender (the "Seventh Amendment"). Under the terms of the Seventh Amendment, our required monthly payments to the Lender were to be comprised of interest only through and including the payment date immediately preceding the following date (the “Second Amortization Date”): (i) April 1, 2019, if we did not receive unrestricted gross cash proceeds of not less than $10 million on or before April 30, 2019 from (a) the issuance and sale of our unsecured subordinated convertible debt and/or equity securities and/or (b) “up front” or milestone payments in connection with a joint venture, collaboration or other partnering transaction other than pursuant to the Sanofi License Agreement (the receipt of such net proceeds, the “ Seventh Amendment Capital Event”), and (ii) May 1, 2019, if the Seventh Amendment Capital Event occurs. The Seventh Amendment Capital event did not occur on or before April 30, 2019.

Commencing on the Second Amortization Date, and continuing on each successive payment date thereafter, we were to be required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender; provided, however, that we were required to make the monthly principal payment due April 1, 2019 on May 1, 2019 (in addition to all other payments due on May 1, 2019) if the Seventh Amendment Capital Event did not occur. The Seventh Amendment also provided that we can irrevocably elect to increase the prepayment percentage for the funds that we are required to prepay under the Term Loan in the event we receive $10.0 million from the first development milestone under the 2018 Sanofi Amendment (the "Milestone Payment") from 25% to 75% (the “Applicable Sanofi Percentage”). Under the Seventh Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million if the Applicable Sanofi Percentage is 25% and if we had not prepaid an aggregate of $5 million under the Term Loan (which amount shall not include any Sanofi License Agreement prepayments) on or before April 30, 2019 (such prepayment, the “Principal Paydown Event”), (ii) $5.0 million if the Applicable Sanofi Percentage is 75% and the Principal Paydown Event had not occurred and (iii) zero if the Principal Paydown Event had occurred.

On May 3, 2019, concurrently with our Securities Purchase Agreement dated May 2019 (the "May 2019 SPA") (as described in further detail in Note 10), we entered into an eighth amendment to the Loan Agreement with the Lender (the "Eighth Amendment"). Pursuant to the terms of the Eighth Amendment and as a result of the completion of the initial closing under the May 2019 SPA, our required monthly payments to the Lender were comprised of interest only from May 2019 through and including the payment to be made in April 2020, in exchange for an interest-only period extension fee of $0.1 million. Additionally, under the Eighth Amendment, the Term Loan maturity date was extended from June 2020 to May 2022, in exchange for a maturity date extension fee of $0.7 million. Pursuant to the Eighth Amendment, as a result of our receipt of over $20.0 million in capital in December 2019 under the second and final closing under the May 2019 SPA, our required monthly payments to the Lender are comprised of interest only through and including the payment to be made in April 2021. Commencing in May 2021, and continuing on each successive payment date thereafter, we are required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender. The Eighth Amendment also provides for an increase in the prepayment percentage for the funds that we are required to prepay under the Term Loan, in the event that we receive the $10.0 million Milestone Payment, from 75% to 100% of the Milestone Payment. Upon payment of the Milestone Payment to the Lender, we will no longer be required to maintain cash in a collateral account controlled by Lender and the positive lien on our intellectual property will be released.

On May 1, 2020 we entered into a ninth amendment to the Term Loan with the Lender (the “Ninth Amendment”). Pursuant to the terms of the Ninth Amendment, (i) the approximately $0.7 million of loan proceeds (the "PPP Loan") we received under the Paycheck Protection Program ("PPP") was included as permitted indebtedness under the terms of the Term Loan, (ii) we agreed to apply for forgiveness of the maximum amount of PPP Loan permissible in accordance with the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and use best efforts to cause not less than $0.5 million of the PPP Loan to be forgiven by the PPP Loan lender on or before September 30, 2020 and (iii) we agreed not to amend any material provision in any document relating to the PPP Loan nor make any prepayment of the PPP Loan unless such

13

prepayment is necessary or advisable due to change in the applicable law or guidance issued by the U.S. Small Business Administration (“SBA”).

On August 25, 2020 we entered into a tenth amendment to the Term Loan with the Lender (the "Tenth Amendment"). Pursuant to the terms of the Tenth Amendment, we are eligible for up to an additional seven months of interest only payments in the event the we pay down $10 million in loan principal before April 30, 2021 (the "Principal Paydown Event"). In the event the Principal Paydown Event does not occur by April 30, 2021, we will make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the terms of the Eighth Amendment. If the Principal Paydown Event occurs after April 30, 2021 but on or before July 31, 2021, we will recommence an extended interest only payment period through December 31, 2021. In the event we receive the additional interest only period, principal and accrued interest payments will recommence on January 1, 2022.

On September 30, 2020, upon our receipt of $1.0 million in proceeds from Sanofi (see Note 7) and under the terms of the Tenth Amendment, we prepaid $1.0 million of outstanding principal to the Lender. We also paid the applicable 5.5% final payment fee related to the $1.0 million prepayment to the Lender. On October 8, 2020, upon receipt of $4.0 million in proceeds from Sanofi (see note 7) and under the terms of the Tenth Amendment, we prepaid $4.0 million of outstanding principal to the Lender. We also paid the applicable 5.5% final payment fee related to the $4.0 million prepayment to the Lender.

We used the proceeds from the Term Loan solely for working capital and to fund our general business requirements. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property, for which Oxford currently has a positive lien, and certain assets under finance lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. As of September 30, 2020 we were in compliance with all covenants under the Loan Agreement.      

As of September 30, 2020, $13.7 million was outstanding under the Term Loan, with an additional $1.8 million payable at the conclusion of the Term Loan. We had less than $0.1 million of debt issuance costs outstanding as of September 30, 2020, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fees are being accrued over the life of the Term Loan through interest expense.

As of September 30, 2020, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):

2020	$	—
2021	8,419
2022	5,262
	$	13,681

Paycheck Protection Program Loan

On April 23, 2020, we received the proceeds from the PPP Loan in the amount of approximately $0.7 million from Silicon Valley Bank, as lender, pursuant to the PPP of the CARES Act. The PPP Loan matures on April 23, 2022 and bears interest at a rate of 1.0% per annum. The PPP Loan is evidenced by a promissory note dated April 23, 2020, which contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan may be prepaid by us at any time prior to maturity with no prepayment penalties.

All or a portion of the PPP Loan may be forgiven by the SBA upon our application and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement. For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, annualized, prorated for the covered period. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and includes accrued interest.

14

We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and are seeking forgiveness in accordance with the program.

6. Stockholders’ Equity

2019 Equity Incentive Plan

On June 15, 2019 our board of directors approved, and on August 1, 2019 our stockholders approved, our 2019 Equity Incentive Plan (the "2019 Plan"). The 2019 Plan is intended as the successor to and continuation of our 2012 Equity Incentive Plan. The number of shares authorized for issuance under the 2019 Plan may be increased by (a) the shares subject to outstanding stock awards granted under our 2009 Equity Incentive Plan (the “2009 Plan”) and our 2012 Equity Incentive Plan (together the with 2009 Plan, the “Prior Plans”) that on or after the effective date of the 2019 Plan (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to us, or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. No further grants will be made under the Prior Plans. In addition, on January 22, 2020, an additional 4,166,860 shares of common stock became available for issuance under the 2019 Plan pursuant to the second and final closing under the May 2019 SPA. Further, on January 1st of each year, for a period of not more than ten years, beginning on January 1, 2021 and continuing through January 1, 2029, the number of shares authorized for issuance under the 2019 Plan will increase by 5.0% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by our Board of Directors.

As of September 30, 2020, 888,432 shares of common stock were available for new equity award grants under the 2019 Plan and 6,850,882 shares of common stock are reserved for issuance pursuant to equity awards outstanding as of September 30, 2020.

Private Placement of Common Stock, Non-Voting Convertible Preferred Stock and Warrants

On May 3, 2019, we entered into the May 2019 SPA with certain institutional and other accredited investors, including certain of our directors, executive officers and employees (the “Purchasers”), pursuant to which we agreed to sell and issue shares of our common stock, shares of our newly designated non-voting convertible preferred stock, and warrants to purchase common stock, in up to two closings, in a private placement transaction (the “Private Placement”).

At an initial closing under the May 2019 SPA that occurred on May 7, 2019 (the “Initial Closing”), we sold and issued to the Purchasers (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the Initial Closing were approximately $16.7 million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 526,083 shares of common stock and warrants to purchase up to 526,083 shares of common stock were purchased for $0.6 million by certain of our directors and executive officers under the Initial Closing.

Pursuant to the May 2019 SPA, in the event our Board of Directors unanimously resolved to recommence our Phase 1 multiple ascending dose clinical trial of our RGLS4326 product candidate for the treatment of ADPKD (the “Phase 1 Trial”) based on correspondence from the U.S. Food and Drug Administration’s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019, we made a public announcement of our plan to recommence the Phase 1 Trial (the “Public Announcement”), we were able to sell and the Purchasers were able to purchase, at a second closing under the May 2019 SPA (“Milestone Closing”), shares of our non-voting convertible preferred stock and accompanying warrants to purchase shares of Common Stock. On December 15, 2019, our Board of Directors unanimously resolved to recommence the Phase 1 Trial based on correspondence from the U.S. Food & Drug Administration’s Division of Cardiovascular and Renal Products and on December 16, 2019, we made the related Public Announcement, triggering the Milestone Closing, which occurred on December 24, 2019. At the Milestone Closing, we sold and issued to the Purchasers 3,288,390 shares of non-voting Class A-2 convertible preferred stock and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock for an aggregate purchase price of approximately $26.0 million. Net proceeds to us from the Milestone Closing

15

were approximately $24.6 million. Each share of non-voting Class A-2 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants will be exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise “cashless” basis. An aggregate of 121,581 shares of Class A-2 convertible preferred stock and warrants to purchase up to 1,215,810 shares of common stock were purchased for approximately $1.0 million by certain of our directors and executive officers under the Milestone Closing.

We evaluated the non-voting Class A-1 convertible preferred stock and common stock warrants sold in the Initial Closing and the Class A-2 convertible preferred stock and common stock warrants sold in the Milestone Closing under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments. The Initial Closing and Milestone Closing did not include any embedded features that required bifurcation. The non-voting Class A-2 convertible preferred stock and warrants issuable under the Milestone Closing were not subject to accounting recognition until the Milestone Closing occurred, as the terms of the Milestone Closing did not provide a right or an obligation on either us nor the Purchasers.

A total of 321,748 and 1,648,875 shares of Class A-2 convertible preferred stock were converted into 3,217,480 and 16,488,750 shares of common stock, respectively, during the three and nine months ended September 30, 2020. A total of 159,198 shares of Class A-1 convertible preferred stock were converted into 1,591,980 shares of common stock during the nine months ended September 30, 2020. No shares of Class A-1 convertible preferred stock were converted into common stock during the three months ended September 30, 2020. No warrants were exercised during the three months and nine months ended September 30, 2020 or 2019.

ATM Offering

On December 12, 2018, we entered into a Common Stock Sales Agreement (the “Stock Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”), pursuant to which we may sell and issue shares of our common stock from time to time through HCW, as our sales agent (the “ATM Offering”). We have no obligation to sell any shares of common stock in the ATM Offering, and may at any time suspend offers under the Stock Sales Agreement or terminate the Stock Sales Agreement. Subject to the terms and conditions of the Stock Sales Agreement, HCW will use its commercially reasonable efforts to sell shares of our common stock from time to time based upon our instructions (including any price, time or size limits or other parameters or conditions the we may impose). We will pay HCW a commission of 3.0% of the gross sales price of any shares sold under the Stock Sales Agreement. No shares were sold under the Stock Sales Agreement during the three and nine months ended September 30, 2020. No shares were sold under the Stock Sales Agreement during the three months ended September 30, 2019. A total of 1,903,880 shares were sold for proceeds of $2.1 million (net of approximately $0.1 million in commissions) under the Stock Sales Agreement during the nine months ended September 30, 2019.

16

Shares Reserved for Future Issuance

The following shares of common stock were reserved for future issuance as of September 30, 2020 (in thousands):

Class A-1 convertible preferred stock outstanding (as-converted)	2,567
Class A-2 convertible preferred stock outstanding (as-converted)	16,395
Initial Closing warrants	13,890
Milestone Closing warrants	32,884
Common stock options outstanding	6,800
RSUs outstanding	51
Common stock available for future grant under 2019 Equity Incentive Plan	888
Employee Stock Purchase Plan	188
Total common shares reserved for future issuance	73,663

The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2020 (shares in thousands): 

	Number of options	Weighted average exercise price		Number of RSUs	Weighted average grant date fair value
Stock Awards outstanding at December 31, 2019	3,098	$	1.17	129	$	1.50
Granted	3,861	$	1.20	—	$	—
Exercised (options) or Vested (RSUs)	(1)	$	0.95	(59)	$	1.50
Canceled/forfeited/expired	(158)	$	4.82	(19)	$	1.50
Stock Awards outstanding at September 30, 2020	6,800	$	1.10	51	$	1.50

Stock-Based Compensation

The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan and 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Stock options
Risk-free interest rate	0.4	%	1.5	%	1.1	%	2.1	%
Volatility	95.3	%	95.1	%	95.4	%	94.4	%
Dividend yield	—		—		—		—
Expected term (years)	6.1		6.1		6.1		6.1
Performance stock options
Risk-free interest rate	—		—		1.4	%	2.6	%
Volatility	—		—		95.4	%	93.8	%
Dividend yield	—		—		—		—
Expected term (years)	0		0		6.1		6.1
Employee stock purchase plan shares
Risk-free interest rate	0.3	%	2.3	%	0.7	%	2.4	%
Volatility	94.9	%	106.7	%	98.2	%	110.1	%
Dividend yield	—		—		—		—
Expected term (years)	0.5		0.5		0.5		0.5

17

The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands): 

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Research and development	$	255	$	45	$	571	$	240
General and administrative	437		491		1,573		1,576
Total	$	692	$	536	$	2,144	$	1,816

7. Collaborations

Revenue recognized from our strategic collaborations was $5.0 million for the three and nine months ended September 30, 2020, compared to less than $0.1 million and $6.8 million for the three and nine months ended September 30, 2019, respectively.

Sanofi

In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic collaboration agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic collaboration with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology collaboration.

In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment was deferred as of December 31, 2017 and recorded as an adjustment to accumulated deficit upon our adoption of Topic 606 on January 1, 2018. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January 2014.

In February 2014, we and Sanofi entered into the 2014 Sanofi Amendment to renew our strategic collaboration to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of the 2014 Sanofi Amendment, Sanofi had opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (“HCC”). We were responsible for developing each of these programs to proof-of-concept, at which time Sanofi had an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi would reimburse us for a significant portion of our preclinical and clinical development costs and would also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. We are eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products relating to our preclinical program targeting miR-221/222. As indicated below, we entered into an additional amendment with Sanofi in November 2018, under which Sanofi's opt-in rights to our miR-21 programs under the 2014 Sanofi Amendment were relinquished. Sanofi's opt-in rights with regard to our miR-221/222 preclinical program under the 2014 Sanofi Amendment remained unchanged.

In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the “Sanofi Purchase Agreement”), pursuant to which we sold 1,303,780 shares of our common stock to Aventisub LLC (“Aventis”), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. Under the terms of the Sanofi Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Sanofi Purchase Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for

18

lack of marketability, approximately $0.4 million of the proceeds from the Sanofi Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. We recognized the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program, though January 2020.

We are eligible to receive milestone payments related to the development and commercialization of miR-221/222 for HCC of up to $38.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $34.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-221/222 program which, in the case of sales in the United States, will be in the middle of the 10% to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10% to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a miR-221/222 product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi’s profits from sales of such product in the United States in lieu of royalties.

In November 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program (the “2018 Sanofi Amendment”). Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements, product-specific patents and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment. Under the terms of the 2018 Sanofi Amendment, we were eligible to receive approximately $6.8 million in upfront payments for the license and for miR-21 program-related materials (collectively, the “Upfront Amendment Payments”). We were also eligible to receive up to $40.0 million in development milestone payments, including a $10.0 million payment for an interim enrollment milestone (the "Enrollment Milestone"). In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. We and Sanofi also agreed to a general release of claims against each other for any claims that arose at any time prior to the date of the 2018 Sanofi Amendment, or that thereafter could arise based on anything that occurred prior to the date of the 2018 Sanofi Amendment. We received $2.5 million and $1.8 million in Upfront Amendment Payments under the 2018 Sanofi Amendment in November 2018 and March 2019, respectively. As the performance obligations associated with these Upfront Amendment Payments had been satisfied under Topic 606 as of March 31, 2019, both amounts were recognized as revenue in the first quarter of 2019. Additionally, we recognized an additional $2.5 million as revenue in the first quarter of 2019 for the final Upfront Amendment Payment allowable under the 2018 Sanofi Amendment, as the performance obligations associated with the final Upfront Amendment Payment were also satisfied under Topic 606 as of March 31, 2019. We received the final $2.5 million Upfront Amendment Payment in April 2019.

In August 2020, we entered into an amendment to the 2018 Sanofi Amendment (the "2020 Sanofi Amendment"). Under the terms of the 2020 Sanofi Amendment, we agreed to transfer to Sanofi additional RG-012 development program materials (the “Materials”) in exchange for a payment from Sanofi of $1.0 million (the “Transfer Payment”). In addition, in lieu of the $10.0 million Enrollment Milestone under the 2018 Sanofi Amendment, Sanofi agreed to pay us a $4.0 million milestone upon the completion of the transfer and verification of the Materials, and $5.0 million upon achievement of the Enrollment Milestone. Additionally, we are eligible to receive $25.0 million upon achievement of an additional development milestone related to Sanofi's development of the miR-21 compounds. In September 2020, we received $1.0 million in exchange for the transfer of the Materials to Sanofi, and received an additional $4.0 million in October 2020 as a result of Sanofi's completion and verification of the Materials in September 2020. As the performance obligations associated with both of these payments had been satisfied under Topic 606 as of September 30, 2020, both amounts were recognized as revenue in the third quarter of 2020. As the $4.0 million payment was received in October 2020, it was recorded in accounts receivable on our balance sheet at September 30, 2020.

As of September 30, 2020, the $30.0 million in development milestone payments (variable consideration) are fully constrained and therefore, do not meet the criteria for revenue recognition.

8. Leases

19

At the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.

In July 2015, we entered into an operating lease agreement (the "Prior Lease") for approximately 59,248 square feet of office and laboratory facility space located at 10614 Science Center Drive, San Diego, California 92121. The lease term was 96 months from the lease commencement date, and we moved our headquarters into this facility in May 2016. In conjunction with the lease, we received $1.4 million of lease incentives and $8.2 million of tenant improvement allowance, which was to be used for non-structural leasehold improvements. The lease incentives and tenant improvement allowance were included within deferred rent. Our deferred rent balance as of December 31, 2018 was $8.0 million. The Prior Lease agreement was with ARE SD Region No. 44 LLC (“Landlord”).

On February 19, 2019, we entered into an agreement, the (“Space Swap Agreement"), with Nitto Biopharma, Inc. ("Nitto"), pursuant to which we agreed, contingent upon the execution of a new lease agreement (the "February Lease") for Nitto's space with Landlord and the termination of the Prior Lease, to, among other things, (i) swap buildings with Nitto, and (ii) sell, convey and transfer all right, title and interest in certain furniture, fixtures and equipment to Nitto, as set forth in the Space Swap Agreement. Under the Space Swap Agreement, we paid Nitto (a) a relocation assistance payment in the amount of $0.1 million; (b) $0.2 million representing the difference between the security deposits under the Prior Lease and Nitto’s prior lease, and (c) $1.3 million as reimbursement for the six monthly installments of base monthly rent due pursuant to the new lease between Nitto and Landlord, subject to certain adjustments, which reimbursements are to be paid as rent comes due for Nitto under its new lease.

On February 25, 2019, we and Landlord entered into a second amendment (the “Prior Lease Amendment”) to the Prior Lease. Under the terms of the Prior Lease Amendment, the expiration date of the Prior Lease was accelerated from April 30, 2024 to March 31, 2019 and the Prior Lease terminated on April 1, 2019. The Prior Lease Amendment eliminated all further cash payments due under the Prior Lease, including aggregate base rent over its remaining term of approximately $14.4 million.

On February 25, 2019, we entered into an operating lease agreement with Landlord (the "February Lease"), for the lease of approximately 24,562 square feet of rentable area of the building located at 10628 Science Center Drive, San Diego, California, 92121 (the "Premises"), which Premises were previously occupied by Nitto. The commencement date of the February Lease was April 1, 2019 (the “Commencement Date”). The Premises served as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the February Lease (“Initial Term”) was 51 months, ending June 30, 2023. The aggregate base rent due over the Initial Term was approximately $4.8 million. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses, the annual tax expenses and the annual utilities costs related to the February Lease.

The execution of the February Lease and Prior Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. The leasehold improvements under the Prior Lease were accounted for as non-cash consideration of $5.6 million paid by us upon termination of the Prior Lease to the Landlord. We accounted for a $1.3 million portion of the reduction in the lease liability for the Prior Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.9 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the Lease. The $1.6 million obligation to reimburse Nitto for six monthly installments of base rent of the Prior Lease and certain other costs were accounted for as cost of terminating the Prior Lease in the unaudited condensed statement of operations. The net impact of the modification was a $0.4 million charge in the unaudited condensed statement of operations. Our payment obligations to Nitto under the Space Swap Agreement were fully satisfied as of September 30, 2019 and no assets

20

or liabilities remained with respect to the Prior Lease as of March 31, 2020. The commencement date of the February Lease did not occur until April 1, 2019 and therefore, as of March 31, 2019, the lease liability for the February Lease was zero. On April 1, 2019, we recorded a $3.8 million lease liability for the February Lease, which was calculated as the present value of future lease payments to be made under the February Lease. A $2.9 million ROU asset was also recorded on April 1, 2019, which represents the difference between the lease liability and the $0.9 million deferred credit for the reduction of the lease liability under the Prior Lease.

On June 19, 2019, we entered into a lease agreement (the “New Lease”) with Landlord for the lease of approximately 8,727 square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the “New Premises”). The commencement date of the New Lease was July 1, 2019 (the “New Commencement Date”). We are using the New Premises as our new principal executive offices and as a laboratory for research and development and other related uses. The term of the New Lease (the “New Initial Term”) is two years, six months, ending December 31, 2021. The base rent payments due for the New Premises are $0.4 million in 2020 and $0.4 million in 2021, net of certain rent abatement terms. We will also be responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.

On June 19, 2019, we entered into a first amendment to the February Lease with Landlord (the “February Lease Amendment”). Under the terms of the February Lease Amendment, the expiration date of the February Lease was accelerated from June 30, 2023 to June 30, 2019 and the February Lease terminated upon the Commencement Date of the New Lease. The February Lease Amendment eliminated all further rents due under the February Lease, including aggregate base rent over its remaining term of approximately $4.8 million.

The execution of the New Lease and February Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $0.5 million portion of the reduction in the lease liability for the February Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.2 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the New Lease. No other assets or liabilities remained with respect to the February Lease as of June 30, 2019. The commencement date of the New Lease did not occur until July 1, 2019 and therefore, as of June 30, 2019, the lease liability for the New Lease was zero. On July 1, 2019, we recorded a $0.8 million lease liability for the New Lease, which was calculated as the present value of future lease payments to be made under the New Lease. A $0.6 million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $0.2 million deferred credit for the reduction of the lease liability under the February Lease.

Our future lease payments under operating and finance leases at September 30, 2020 are as follows (in thousands):

	Operating Leases		Finance Leases
Remaining 2020	$	109	$	72
2021	442		57
Total lease payments	$	551	$	129
Less: amount representing interest	(38)		(2)
Present value of obligations under leases	513		127
Less: current portion	(403)		(127)
Long-term lease obligations	$	110	$	—

9. Subsequent Events

On October 29, 2020, we were informed by Sanofi that the remaining $5.0 million payment associated with the Enrollment Milestone under our Collaboration and License Agreement with Sanofi for its development of miR-21 programs was triggered upon achievement of an enrollment metric by Sanofi in its Phase 2 clinical study evaluating RG-012 for the treatment of patients with Alport Syndrome. The proceeds from this milestone payment will be used to pay down principal outstanding under our Term Loan. The payment to the Lender will reduce the remaining principal due under the Term Loan to approximately $4.7 million and enable the Company to receive an extension of interest-only payments through 2021, which represents an extension of seven months from the previous terms.

21

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The interim unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2019 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2019, or Annual Report, filed with the Securities and Exchange Commission on March 12, 2020. Past operating results are not necessarily indicative of results that may occur in future periods.

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, “Risk Factors” in this quarterly report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:

•the initiation, cost, timing, progress and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to our research and development activities, preclinical studies and clinical trials;

•our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;

•our ability to obtain funding for our operations;

•our plans to research, develop and commercialize our product candidates;

•the potential election of any strategic collaboration partner to pursue development and commercialization of any programs or product candidates that are subject to a collaboration with such partner;

•our ability to attract collaborators with relevant development, regulatory and commercialization expertise;

•future activities to be undertaken by our strategic collaboration partners, collaborators and other third parties;

•our ability to obtain and maintain intellectual property protection for our product candidates;

•the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

•our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to our product candidates;

•the rate and degree of market acceptance of our product candidates;

•our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;

•regulatory developments in the United States and foreign countries;

•the performance of our third-party suppliers and manufacturers;

•the success of competing therapies that are or may become available;

•the loss of key scientific or management personnel;

•our ability to successfully secure and deploy capital;

•our ability to satisfy our debt obligations;

•the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing;

•the potential impact of the COVID-19 pandemic on our business; and

•the risks and other forward-looking statements described under the caption “Risk Factors” under Part II, Item 1A of this quarterly report on Form 10-Q.

22

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

OVERVIEW

We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. We were formed in 2007 when Alnylam Pharmaceuticals, Inc. ("Alnylam") and Ionis Pharmaceuticals, Inc. ("Ionis") contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. Our most advanced product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease with no approved therapy available. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program. As a result, Sanofi became responsible for all costs incurred in the development of RG-012 and any other miR-21 programs. The transition activities were completed in the second quarter of 2019. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease ("ADPKD"). In addition to these clinical programs, we continue to develop a pipeline of preclinical drug product candidates.

microRNAs are naturally occurring ribonucleic acid ("RNA") molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of microRNAs is directly linked to many diseases. Furthermore, many different infectious pathogens interact and bind to host microRNA to survive. To date, over 500 microRNAs have been identified in humans, each of which can bind to multiple messenger RNAs that control key aspects of cell biology. Since many diseases are multi-factorial, involving multiple targets and pathways, the ability to modulate multiple pathways by targeting a single microRNA provides a new therapeutic approach for treating complex diseases.

RNA plays an essential role in the process used by cells to encode and translate genetic information from deoxyribonucleic acid, or DNA, to proteins. RNA is comprised of subunits called nucleotides and is synthesized from a DNA template by a process known as transcription. Transcription generates different types of RNA, including messenger RNAs that carry the information for proteins in the sequence of their nucleotides. In contrast, microRNAs are RNAs that do not code for proteins but rather are responsible for regulating gene expression by modulating the translation and decay of target messenger RNAs. By interacting with many messenger RNAs, a single microRNA can regulate the expression of multiple genes involved in the normal function of a biological pathway. Many pathogens, including viruses, bacteria and parasites, also use host microRNAs to regulate the cellular environment for survival. In some instances, the host microRNAs are essential for the replication and/or survival of the pathogen. For example, miR-122 is a microRNA expressed in human hepatocytes and is a key factor for the replication of the hepatitis C virus ("HCV").

We believe that microRNA therapeutics have the potential to become a new and major class of drugs with broad therapeutic application for the following reasons:

•microRNAs play a critical role in regulating biological pathways by controlling the translation of many target genes;

•microRNA therapeutics regulate disease pathways which may result in more effective treatment of complex multi-factorial diseases;

•many human pathogens, including viruses, bacteria and parasites, use microRNAs (host and pathogen encoded) to enable their replication and suppression of host immune responses; and

•microRNA therapeutics may be synergistic with other therapies because of their different mechanism of action.

We have assembled significant expertise in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, relationships with key opinion leaders and a disciplined drug discovery and development process. We are using our microRNA expertise to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs to modulate microRNAs and address underlying disease. We believe microRNAs may play a critical role in complex disease and that targeting them with anti-miRs may become a source of a new and major class of drugs with broad therapeutic application, much like small molecules, biologics and monoclonal antibodies.

23

We believe that microRNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse. We believe these microRNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate.

Since our inception through September 30, 2020, we have received $342.5 million from the sale of our equity and convertible debt securities, $92.8 million from our strategic collaborations, principally from upfront payments, research funding and preclinical and clinical milestones, and $19.8 million in net proceeds from our Term Loan. As of September 30, 2020, we had cash and cash equivalents of $17.8 million.

Development Stage Pipeline

We currently have two programs in clinical development.

RG-012: In May 2017, we completed a Phase 1 multiple-ascending dose ("MAD") clinical trial in 24 healthy volunteers (six-week repeat dosing) to determine safety, tolerability and pharmacokinetics ("PK") of RG-012 prior to chronic dosing in patients. In Phase 1 clinical trials to date, RG-012 was well-tolerated, and there were no serious adverse events ("SAEs") reported. In the third quarter of 2017, we initiated HERA, a Phase 2 randomized (1:1), double-blinded, placebo-controlled clinical trial evaluating the safety and efficacy of RG-012 in 40 Alport syndrome patients. In parallel, a renal biopsy study was also initiated in the third quarter of 2017 to evaluate RG-012 renal tissue PK, target engagement and downstream effects on genomic disease biomarkers. Kidney tissue concentrations were achieved in biopsy patients that would be predictive of therapeutic benefit based on animal disease models. In addition, modulation of the target, miR-21, was observed. In December 2017, we concluded our global ATHENA natural history of disease study. RG-012 has received orphan designation in both the United States and Europe. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program to Sanofi. As a result, Sanofi became responsible for all costs incurred in the development of these miR-21 programs. The transition activities, including the transfer of the investigational new drug application ("IND"), were completed in the second quarter of 2019. While Sanofi is currently enrolling patients into a Phase 2 clinical trial, with sites in the United States, France, United Kingdom, Australia and China, we believe new site initiation and patient enrollment has been, and will continue to be, impacted by the COVID-19 pandemic.

RGLS4326: RGLS4326 is a novel oligonucleotide designed to inhibit miR-17 using a unique chemistry designed to preferentially deliver to the kidney. Preclinical studies with RGLS4326 have demonstrated a reduction in kidney cyst formation, improved kidney weight/body weight ratio, decreased cyst cell proliferation and preserved kidney function in mouse models of ADPKD. In March 2018, we completed dose escalation of a Phase 1 single ascending dose ("SAD") clinical trial in healthy volunteers and found RGLS4326 was well tolerated and no SAEs were reported. In April 2018, we initiated a Phase 1 randomized, double-blind, placebo-controlled, MAD clinical trial in healthy volunteers designed to characterize the safety, tolerability, PK and pharmacodynamics of multiple doses of RGLS4326. In July 2018, we voluntarily paused this study due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase 2 proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. The observations in the mouse chronic toxicity study were unexpected, given the favorable safety profile of RGLS4326 in previous 7-week non-GLP and GLP toxicity studies in mouse and non-human primates required for Phase 1 testing, which had no significant findings across similar dose levels and frequencies. In September 2018, we initiated a new mouse chronic toxicity study with several changes believed to address the unexpected findings in the earlier terminated chronic mouse toxicity study.

In January 2019, we submitted a comprehensive data package for RGLS4326 to the U.S. Food and Drug Administration ("FDA") that included the results from the planned 13-week interim analysis of the ongoing repeat mouse chronic toxicity study, as well as results from additional investigations, analytical testing, additional data from the previously terminated mouse chronic toxicity study, data from the completed Phase 1 SAD study and data from the first cohort of the Phase 1 MAD study to support our plan to resume the Phase 1 MAD study. In July 2019, FDA notified us of additional nonclinical data requirements and placed the IND on a partial clinical hold, formalizing the specific requirements to re-initiate the MAD study and further proceed into studies of extended duration. The additional data requirements were outlined in two parts. In order to resume the MAD study, FDA requested the final reports from the chronic toxicity studies in both mice and non-human primates and satisfactory related analyses to ensure subjects can be safely dosed. In November 2019, we submitted a complete response to the partial clinical hold in order to be able to resume the MAD study and in December 2019, FDA lifted the partial clinical hold on the MAD study. We recommenced the MAD study in February 2020 and have completed all dosing. Top-line results showed that RGLS4326 is well-tolerated with no serious adverse events reported. Preliminary results suggest plasma exposure is dose proportional.

In October 2020, we commenced dosing in a Phase 1b short-term dosing study in patients with ADPKD. The study is an open-label study evaluating RGLS4326 for safety, PK, and changes in levels of polycystin 1 (PC1) and polycystin 2 (PC2).

24

Patients with ADPKD, due to the mutation in the polycystic kidney disease gene, have been reported to have low levels of PC1 and PC2, the proteins encoded by the PKD1 and PKD2 genes, respectively. This study is designed to evaluate whether different dose levels of RGLS4326 can increase levels of PC1 and PC2, in ADPKD patients. The first cohort is expected to enroll up to nine patients who will receive RGLS4326 every two weeks over a six week period. We anticipate availability of results from the first cohort by the end of the first quarter of 2021. Additional non-clinical studies initiated last year in mice and non-human primates to further characterize the PK properties of RGLS4326 have also been recently completed. The RGLS4326 IND is currently on a partial clinical hold for treatment of extended duration beyond the current Phase 1b study until the second set of requirements outlined by FDA have been satisfactorily addressed. Information from the Phase 1 clinical studies, together with information from the recently completed additional nonclinical studies, will be used to address the second set of requirements to support studies of extended duration. In July 2020, the FDA granted orphan drug designation to RGLS4326.

Preclinical Pipeline

A major focus of our preclinical research has historically targeted dysregulated microRNAs implicated in diseases of high unmet medical need where we know we can effectively deliver to the target tissue or organ, such as the liver and kidney. We also have early discovery programs investigating additional microRNA targets for infectious diseases, immunology and indications for which there is microRNA dysregulation or in disease settings where the host microRNAs are essential for the replication and/or survival of the pathogen.

We currently have multiple programs in various stages of preclinical development.

Glioblastoma multiforme program: In January 2019, we announced RGLS5579 as a clinical candidate in our glioblastoma multiforme (“GBM”) program. RGLS5579, which targets microRNA-10b, demonstrated statistically significant improvements in survival as both a monotherapy as well as in combination with temozolamide ("TMZ") in an orthotopic GBM animal model. In combination with TMZ, the addition of a single dose of anti-mir-10b, delivered intracranially, led to a more than two-fold improvement in survival compared to TMZ alone. These, and additional survival data on RGLS5579, were presented in November 2018 at the Society for Neuro-Oncology Meeting in New Orleans, Louisiana. We plan to seek a partner to further advance development of RGLS5579.

Hepatitis B virus program: We have determined that advancing our preclinical programs targeting the Hepatitis B virus ("HBV") represents an attractive opportunity in our pipeline for investment, affecting an estimated 250 million people worldwide. We have identified several microRNA targets that serve as host factors for the virus. Our lead compound directed to one of the host microRNAs has demonstrated sub-nanomolar potency against HBV DNA replication and more than 95% reduction in Hepatitis B surface antigen in in vitro studies. Additionally, we have demonstrated reduction of both HBV DNA and surface antigen in an in vivo efficacy model. We believe that targeting a host factor in the liver represents a unique mechanism of action for treatment of the virus compared to other programs in development and holds the potential for achieving a functional cure. We have nominated a development candidate and plan to commence IND-enabling activities.

Non-Alcoholic Steatohepatitis program: Across multiple animal models of non-alcoholic steatohepatitis ("NASH"), our lead candidate has demonstrated improvement in key endpoints, including NAFLD Activity Score (NAS), liver transaminases, hyperglycemia, and disease-related gene expression. In the diet-induced NASH mouse model (Amylin model) after two to four weekly doses, early onset of improvement across multiple disease parameters including liver triglycerides and blood levels of transaminases was observed.  After nine weeks of treatment, there was evidence of sustained benefit with significant improvement of liver fibrosis and hyperglycemia compared to control-treated animals. We believe that targeting dysregulated microRNA in a complex disease like NASH may offer a unique mechanism of action from other programs in development. We are seeking a partner to further advance its development.

FINANCIAL OPERATIONS OVERVIEW

Revenue

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under collaboration agreements.

In the future, we may generate revenue from a combination of license fees and other upfront payments, payments for research and development services, milestone payments, product sales and royalties in connection with strategic collaborations. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized by us or our strategic

25

collaboration partners. If our current or future collaboration partners do not elect or otherwise agree to fund our development costs pursuant to our current or future strategic collaboration agreements, or we or our strategic collaboration partner fails to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected.

Research and development expenses

Research and development expenses consist of costs associated with our research activities, including our drug discovery efforts and the development of our therapeutic programs. Our research and development expenses include:

•employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;

•external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, other clinical trial related vendors, consultants and our scientific advisors;

•license fees; and

•facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, amortization of leasehold improvements and equipment, and laboratory and other supplies.

We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Certain of the raw materials used in the process of manufacturing drug product are capitalized upon their acquisition and expensed upon usage, as we have determined these materials have alternative future use.

To date, we have conducted research on many different microRNAs with the goal of understanding how they function and identifying those that might be targets for therapeutic modulation. At any given time we are working on multiple targets, primarily within our therapeutic areas of focus. Our organization is structured to allow the rapid deployment and shifting of resources to focus on the most promising targets based on our ongoing research. As a result, in the early phase of our development programs, our research and development costs are not tied to any specific target. However, we are currently spending the vast majority of our research and development resources on our lead development programs.

Since our inception, we have spent a total of approximately $369.4 million in research and development expenses through September 30, 2020.

The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic collaboration partners, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.

Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new collaborations with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, as well as ongoing assessments as to each future product candidate’s commercial potential. We will need to raise additional capital and may seek additional collaborations in the future in order to advance our various programs.

General and administrative expenses

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses and professional fees for auditing, tax and legal services, some of which are incurred as a result of being a publicly-traded company.

Other income (expense), net

Other income (expense) consists primarily of interest income and expense and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents

26

and marketable securities, such as interest-bearing bonds, for our short-term investments. Interest expense is primarily attributable to interest charges associated with borrowings under our secured Term Loan.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no significant changes to our critical accounting policies since December 31, 2019. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our financial statements, refer to Item 7 in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our Annual Report and Note 1 to our condensed financial statements contained in this quarterly report on Form 10-Q.

RESULTS OF OPERATIONS

Comparison of the three and nine months ended September 30, 2020 and 2019

The following table summarizes our results of operations for the three and nine months ended September 30, 2020 and 2019 (in thousands):    

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Revenue under collaborations	$	5,000	$	18	$	5,006	$	6,814
Research and development expenses	4,036		2,440		11,396		10,259
General and administrative expenses	2,059		2,571		6,736		8,954
Interest and other expenses, net	(428)		(430)		(1,289)		(1,299)

Revenue under collaborations

Our revenues are generated from ongoing collaborations, and generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services. Revenue under our collaboration with Sanofi was $5.0 million for the three and nine months ended September 30, 2020, which was attributable to recognizing $4.0 million and $1.0 million of revenue upon the completion of transfer and verification of certain materials sold to Sanofi. Revenue under our collaboration with Sanofi was less than $0.1 million and $6.8 million for the three and nine months ended September 30, 2019, respectively, which was attributable to recognition of the Upfront Amendment Payments under the 2018 Sanofi Amendment as revenue during the three months ended March 31, 2019.

Research and development expenses

The following tables summarize the components of our research and development expenses for the periods indicated, together with year-over-year changes (dollars in thousands):

									Increase (decrease)
	Three months ended September 30, 2020		% of total		Three months ended September 30, 2019		% of total		$		%
Research and development
Personnel and internal expenses	$	1,736	43	%	$	1,321	54	%	$	415	31	%
Third-party and outsourced expenses	1,935		48	%	960		39	%	975		102	%
Non-cash stock-based compensation	255		6	%	45		2	%	210		467	%
Depreciation	110		3	%	114		5	%	(4)		(4)	%
Total research and development expenses	$	4,036	100	%	$	2,440	100	%	$	1,596	65	%

27

									Increase (decrease)
	Nine months ended September 30, 2020		% of total		Nine months ended September 30, 2019		% of total		$		%
Research and development
Personnel and internal expenses	$	4,384	38	%	$	5,267	52	%	$	(883)	(17)	%
Third-party and outsourced expenses	6,094		54	%	4,301		42	%	1,793		42	%
Non-cash stock-based compensation	571		5	%	240		2	%	331		138	%
Depreciation	347		3	%	451		4	%	(104)		(23)	%
Total research and development expenses	$	11,396	100	%	$	10,259	100	%	$	1,137	11	%

Research and development expenses were $4.0 million and $11.4 million for the three and nine months ended September 30, 2020, compared to $2.4 million and $10.3 million for the three and nine months ended September 30, 2019. The aggregate increase for the three months ended September 30, 2020, as compared to the three months ended September 30, 2019, was primarily driven by a $1.0 million increase in external development expenses, attributable to the fact that the FDA lifted the partial clinical hold on the RGLS4326 Phase 1 MAD study in December 2019 and we recommenced the Phase 1 MAD study in February 2020, with the final dosing of the final cohort completing in July 2020, as well as start-up activities leading up to the first patient dosing in our RGLS4326 Phase 1b study in October 2020. The aggregate increase for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019, was driven by a $1.8 million increase in external development expenses, attributable to RGLS4326 Phase 1 MAD and Phase 1b study activities, partially offset by a $0.9 million reduction in personnel and internal expenses, primarily attributable to continued cost reduction efforts subsequent to our corporate restructurings.

General and administrative expenses

General and administrative expenses were $2.1 million and $6.7 million for the three and nine months ended September 30, 2020, compared to $2.6 million and $9.0 million for the three and nine months ended September 30, 2019. These amounts reflect personnel-related and ongoing general business operating costs. The decreases for the three and nine months ended September 30, 2020, as compared to the three and nine months ended September 30, 2019, are primarily attributable to continued cost reduction efforts subsequent our corporate restructurings.

Interest and other expenses, net

Net interest and other expenses were $0.4 million and $1.3 million for each the three and nine months ended September 30, 2020 and 2019, respectively. These amounts are primarily related to interest charges associated with our outstanding Term Loan.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception through September 30, 2020, we have received $342.5 million from the sale of our equity and convertible debt securities, $92.8 million from our collaborations, principally from upfront payments, research funding and preclinical and clinical milestones, and $19.8 million in net proceeds from our Term Loan. As of September 30, 2020, we had cash and cash equivalents of $17.8 million.

The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. 

If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders. These factors raise substantial doubt about our ability to continue as a going concern.

Our future capital requirements are difficult to forecast and will depend on many factors, including:

•whether and when we achieve any milestones under our collaboration and license agreement with Sanofi;

•the terms and timing of any other strategic collaboration, licensing and other arrangements that we may establish;

•the initiation, progress, timing and completion of preclinical studies and clinical trials for our development programs and product candidates, and associated costs;

28

•the number and characteristics of product candidates that we pursue;

•the outcome, timing and cost of regulatory approvals;

•delays that may be caused by changing regulatory requirements;

•the cost and timing of hiring new employees to support our continued growth;

•the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;

•the costs and timing of procuring clinical and commercial supplies of our product candidates;

•the costs and timing of establishing sales, marketing and distribution capabilities, and the pricing and reimbursement for any products for which we may receive regulatory approval;

•the extent to which we acquire or invest in businesses, products or technologies;

•the extent to which our PPP Loan is forgiven; and

•payments under our Term Loan.

The following table shows a summary of our cash flows for the nine months ended September 30, 2020 and 2019 (in thousands):

	Nine months ended September 30,
	2020		2019
	(unaudited)
Net cash (used in) provided by:
Operating activities	$	(15,725)	$	(14,844)
Investing activities	(11)		133
Financing activities	(542)		15,422
Total	$	(16,278)	$	711

Operating activities

Net cash used in operating activities was $15.7 million for the nine months ended September 30, 2020, compared to $14.8 million for the nine months ended September 30, 2019. The increase in net cash used in operating activities was attributable to a net loss of $14.4 million for the nine months ended September 30, 2020, compared to a net loss of $13.7 million for the nine months ended September 30, 2019.

Investing activities

Net cash used in investing activities was less than $0.1 million for the nine months ended September 30, 2020. Net cash provided by investing activities was $0.1 million for the nine months ended September 30, 2019, attributable to the sale of property and equipment.

Financing activities

Net cash used in financing activities was $0.5 million for the nine months ended September 30, 2020, compared to net cash provided by financing activities of $15.4 million for the nine months ended September 30, 2019. Net cash provided by financing activities for the nine months ended September 30, 2019 was primarily attributable to proceeds from the issuance of our common stock, partially offset by the remittance of principal amortization payments under our Term Loan.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

As of September 30, 2020, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed within the contractual obligations table under “Management's Discussion and Analysis of Financial Condition and Results of Operations”, as contained in our Annual Report, with the exceptions of the amendments with Sanofi concerning the receipt of potential milestones in exchange for certain mir-21 program materials (refer to note 7 for information), the Tenth Amendment to the Term Loan with our Lender (refer to note 5 for information) and the PPP Loan received in April 2020 (refer to note 5 for information).

OFF-BALANCE SHEET ARRANGEMENTS

29

As of September 30, 2020, we did not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Some of the securities that we invest in have market risk where a change in prevailing interest rates may cause the principal amount of short-term investments to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. We invest our excess cash primarily in debt instruments of U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. We have established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Because of the short-term maturities of our cash equivalents, we do not believe that an increase in market rates would have any significant impact on the realized value of our cash equivalents. If a 10% change in interest rates were to have occurred on September 30, 2020, this change would not have had a material effect on the fair value of our cash equivalents as of that date.

We also have interest rate exposure as a result of our outstanding Term Loan. As of September 30, 2020, the outstanding principal amount of the Term Loan was $13.7 million. The Term Loan bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Changes in the U.S. Dollar LIBOR rate may therefore affect our interest expense associated with the Term Loan. LIBOR is currently scheduled to be phased out in 2021. Before LIBOR is phased out, we may need to renegotiate the Term Loan to replace LIBOR with a new standard, which has yet to be established. The consequences of these developments cannot be entirely predicted, but could result in higher interest rates on the principal amount of the Term Loan.

If a 10% change in interest rates were to have occurred on September 30, 2020, this change would not have had a material effect on our interest expense as of that date.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2020.

Changes in Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is

30

reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On January 31, 2017, a putative class action complaint was filed by Baran Polat in the United States District Court for the Southern District of California, or District Court, against us, Paul C. Grint (our former Chief Executive Officer), and Joseph P. Hagan (then our Chief Operating Officer and currently our President and Chief Executive Officer). The complaint includes claims asserted, on behalf of certain purchasers of our securities, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. In general, the complaint alleges that, between January 21, 2016, and June 27, 2016, the defendants violated the federal securities laws by making materially false and misleading statements regarding our business and the prospects for RG-101, thereby artificially inflating the price of our securities. The plaintiff seeks unspecified monetary damages and other relief. On February 10, 2017, a second putative class action complaint was filed by Li Jin in the District Court against the Company, Mr. Hagan, Dr. Grint, and Timothy Wright, the Company’s former Chief Research and Development Officer. The Complaint alleges claims similar to those asserted by Mr. Polat. The actions have been related. On February 17, 2017, the District Court entered an order stating that defendants need not answer, or otherwise respond, until the District Court enters an order appointing, pursuant to the Private Securities Litigation Reform Act of 1995, lead plaintiff and lead counsel, and the parties then submit a schedule to the District Court for the filing of an amended or consolidated complaint and the timing of defendants’ answer or response. On April 3, 2017, two motions for consolidation of the two actions, appointment of lead plaintiff and approval of counsel were filed in the actions. On October 26, 2017, the District Court entered an order consolidating the cases, appointing lead plaintiffs, and appointing lead counsel for lead plaintiffs. On December 22, 2017, lead plaintiffs filed a consolidated complaint against the Company, Dr. Grint, Mr. Hagan, and Michael Huang (our former Vice President of Clinical Development). The consolidated complaint alleges that between February 17, 2016 and June 12, 2017, the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making materially false and misleading statements regarding RG-101. The consolidated complaint seeks unspecified monetary damages and an award of attorneys’ fees and costs. On February 6, 2018, defendants filed a motion to dismiss the consolidated complaint. On March 23, 2018, plaintiff filed their opposition to the motion and on April 24, 2018, defendants filed their response. On September 5, 2019, the court granted the defendants’ motion to dismiss with leave to amend. Plaintiffs filed their amended complaint on October 1, 2019. Subsequent to the filing of the amended complaint, counsel for the parties engaged in negotiations to resolve the case. On November 4, 2019, the parties agreed in principle to settle the case for $0.9 million, with approximately $0.2 million to be paid by us and the balance to be paid by our D&O insurance carrier. On December 11, 2019, the parties entered into a stipulation and agreement of settlement, which was amended on February 6, 2020. On February 7, 2020, plaintiffs filed a motion for preliminary approval of the settlement. On May 27, 2020, the court entered an order preliminarily approving the settlement. On October 21, 2020, the court held a hearing regarding approval of the settlement and on October 29, 2020 the court entered its order granting final approval of the settlement. In July 2020, in connection with the proposed settlement, we remitted approximately $0.2 million into escrow, which represents the amount payable by us under the settlement, net of $0.7 million of D&O insurance carrier proceeds. We relieved the $0.9 million loss contingency that was recorded as a current liability on our balance sheet at June 30, 2020, as well as the $0.7 million of insurance proceeds that was recorded as a current receivable on our balance sheet at June 30, 2020. The $0.2 million settlement amount payable by the Company was recorded to the statement of operations and comprehensive loss for the year ended December 31, 2019.

ITEM 1A. RISK FACTORS

You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all the factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in, Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.

RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF PRODUCT CANDIDATES

The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.

31

We have concentrated our therapeutic product research and development efforts on microRNA technology, and our future success depends on the successful development of this technology and products based on our microRNA product platform. Neither we, nor any other company, has received regulatory approval to market therapeutics targeting microRNAs. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable and the value of our common stock may decline.

Further, our focus solely on microRNA technology for developing drugs as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using microRNA technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.

We may not be successful in our efforts to identify or discover potential product candidates.

The success of our business depends primarily upon our ability to identify, develop and commercialize microRNA therapeutics. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

•our research methodology or that of any collaboration partner may be unsuccessful in identifying potential product candidates;

•potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or

•our current or future collaboration partners may change their development profiles for potential product candidates or abandon a therapeutic area.    

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.

Preclinical and clinical studies of our product candidates may not be successful. If we are unable to generate successful results from our preclinical and clinical studies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.

We have invested a significant portion of our efforts and financial resources in the identification and development of product candidates that target microRNAs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates.

The success of our product candidates will depend on several factors, including the following:

•successfully designing preclinical studies which may be predictive of clinical outcomes;

•successful results from preclinical and clinical studies;

•receipt of marketing approvals from applicable regulatory authorities;

•obtaining and maintaining patent and trade secret protection for future product candidates;

•establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and

•successfully commercializing our products, if and when approved, whether alone or in collaboration with others.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development of, or commercialize, our product candidates, which would materially harm our business.

32

If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.*

Before obtaining marketing approval from regulatory authorities for the sale of product candidates, we or a collaboration partner must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

Events which may result in a delay or unsuccessful completion of clinical development include:

•delays in reaching an agreement with the FDA or other regulatory authorities on final trial design;

•imposition of a clinical hold of our clinical trial operations or trial sites by the FDA or other regulatory authorities;

•delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;

•our inability to adhere to clinical trial requirements directly or with third parties such as CROs;

•delays in obtaining required institutional review board approval at each clinical trial site;

•delays in recruiting suitable patients to participate in a trial;

•delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;

•delays in having patients complete participation in a trial or return for post-treatment follow-up;

•delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression;

•clinical sites dropping out of a trial to the detriment of enrollment;

•time required to add new clinical sites; or

•delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.

For example, in July 2018, we voluntarily paused our Phase 1 MAD clinical trial for RGLS4326 due to unexpected observations in our 27-week mouse chronic toxicity study, which was designed to support the Phase 2 proof-of-concept clinical trial in ADPKD previously planned to start in mid-2019. The observations in the mouse chronic toxicity study were unexpected, given the favorable safety profile of RGLS4326 in previous non-GLP and GLP toxicity studies at the same or similar doses supporting the IND and Phase 1 clinical trial. In consultation with the FDA, we initiated a new mouse chronic toxicity study with certain changes that are believed to address the unexpected observations. In January 2019, we announced data from a planned interim analysis of this study after 13 weeks of dosing in which no adverse or other significant findings across the range of doses tested were shown. We submitted a comprehensive data package for RGLS4326 to FDA that included the results from the planned 13-week interim analysis of the ongoing repeat mouse chronic toxicity study, as well as results from additional investigations, analytical testing, additional data from the previously terminated mouse chronic toxicity study, data from the completed Phase 1 SAD study and data from the first cohort of the Phase 1 MAD study to support our plan to resume the Phase 1 MAD study. In July 2019, FDA notified us of additional nonclinical data requirements and placed the IND on a partial clinical hold, formalizing the specific requirements to initiate the MAD study and further proceed into chronic dosing. The additional data requirements have been outlined in two parts. In order to resume the MAD study, FDA requested the final reports from the chronic toxicity studies in both mice and non-human primates and satisfactory related analyses to ensure subjects can be safely dosed. In November 2019, we submitted a complete response to the partial clinical hold in order to be able to resume the MAD study and in December 2019 FDA lifted the partial clinical hold of the MAD study. We recommenced the MAD study in February 2020 and have completed all dosing. Information from the clinical studies, together with information from additional nonclinical studies, will be used to address the requirements to support studies of extended duration. In addition to the MAD study in healthy volunteers, we have initiated a Phase 1b study in patients with ADPKD to evaluate RGLS4326 for safety, PK, and changes in levels of PC1 and PC2. We cannot be certain that we will be able to satisfy the requirements to initiate studies of extended duration in a timely manner, or at all.

In addition, enrollment and retention of patients in clinical trials could be disrupted by man-made or natural disasters, public health pandemics or epidemics or other business interruptions, including the ongoing COVID-19 pandemic. For

33

example, we expect new site initiation and patient enrollment will be delayed in the RG-012 Phase 2 clinical trial, delaying receipt of the remaining $5.0 million milestone payment under the 2020 Sanofi Amendment, and COVID-19 may impact site initiation activities and subsequent study enrollment for our RGLS4326 studies.

If we or our current or future collaboration partners are required to conduct additional clinical trials or other testing of any product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we or our current or future collaboration partners may:

•be delayed in obtaining marketing approval for our future product candidates;

•not obtain marketing approval at all;

•obtain approval for indications or patient populations that are not as broad as originally intended or desired;

•obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;

•be subject to additional post-marketing testing requirements; or

•have the product removed from the market after obtaining marketing approval.

Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete preclinical and clinical development, whether independently or with a collaboration partner, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.

Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.

Adverse events ("AEs") caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar AEs.

If AEs are observed in any clinical trials of our product candidates, including those that a collaboration partner may develop under an agreement with us, our or our collaboration partners’ ability to obtain regulatory approval for product candidates may be negatively impacted.

Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:

•regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;

•regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;

•we may be required to change the way the product is administered or conduct additional clinical trials;

•we could be sued and held liable for harm caused to patients; or

•our reputation may suffer.

Any of these events could prevent us or our collaboration partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either on our own or with a collaboration partner.

34

Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.

Neither we nor any collaboration partner can commercialize a product until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee recommends restrictions on approval or recommends non-approval. In addition, we or a collaboration partner may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.

Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.

Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.

In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices ("cGMP") and adherence to commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

If we or our partners fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:

•issue a warning letter asserting that we are in violation of the law;

•seek an injunction or impose civil or criminal penalties or monetary fines;

•suspend or withdraw regulatory approval;

•suspend any ongoing clinical trials;

•refuse to approve a pending NDA or supplements to an NDA submitted by us;

•seize product; or

•refuse to allow us to enter into supply contracts, including government contracts.

Moreover, the FDA closely regulates the marketing, labeling, advertising and promotion of pharmaceutical products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. Companies may also share truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in significant civil, criminal and administrative penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products and generate revenues.

35

We may not be successful in obtaining or maintaining necessary rights to microRNA targets, drug compounds and processes for our development pipeline through acquisitions and in-licenses.

Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to modulate only a subset of the known microRNA targets. Because our programs may involve a range of microRNA targets, including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

For example, we may collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.    

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.

We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and human resources, our existing strategy is to pursue collaboration agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large commercial markets such as ADPKD, HCC, fibrosis, HCV, and HBV, while focusing our internal development resources and any internal sales and marketing organization that we may establish on research programs and product candidates for selected markets, such as orphan diseases. As a result, we may forego or delay pursuit of opportunities with other programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our

36

research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL

We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern.*

This Form 10-Q includes disclosures regarding management’s assessment of our ability to continue as a going concern as our current liquidity position and recurring losses from operations since inception and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. As of September 30, 2020, we had approximately $17.8 million of cash and cash equivalents and we had $15.5 million of outstanding debt obligations (which includes $13.7 million of outstanding principal and $1.8 million of final payment and loan amendment fees) under our $20.0 million term loan (“Term Loan”) with Oxford Finance, LLC (“Oxford” or the “Lender”), which we borrowed under a loan and security agreement with Oxford dated June 2016 (as amended, the “Loan Agreement”). Additionally, we had $0.7 million of debt obligations outstanding under our PPP Loan. We will need to raise additional capital to fund our operations and service our debt obligations, and if we are unable to raise additional capital when needed, we will not be able to continue as a going concern.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates towards or through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all.

Additionally, our collaboration partners may not elect to pursue the development and commercialization of any of our microRNA product candidates that are subject to their respective collaboration agreements with us. Any of these events may increase our development costs more than we expect. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, which will be responsible for all costs incurred in the development of our miR-21 programs. As a result, we will not receive royalties in the event our miR-21 programs are eventually commercialized and will also receive significantly reduced milestones for these programs. We may need to raise additional capital or otherwise obtain funding through additional collaborations if we choose to initiate clinical trials for new product candidates other than programs currently partnered. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates.

For the foreseeable future, we expect to rely primarily on equity and/or debt financings to fund our operations. Raising additional capital through the sale of securities could cause significant dilution to our stockholders. For example, in May 2019, we completed the initial closing of a private placement under a Securities Purchase Agreement between us and various investors (the “May 2019 SPA”), pursuant to which we sold and issued (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. In December 2019, following our announcement of our plan to recommence our Phase 1 MAD clinical trial of RGLS4326 in the first quarter of 2020, we completed a second and final closing under the May 2019 SPA (the “Milestone Closing”), pursuant to which we sold and issued (i) 3,288,390 shares of non-voting Class A-2 convertible preferred stock, in lieu of shares of common stock, at a price of $6.66 per share, and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Each share of the non-voting Class A-2 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, pursuant to proportional adjustments in the event of stock splits or combinations or similar events. Current stockholders may be diluted by the exercise of the warrants and/or the conversion of the convertible preferred stock issued under the May 2019 SPA.

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part,

37

on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. In addition, the COVID-19 pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital or to comply with the covenants contained in the Loan Agreement, which could negatively affect our liquidity.

If we are unable to raise additional capital when required or on acceptable terms, we may be required to:

•significantly delay, scale back or discontinue the development or commercialization of any future product candidates;

•seek collaborations, or amend existing collaborations, for research and development programs at an earlier stage than otherwise would be desirable or for the development of programs that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available;

•dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves;

•pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or

•file for bankruptcy or cease operations altogether.

Any of these events could have a material adverse effect on our business, operating results and prospects.

Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our loan and security agreement could cause a material adverse effect on our financial position.*

In June 2016, we entered into a loan and security agreement with Oxford (the "Loan Agreement"). Under the terms of the Loan Agreement, Oxford provided us with a term loan of $20.0 million ("Term Loan"). Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, except for the assets that were licensed, assigned and transferred to Sanofi pursuant to a November 2018 amendment (the “2018 Sanofi Amendment”) to our collaboration and license agreement with Sanofi dated February 4, 2014 (the “Sanofi License Agreement”) that modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program, provided that Oxford will continue to have liens on all proceeds received by us pursuant to the Sanofi License Agreement. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement.

As a result of our completion of the Milestone Closing under the May 2019 SPA, our required monthly payments to the Lender are comprised of interest only through and including the payment to be made in April 2021. Commencing in May 2021, and continuing on each successive payment date thereafter, we are required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender. In the event we receive the remaining $5.0 million of the first development milestone payment (the “Milestone Payment”) under the 2020 Sanofi Amendment, we will be required to use 100% of the Milestone Payment to partially prepay the Term Loan. Upon payment of the Milestone Payment to the Lender, we will be entitled to an additional interest only period and will be required to maintain $3.0 million in cash in a collateral account and the lien on our intellectual property will be maintained.

Amounts outstanding under the Term Loan mature on May 1, 2022.

Under the Term Loan, our interest rate on borrowed amounts is dependent on LIBOR. LIBOR, which is the basic rate of interest used in lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally, is currently scheduled to be phased out in 2021. Once LIBOR is phased out, LIBOR will be replaced with a new standard. The consequences of these developments cannot be entirely predicted, but could result in higher interest rates on our outstanding principal amount under the Term Loan. We cannot provide assurance that future interest rate changes will not have a material negative impact on our business, financial position, or operating results.

The Loan Agreement requires us, and any debt arrangements we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:

• dispose of assets;

• complete mergers or acquisitions;

38

• incur indebtedness;

• encumber assets;

• pay dividends or make other distributions to holders of our capital stock;

• make specified investments; and

• engage in transactions with our affiliates.

These restrictions could inhibit our ability to pursue our business strategies. If we default under our obligations under the Loan Agreement, the lender could proceed against the collateral granted to it to secure our indebtedness or declare all obligation under the Loan Agreement to be due and payable. In certain circumstances, procedures by the lenders could result in a loss by us of all of our equipment and inventory, which are included in the collateral granted to the lenders. If any indebtedness under the Loan Agreement were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, the holders of secured indebtedness will be entitled to receive payment in full from the proceeds of the collateral securing our secured indebtedness before the holders of other indebtedness or our common stock will be entitled to receive any distribution with respect thereto.

We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Loan Agreement. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.

In addition, in April 2020 we received proceeds of approximately $0.7 million from a loan under the Paycheck Protection Program of the CARES Act, all or a portion of which may be forgiven, which we have used to retain employees, maintain payroll and make lease and utility payments. The PPP Loan matures on April 23, 2022 and bears interest at a rate of 1.00% per annum. We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and are seeking forgiveness in accordance with the program. Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement. Not more than 40% of the forgiven amount may be for non-payroll costs. The amount of the PPP Loan eligible to be forgiven will be reduced if our full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are met. We will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest, in accordance with the amortization schedule described above, and we cannot provide any assurance that we will be eligible for loan forgiveness or that any amount of the PPP Loan will ultimately be forgiven by the SBA.

If we are found to be in violation of any of the laws or governmental regulations that apply to us in connection with the PPP Loan, including the False Claims Act, or it is otherwise determined that we were not eligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties and could be required to repay the PPP Loan in its entirety. In addition, our receipt of the PPP Loan may result in adverse publicity and damage to our reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources.

We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.*

Since inception, our operations have been primarily limited to acquiring and in-licensing intellectual property rights, developing our microRNA product platform, undertaking basic research around microRNA targets and conducting preclinical and clinical studies for our initial programs. We have not yet obtained regulatory approval for any product candidates. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate.

We have incurred losses in each year since our inception in September 2007. Our net losses were $1.5 million and $14.4 million for the three and nine months ended September 30, 2020, respectively, and $5.4 million and $13.7 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, we had an accumulated deficit of $425.7 million.

We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. To date, we have financed our operations primarily through the sale of equity securities and convertible

39

debt, through our Term Loan and from revenue received from our collaboration partners. We have a collaboration with Sanofi relating to the development of our miR-221/222 program for oncology indications. Under our collaboration and license agreement with Sanofi, Sanofi has an option to obtain exclusive worldwide licenses for the development, manufacture and commercialization of our preclinical program targeting miR-221/222 for HCC. If Sanofi exercises its option, it will assume responsibility for funding and conducting further clinical development and commercialization activities for such product candidate. However, if Sanofi does not exercise its option, we will be responsible for funding further development of the applicable product candidate and may not have the resources to do so unless we are able to enter into another collaboration for such product candidate. Pursuant to the 2018 Sanofi Amendment, we completed the transition of further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, in the second quarter of 2019. As a result, Sanofi became responsible for all costs incurred in the development of our miR-21 programs.

The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, collaborations or grants. We re-initiated clinical development of RGLS4326 for the treatment of ADPKD. We had also initiated clinical development of RG-012, which we subsequently transferred to Sanofi, and it will be several years, if ever, before Sanofi has a product candidate ready for commercialization. Even if we or a collaboration partner successfully obtains regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval, and our ability to achieve sufficient market acceptance and adequate market share for our products.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: continue our research and preclinical and clinical development of our product candidates, both independently and under our collaboration agreements; seek to identify additional microRNA targets and product candidates; acquire or in-license other products and technologies; continue with clinical development of our product candidates; seek marketing approvals for our product candidates that successfully complete clinical trials; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; maintain, expand and protect our intellectual property portfolio; hire additional clinical, regulatory, research and administrative personnel; and create additional infrastructure to support our operations and our product development and planned future commercialization efforts.

We have never generated any revenue from product sales and may never be profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:

•identifying and validating new microRNAs as therapeutic targets;

•completing our research and preclinical development of product candidates;

•initiating and completing clinical trials for product candidates;

•seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials;

•establishing and maintaining supply and manufacturing relationships with third parties;

•launching and commercializing product candidates for which we obtain marketing approval, with a collaboration partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;

•maintaining, protecting and expanding our intellectual property portfolio; and

•attracting, hiring and retaining qualified personnel.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase beyond expectations if we are required by the FDA or foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate.

Even if one or more of the product candidates that we independently develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

40

RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES

We will depend upon collaborations for the development and eventual commercialization of certain microRNA product candidates. If these collaborations are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs.

We are likely to depend upon third party collaboration partners for financial and scientific resources for the clinical development and commercialization of certain of our microRNA product candidates. These collaborations will likely provide us with limited control over the course of development of a microRNA product candidate, especially once a candidate has reached the stage of clinical development. For example, in our strategic collaboration with Sanofi, Sanofi has the option to obtain an exclusive worldwide license to develop, manufacture and commercialize our preclinical program targeting miR-221/222 for HCC upon the achievement of relevant endpoints in clinical trials. However, Sanofi is not under any obligation to exercise this option. While Sanofi has development obligations with respect to programs that it may elect to pursue under our agreement, our ability to ultimately recognize revenue from this and future relationships will depend upon the ability and willingness of our collaboration partners to successfully meet their respective responsibilities under our agreements with them. In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi. As a result, Sanofi became responsible for all costs incurred in the development of our miR-21 program, but we will not receive royalties in the event our miR-21 programs are eventually commercialized, and the milestone payments we are eligible to receive for these programs has been significantly reduced.

Our ability to recognize revenues from successful collaborations may be impaired by several factors including:

•a collaboration partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;

•a collaboration partner may cease development in therapeutic areas which are the subject of our collaborations;

•a collaboration partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate;

•a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;

•a collaboration partner could develop a product that competes, either directly or indirectly, with a collaboration product;

•a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;

•a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;

•a collaboration partner may exercise its rights under the agreement to terminate the collaboration;

•a dispute may arise between us and a collaboration partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and

•a collaboration partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our rights in such property are jeopardized.

Specifically, with respect to termination rights, Sanofi may terminate the entire collaboration or its current collaboration target program for any or no reason upon 30 days’ written notice to us. The agreement with Sanofi may also be terminated by either party for material breach by the other party, including a failure to comply with such party’s diligence obligations that remains uncured after 120 days. Depending on the timing of any such termination, we may not be entitled to receive the option exercise fees or milestone payments, as these payments terminate with termination of the respective program or agreement.

If Sanofi does not elect to pursue the development and commercialization of the microRNA development candidates covered by our collaboration and license agreement with Sanofi or if Sanofi terminates the agreement, then, depending on the event:

•under certain circumstances, we may owe Sanofi royalties with respect to product candidates covered by our agreement with Sanofi that we elect to continue to commercialize, depending upon the stage of development at which

41

such product commercialization rights reverted back to us, or additional payments if we license such product candidates to third parties;

•product candidates subject to the Sanofi agreement, as applicable, may be terminated or significantly delayed;

•our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded by Sanofi;

•we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the Sanofi agreement, including the reimbursement of third parties; and

•in order to fund further development and commercialization, we may need to seek out and establish alternative collaborations with third-party partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.

Any of these events could have a material adverse effect on our results of operations and financial condition.

We rely on third parties to conduct some aspects of our compound formulation, research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing.

We do not expect to independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical studies of product candidates. We currently rely and expect to continue to rely on third parties to conduct some aspects of our preclinical studies and formulation development.

Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the trial.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our collaboration partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.

We rely on third-party manufacturers to produce our preclinical and clinical product candidates, and we intend to rely on third parties to produce future clinical supplies of product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.*

Reliance on third-party manufacturers entails risks, including risks that we would not be subject to if we manufactured the product candidates ourselves, including:

•the inability to meet any product specifications and quality requirements consistently;

•a delay or inability to procure or expand sufficient manufacturing capacity;

•manufacturing and product quality issues related to scale-up of manufacturing;

•costs and validation of new equipment and facilities required for scale-up;

•a failure to comply with cGMP and similar foreign standards;

•the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms;

•termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;

•the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms;

42

•the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier;

•operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;

•carrier disruptions or increased costs that are beyond our control;

•disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and

•the failure to deliver products under specified storage conditions and in a timely manner.

Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.

We rely on limited sources of supply for the drug substance of product candidates and any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates.

We have established manufacturing relationships with a limited number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

In addition, if our collaboration partners elect to pursue the development and commercialization of certain programs, we will lose control over the manufacturing of the product candidate subject to the agreement. For example, in November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi, who is responsible for all costs incurred in the development of our miR-21 programs. As a result, we will no longer be involved in the development or commercialization of our miR-21 programs. Sanofi will be free to use a manufacturer of its own choosing or manufacture the product candidates in its own manufacturing facilities. In such a case, we will have no control over Sanofi’s processes or supply chains to ensure the timely manufacture and supply of the product candidates. In addition, we will not be able to ensure that the product candidates will be manufactured under the correct conditions to permit the product candidates to be used in such clinical trials.

These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, delay milestone payments owed to us or cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredients on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.

As we scale-up manufacturing of product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for product candidates or any approved products.

We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.

We or our collaboration partners rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we and our collaboration partners have limited influence over their actual performance. We control only certain aspects of our CROs’ activities. Nevertheless, we or our collaboration partners are responsible for ensuring that each of our clinical trials are conducted in accordance with the

43

applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.

We, our collaboration partners and our CROs are required to comply with the FDA’s or other regulatory agency’s good clinical practices ("GCPs") for conducting, recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA and non-U.S. regulatory agencies enforce these GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or applicable non-U.S. regulatory agency may require us to perform additional clinical trials before approving any marketing applications for the relevant jurisdiction. Upon inspection, the FDA or applicable non-U.S. regulatory agency may determine that our clinical trials did not comply with GCPs. In addition, our clinical trials will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.

Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for such products and any product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.                

We also rely on other third parties to store and distribute drug products for any clinical trials that we may conduct. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our future products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found; such prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims.

If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. A patent may be challenged through one or more of several administrative proceedings including post-grant challenges, re-examination or opposition before the U.S. PTO or foreign patent offices. Any successful challenge of patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we or our collaboration partners may develop.

Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding, known as an interference, can be initiated to determine which applicant is entitled to the patent on that subject matter. Such an interference proceeding provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent

44

applications, or those of our collaboration partners or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of a patent or patent application in such a proceeding may not be successful and, even if successful, may result in substantial costs and distract our management and other employees.

In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets and proprietary information.

Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaboration partners are pursuing development candidates. For example, we are aware that Roche Innovation Center Copenhagen has patents and patent applications in the microRNA therapeutics space, including patents and patent applications related to targeting microRNAs, such as miR-122, for the treatment of disease. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In

45

the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, our exclusive license agreements with our founding companies, Alnylam and Ionis, provide us with rights to nucleotide technologies in the field of microRNA therapeutics based on oligonucleotides that modulate microRNAs. Some of these technologies, such as intellectual property relating to the chemical modification of oligonucleotides, are relevant to our product candidate development programs. If our license agreements with Alnylam or Ionis are terminated, or our business relationships with either of these companies or our other licensors are disrupted by events that may include the acquisition of either company, our access to critical intellectual property rights will be materially and adversely affected.

We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Our defense in a litigation may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

RISKS RELATED TO COMMERCIALIZATION OF PRODUCT CANDIDATES

The commercial success of our programs that are part of our collaboration agreements with Sanofi or others will depend in large part on the development and marketing efforts of our collaboration partners. If our collaboration

46

partners are unable or unwilling to perform in accordance with the terms of our agreements, our potential to generate future revenue from these programs would be significantly reduced and our business would be materially and adversely harmed.

In November 2018, we and Sanofi agreed to transition further development activities of our miR-21 programs, including our RG-012 program, to Sanofi. The transition activities were completed in the second quarter of 2019. As a result, we have no influence and/or control over their approaches to development and commercialization of our miR-21 programs. If Sanofi or any potential future collaboration partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to such collaboration partners could be delayed or terminated. If we terminate any of our collaborations or any program thereunder due to a material breach by Sanofi, and except in the case of RG-012, we have the right to assume the responsibility at our own expense for the development of the applicable microRNA product candidates. Assuming sole responsibility for further development will increase our expenditures and may mean we will need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such microRNA product candidates and our business could be materially and adversely affected. Further, under certain circumstances, we may owe Sanofi royalties on any product candidate that we may successfully commercialize.

We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Our competitors may have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product candidate that we may develop.    

Most of our programs are targeted toward indications for which there are approved products on the market or product candidates in clinical development. We will face competition from other drugs currently approved or that will be approved in the future for the same therapeutic indications. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development to:

•discover and develop therapeutics that are superior to other products in the market;

•attract qualified scientific, product development and commercial personnel;

•obtain patent and/or other proprietary protection for our microRNA product platform and future product candidates;

•obtain required regulatory approvals; and

•successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics.

The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. We will not achieve our business plan if the acceptance of any of these products is inhibited by price competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to reserve our future products for use in limited circumstances. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing product candidates before we do, which would have a material adverse impact on our business.

47

The commercial success of our product candidates will depend upon the acceptance of these product candidates by the medical community, including physicians, patients and healthcare payors.

The degree of market acceptance of any product candidates will depend on a number of factors, including:

•demonstration of clinical safety and efficacy compared to other products;

•the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors;

•the prevalence and severity of any AEs;

•limitations or warnings contained in the FDA-approved label for such products;

•availability of alternative treatments;

•pricing and cost-effectiveness;

•the effectiveness of our or any collaborators’ sales and marketing strategies;

•our ability to obtain hospital formulary approval;

•our ability to obtain and maintain sufficient third party coverage and adequate reimbursement; and

•the willingness of patients to pay out-of-pocket in the absence of third party coverage.

Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable form. Injectable medications may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If a product is approved, but does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable. For example, several new antivirals and antiviral combinations have been approved for the treatment of the HCV since we commenced our HCV program. Such increased competition may decrease any future potential revenue for future product candidates due to increasing pressure for lower pricing and higher discounts in the commercialization of our product.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues.

We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. For example, in order to exercise our co-promotion rights with Sanofi with respect to our miR-221/222 program, we would need to build our sales, marketing, managerial and other non-technical capabilities in order to effectively carry out sales or co-promotion activities with respect to any approved products that are developed through these programs. With respect to certain of our current programs as well as future programs, we may rely completely on a collaboration partner for sales and marketing. In addition, we intend to enter into collaborations with third parties to commercialize other product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. Although we intend to establish a sales organization if we are able to obtain approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into collaborations for future product candidates in the United States if commercialization requirements exceed our available resources. This will reduce the revenue generated from the sales of these products.

Our current and any future collaboration partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future collaboration partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.

If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

48

If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.*

If any product candidates that we develop are approved for commercialization, we may also enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:

•different regulatory requirements for drug approvals in foreign countries;

•different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;

•reduced protection for intellectual property rights;

•unexpected changes in tariffs, trade barriers and regulatory requirements;

•economic weakness, including inflation, or political instability in particular foreign economies and markets;

•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•foreign taxes, including withholding of payroll taxes;

•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;

•workforce uncertainty in countries where labor unrest is more common than in the United States;

•production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

•business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic

Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell products profitably.

Market acceptance and sales of any product candidates that we develop will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, government payors and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. Also, inadequate reimbursement amounts may reduce the demand for, or the price of, our future products. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize product candidates that we develop.

In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products that we may develop and commercialize into our target markets. Obtaining formulary approval from hospitals and from payors can be an expensive and time-consuming process. Failure to obtain timely formulary approval will limit our commercial success.

There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. The potential application of user fees to generic drug products may expedite the approval of additional generic drug treatments. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.

In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement

49

limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.

RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.

We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.*

As of September 30, 2020, we had 24 employees, all of which were full-time employees. In the future, we may need to expand our organization.

Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative sanctions.

We may undertake internal restructuring activities that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.

50

From time to time we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. For example, we initiated a corporate restructuring in May 2017 and in July 2018, each of which resulted in a reduction in our workforce. Any such restructuring activities may result in write-offs or other restructuring charges. There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal restructurings can require a significant amount of time and focus from management and other employees, which may divert attention from commercial operations. If any internal restructuring activities we have undertaken or undertake in the future fail to achieve some or all of the expected benefits therefrom, our business, results of operations and financial condition could be materially and adversely affected.

Certain current and future relationships with customers and third party payors as well as certain of our business operations may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Our operations may be directly, or indirectly through our relationships with customers, third party payors, healthcare providers, and others subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect our ability to operate include:

•the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs;

•federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including Medicare or Medicaid, that are false or fraudulent;

•the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

•HIPAA, as amended by HITECH, and their implementing regulations, which imposes certain requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information;

•the European General Data Protection Regulation ("GDPR") adopted by the European Union ("EU") in May 2018, which contains provisions specifically directed at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-EU companies under the regulation; we anticipate that over time we may expand our business operations to include additional operations in the EU, including potentially conducting preclinical and clinical trials and, with such expansion, we would be subject to increased governmental regulation in the EU countries in which we might operate, including the GDPR;

•California recently enacted legislation that has been dubbed the first “GDPR-like” law in the United States. Known as the California Consumer Privacy Act ("CCPA"), it has created new individual privacy rights for consumers (as that word is broadly defined in the law) and placed increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allows for a new cause of action for data breaches. The CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information;

51

•the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services ("CMS") information related to payments or other transfers of value made to physicians, as defined by such law, and teaching hospitals, and further requires applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and

•state and foreign law equivalents of each of the above federal laws, such as: anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, disgorgement, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Recent and future healthcare legislation may further impact our business operations.*

The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) was passed and includes measures to significantly change the way healthcare is financed by both governmental and private insurers. There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (the "Tax Act") includes a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.

Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in

52

2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, the Trump administration’s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. In addition, the Trump administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services (“HHS”) has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019. Additionally, on July 24, 2020, President Trump announced four executive orders related to prescription drug pricing that attempt to implement several of the Trump administration proposals, including (i) a policy that would tie certain Medicare Part B drug prices to international drug prices, or the “most favored nation price,” the details of which were released on September 13, 2020 and also expanded to cover certain Part D drugs; (ii) an order that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; (iii) an order that directs HHS to finalize the rulemaking process on modifying the Anti-Kickback Statute safe harbors for discounts for plans, pharmacies, and pharmaceutical benefit managers; (iv) a policy that reduces costs of insulin and epipens to patients of federally qualified health centers. The FDA also recently released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. On August 6, 2020, the Trump administration issued another executive order that instructs the federal government to develop a list of “essential” medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States.

We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.

In addition, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.

53

The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our current and future product candidates may induce similar adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

•impairment of our business reputation;

•withdrawal of clinical trial participants;

•costs due to related litigation;

•distraction of management’s attention from our primary business;

•substantial monetary awards to patients or other claimants;

•the inability to commercialize our product candidates; and

•decreased demand for our product candidates, if approved for commercial sale.

We maintain product liability insurance relating to the use of our therapeutics in clinical trials. However, such insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications and related tools and functions could result in damage to our reputation and/or subject us to costs, fines or lawsuits.

Our business requires manipulating, analyzing and storing large amounts of data. In addition, we rely on a global enterprise software system to operate and manage our business. We also maintain personally identifiable information about our employees. Our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, networks, Internet servers, and related infrastructure. To the extent that our hardware or software malfunctions or access to our data by internal research personnel is interrupted, our business could suffer. The integrity and protection of our employee and company data is critical to our business and employees have a high expectation that we will adequately protect their personal information. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs. Although our computer and communications hardware is protected through physical and software safeguards, it is still vulnerable to fire, storm, flood, power loss, earthquakes, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war, telecommunications failures, physical or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and use of non-public information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. In addition, any sustained disruption in internet access provided by other companies could harm our business.

Changes in funding for FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government

54

funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

The withdrawal of the United Kingdom from the European Union, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.*

Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as “Brexit.” Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules will continue to apply. Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the expiry of the Transition Period. Under the formal withdrawal arrangements between the United Kingdom and the European Union, the parties had until June 30, 2020 to agree to extend the Transition Period if required. No such extension was agreed prior to such date. No agreement has yet been reached between the United Kingdom and the European Union and it may be the case that no formal customs and trading agreement will be reached prior to the expiry of the Transition Period on December 31, 2020.

Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. For example, as a result of the uncertainty surrounding Brexit, the EMA relocated to Amsterdam from London. Following the Transition Period, the United Kingdom will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the United Kingdom, the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom.

Our business and operations might be disrupted or adversely affected by catastrophic events.*

Our headquarters are located in San Diego County. We are vulnerable to natural disasters such as earthquakes and wild fires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations. In addition, natural disasters or other catastrophic events in various parts of the world, including interruptions in the supply of natural resources, political and governmental changes, disruption in transportation networks or delivery services, severe weather conditions, wildfires and other fires, explosions, actions of animal rights activists, terrorist attacks, earthquakes, wars and public health issues (including, for

55

example, the COVID-19 pandemic) could disrupt our operations or those of our collaborators, contractors and vendors or contribute to unfavorable economic or other conditions that could adversely impact us.

Our business could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations globally, including at our headquarters in San Diego, which is currently subject to a state executive order, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.*

Our business may be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which was declared by the World Health Organization as a global pandemic, and is resulting in travel and other restrictions to reduce the spread of the disease, including a California executive order and several other state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. As a result of these recent developments, we have implemented work-from-home policies for most of our employees. The effects of the state executive order, government-imposed quarantines and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.

Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. For example, some of our CROs have delayed the commencement of preclinical studies due to shelter in place orders.

Beginning the week of March 16, 2020, substantially all of our workforce began working from home either all or substantially all of the time, except for a limited number of staff in our research and development laboratory. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs and regulatory timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.

In addition, our clinical trials are likely to be affected by the ongoing COVID-19 pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic, and some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be delayed or disrupted, which would adversely impact our clinical trial operations.

The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic, may be difficult to assess or predict, it is currently resulting in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital or to comply with the covenants contained in the Loan Agreement, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

The COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.

RISKS RELATED TO OUR COMMON STOCK

The market price of our common stock may be highly volatile.*

Our stock price has historically been, and is expected to continue to be, highly volatile.

56

Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

•adverse results or delays in preclinical studies or clinical trials;

•inability to obtain additional funding;

•any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

•failure to maintain our existing collaborations or enter into new collaborations;

•failure of our collaboration partners to elect to develop and commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements;

•failure by us or our licensors and collaboration partners to prosecute, maintain or enforce our intellectual property rights;

•failure to successfully develop and commercialize our product candidates;

•changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products;

•inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;

•adverse regulatory decisions;

•changes in the structure of healthcare payment systems;

•introduction of new products, services or technologies by our competitors;

•failure to meet or exceed financial projections we may provide to the public;

•failure to meet or exceed the estimates and projections of the investment community;

•the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•disruptions caused by man-made or natural disasters, public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic;

•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our collaboration partners or our competitors;

•disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•additions or departures of key scientific or management personnel;

•significant lawsuits, including patent or stockholder litigation;

•changes in the market valuations of similar companies;

•sales of our common stock by us or our stockholders in the future; and

•trading volume of our common stock.

In addition, companies trading in the stock market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility.

The requirements of being a publicly traded company may strain our resources and divert management’s attention.

As a publicly traded company, we have incurred, and will continue to incur, significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The Nasdaq Capital Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act") was enacted. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel have devoted and will need to continue to devote a

57

substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.*

From time to time, the Financial Accounting Standards Board ("FASB"), either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our financial position, results of operations or reported cash flows. In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue when promised goods or services are transferred to customers. The standard requires a company to recognize revenue to depict the transfer of goods or services to customers in the amount that reflects the consideration it expects to be entitled to receive in exchange for those goods or services. The FASB subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date.

Any difficulties in adopting or implementing any new accounting standard could result in our failure to meet our financial reporting obligations, which could result in regulatory discipline and harm investors’ confidence in us. Finally, if we were to change our critical accounting estimates, including those related to the recognition of collaboration revenue, our operating results could be significantly affected.

Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall.

Substantially all of our outstanding shares of common stock are available for public sale, subject in some cases to volume and other limitations. If our existing stockholders sell substantial amounts of our common stock in the public market, or the market perceives that such sales may occur, the trading price of our common stock could decline. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, preferred stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, any of which may result in material dilution to investors and/or our existing stockholders. New investors could also be issued securities with rights superior to those of our existing stockholders. For example, on May 7, 2019, we completed the initial closing of the private placement under the May 2019 SPA, pursuant to which we sold and issued (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. As of September 30, 2020, 159,198 shares of Class A-1 convertible preferred stock have been converted into 1,591,980 shares of our common stock, and 256,700 shares of Class A-1 convertible preferred stock remained outstanding. The warrants will be exercisable for a period of five years following the date of issuance and will have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. In December 2019 following our announcement of resumption of our Phase 1 MAD clinical trial of RGLS4326, we completed the Milestone Closing under the May 2019 SPA, pursuant to which we sold and issued (i) 3,288,390 shares of non-voting Class A-2 convertible preferred stock, in lieu of shares of common stock, at a price of $6.66 per share, and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Each share of the non-voting Class A-2 convertible preferred stock is convertible into 10 shares of common stock, subject to certain beneficial ownership conversion limitations. As of September 30, 2020, 1,648,875 shares of Class A-2 convertible preferred stock have been converted into 16,488,750 shares of our common stock, and 1,639,515 shares of Class A-2 convertible preferred stock remained outstanding. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, pursuant

58

to proportional adjustments in the event of stock splits or combinations or similar events. Current stockholders may be diluted by the exercise of the warrants issued in the Private Placement.

Pursuant to our 2019 Equity Incentive Plan (the "2019 Plan"), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Commencing in January 2021, the number of shares available for future grant under the 2019 Plan will automatically increase each year by up to 5% of all shares of our capital stock outstanding as of December 31st of the preceding calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Furthermore, we may grant or provide for the grant of rights to purchase shares of our common stock pursuant to our 2012 Employee Stock Purchase Plan ("ESPP"). The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year by the lessor of 1% of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year and 41,666 shares, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2019 Plan and the ESPP each year.

We may be unable to comply with the applicable continued listing requirements of The Nasdaq Capital Market.*

Our common stock is currently listed on The Nasdaq Capital Market. In order to maintain the listing of our common stock on The Nasdaq Capital Market, we must satisfy minimum financial and other continued listing requirements and standards, including a minimum closing bid price requirement for our common stock of $1.00 per share and a minimum stockholders’ equity requirement of $2.5 million. In March 2020 we received a letter from The Nasdaq Stock Market advising us in each case that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum price required for continued listing on The Nasdaq Stock Market, and therefore we could become subject to delisting if our common stock did not meet the $1.00 minimum bid price for 10 consecutive trading days within the 180-day period following the date of the letter. In April 2020, Nasdaq announced that it would toll minimum closing bid price compliance periods through and including June 30, 2020, meaning we have until December 2020 to comply with the minimum bid price requirement. We will continue to monitor our stock price and we intend to take appropriate action if our stock does not regain compliance before the end of the compliance period.

In addition, we have failed to comply with Nasdaq’s minimum bid price requirement and minimum stockholders’ equity requirement on multiple other occasions during the last several years, although we have regained compliance in such previous occasions. There can be no assurance that we will continue to maintain compliance with the $1.00 minimum bid price requirement or the minimum stockholders’ equity requirement, or continuously satisfy Nasdaq's other continued listing standards in the future. In the future, if we are ultimately not able to maintain or timely regain compliance with Nasdaq’s continued listing requirements, our common stock will be subject to delisting. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for our common stock and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further. In addition, the delisting of our common stock from The Nasdaq Capital Market would constitute an event of default under our Loan Agreement with Oxford.

We are the subject of a putative securities class action lawsuit, and additional securities litigation may be brought against us in the future.*

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. On January 31, 2017, a putative class action complaint was filed in the United States District Court for the Southern District of California against us, Paul C. Grint (our former Chief Executive Officer) and Joseph P. Hagan (then our Chief Operating Officer and currently our President and Chief Executive Officer). The complaint includes claims asserted, on behalf of certain purchasers of our securities, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. In general, the complaint alleges that between January 21, 2016, and June 27, 2016, the defendants violated the federal securities laws by making materially false and misleading statements regarding our business and the prospects for RG-101, thereby artificially inflating the price of our securities. A second action has subsequently been filed making the same allegations but extending the period of alleged violations to January 27, 2017 and also naming our former Chief Research & Development Officer, Timothy M. Wright, as a defendant. These actions were consolidated and on December 22, 2017, lead plaintiffs filed a consolidated complaint against the Company, Dr. Grint, Mr. Hagan, and Michael Huang (our former Vice President of Clinical Development). The consolidated complaint alleges that between February 17, 2016 and June 12, 2017, the Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making materially false and misleading statements regarding RG-101. The consolidated complaint seeks unspecified monetary damages and an award of attorneys’ fees and costs. On February 6, 2018, defendants filed a motion to dismiss the consolidated

59

complaint. On March 23, 2018, plaintiff filed their opposition to the motion and on April 24, 2018, defendants filed their response. On September 5, 2019, the court granted the defendants’ motion to dismiss with leave to amend. The plaintiffs filed their amended complaint on October 1, 2019. Subsequent to the filing of the amended complaint, counsel for the parties engaged in negotiations to resolve the case. On November 4, 2019, the parties agreed in principle to settle the case for $0.9 million, with approximately $0.3 million to be paid by us and the balance to be paid by our D&O insurance carrier. On December 11, 2019, the parties entered into a stipulation and agreement of settlement, which was amended on February 6, 2020. On February 7, 2020, plaintiffs filed a motion for preliminary approval of the settlement. On May 27, 2020, the court entered an order preliminarily approving the settlement. On October 21, 2020, the court formally approved the settlement. It is possible that additional lawsuits will be filed, or allegations made by stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. While we carry liability insurance, there is no assurance that any losses we incur in connection with the current lawsuits or any future lawsuits will be covered or that coverage, if any, will be sufficient. In addition, the current lawsuits and similar future litigation could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.*

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.*

As of December 31, 2019, we had net operating loss ("NOL") carryforwards for U.S. federal and California state tax purposes of $326.6 million and $274.6 million, respectively. A portion of the federal and California state NOL carryforwards will begin to expire, if not utilized, in 2030 and 2031, respectively. NOLs that expire unused will be unavailable to offset future income tax liabilities. Under the Tax Act, federal NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the "Code"), and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We have determined that we triggered an “ownership change” limitation at the completion of our initial public offering in October 2012 and again in July 2015, May 2019 and December 2019. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset U.S. federal taxable income will be subject to limitations, which could harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our ability to pay cash dividends is currently prohibited by the terms of our secured debt, and any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.

60

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:

•authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

•prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

•eliminating the ability of stockholders to call a special meeting of stockholders;

•establishing the state of Delaware as the sole forum for certain legal actions against the Company, its officers and directors; and

•establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

61

ITEM 6. EXHIBITS

Exhibit Number	Description
3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on August 3, 2016).
3.2		Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on October 2, 2018).
3.3		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 8, 2016).
3.4		Certificate of Designation of Preferences, Rights and Limitations of Class A-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on May 9, 2019).
3.5		Certificate of Designation of Preferences, Rights and Limitations of Class  A-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (file No.  001-35670), filed with the SEC on December 26, 2019).
4.1		Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4 and 3.5.
4.2		Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on November 9, 2018).
4.3		Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K (File No. 001-35670), filed with the SEC on May 9, 2019).
10.1†		Second Amendment to Second Amended and Restated Collaboration and License Agreement, dated August 25, 2020, by and between the Registrant and Sanofi.
10.2		Tenth Amendment to Loan and Security Agreement, dated August 25, 2020, by and between the Registrant and Oxford Finance, LLC.
31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
32.1**		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

62

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

† Certain portions of this exhibit (indicated by “[***]”) have been omitted as the Registrant has determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to the Registrant if publicly disclosed.

** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Regulus Therapeutics Inc.
Date: November 5, 2020	By:	/s/ Joseph P. Hagan
		Joseph P. Hagan
		President and Chief Executive Officer
		(Principal Executive Officer)
Date: November 5, 2020	By:	/s/ Cris Calsada
		Cris Calsada
		Chief Financial Officer
		(Principal Financial Officer)

63

EX-10.1

Exhibit 10.1

CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

SECOND AMENDMENT TO

SECOND AMENDED AND RESTATED

COLLABORATION AND LICENSE AGREEMENT

This Second Amendment to Second Amended and Restated Collaboration and License Agreement (“Second Amendment”) is made and entered into as of the date of the last signature below(the “Second Amendment Date”), by and between Sanofi, a company organized under the laws of France (“Sanofi”) having a place of business at 54, rue la Boétie, 75008, Paris, France, registered in the Paris Trade and Company Register under no. 395 030 844, and Regulus Therapeutics Inc., a corporation organized under the laws of the State of Delaware, USA (“Regulus”) having a place of business at 10628 Science Center Drive, Suite 225, San Diego, California 92121, USA. Sanofi and Regulus each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

Whereas, Sanofi and Regulus entered into that certain Second Amended and Restated Collaboration and License Agreement effective February 4, 2014 (as in effect prior to the First Amendment Date, the “Agreement”), pursuant to which, among other things, Regulus is responsible for all activities under each POC Program Plan (other than Sanofi Program Activities) through the Achievement of Proof of Concept (as such term is defined in the Agreement); and

Whereas, Sanofi and Regulus entered into that certain First Amendment to Second Amended and Restated Collaboration and License Agreement dated November 5, 2018 (the “First Amendment”), pursuant to which, among other things, restructured the Agreement as it pertains to the Mir21 POC Programs, Mir21 Compounds, and Mir21 Products; and

Whereas, [***] and therefore the Parties have agreed to further restructure the Agreement as it pertains to the Milestone Events and Milestone Payment and materials assigned by Regulus to Sanofi and on the terms and subject to the conditions set forth in this Second Amendment.

Now, Therefore, in consideration of the foregoing and the mutual covenants herein contained, the Parties do hereby agree as follows:

Capitalized terms used but not otherwise defined in this Second Amendment shall have the meanings ascribed to them in the Agreement.

1.Transfer of Additional Mir-21 Fibrosis POC Program Specific Materials.

Concurrently with the execution of the Second Amendment, Regulus shall sell, transfer and assign or cause to be transferred and assigned to Sanofi, as set forth in this Second Amendment, such additional Mir 21 Fibrosis POC Program-Specific materials as set forth on the Amended Schedule 5.5 attached hereto. The transfer and assignment shall be memorialized in an amendment to the Material Assignment and Assumption Agreement to be entered into by the Parties concurrently with this Second Amendment. Sanofi shall pay Regulus one million US Dollars corresponding to the value of the additional Mir-21 Fibrosis POC Program-Specific materials as indicated in the Amended Schedule 5.5 (the “Transfer Price”). Regulus shall invoice Sanofi upon execution of this Second Amendment and Sanofi shall make payment of the Transfer Price within 30 days after

[***] = Certain Confidential Information Omitted

Sanofi’s confirmation and receipt of invoice therefor from Regulus, and Section 5.5 of the Agreement shall not apply to the additional Mir-21 Fibrosis POC Program-Specific materials transferred pursuant to this Second Amendment.

Amendment of Section 6.2. Section 6.2 of the Agreement shall be deleted in its entirety and replaced as follows:

6.2    Milestone Payments for Sanofi Mir21 Fibrosis POC Program. Sanofi shall give Regulus written notice of the first achievement (by Sanofi, its sublicensees or their respective Affiliates) of each of the milestone events set forth below within 10 Business Days after such achievement. After receiving such written notice of the achievement of any such milestone event, Regulus shall submit an invoice to Sanofi for the amount of the milestone payment corresponding to the applicable milestone event set forth below, and Sanofi will pay Regulus such milestone payment amount within 30 days after receipt of such invoice. Each of the milestone payments set forth below in this Paragraph 0 shall be payable only one time, and only for the first achievement of the applicable milestone event.

Milestone Event	Milestone Payment
Transfer of the additional Mir-21 Fibrosis POC Program Specific materials listed in the Amended Schedule 5.5 attached to this Second Amendment or enrollment of the [***] in the HERA Study or Other Fibrosis POC Study, whichever occurs first. Transfer shall be considered completed and Milestone Payment owed based on Sanofi’s confirmative analysis by quality control and final review of documentation to determine chain of custody. Sanofi shall complete its confirmative analysis within ten (10) days of receipt of the additional Mir-21 Fibrosis POC Program Specific material at Sanofi’s Frankfurt site (Germany) and Milestone Payment for the transfer will be paid within ten (10) days after Sanofi’s confirmation and receipt of an invoice therefor from Regulus.	$4 million
[***] in the HERA Study or Other Fibrosis POC Study, whichever occurs first	$5 million
Occurrence of [***] the HERA Study or Other Fibrosis POC Study, whichever occurs first*	$25 million

*     If this milestone event is not achieved, but [***] of the Mir-21 Product RG-012 is initiated by or on behalf of Sanofi, its sublicensees or their respective Affiliates, the milestone payment corresponding to this milestone event shall be payable to Regulus upon [***] (as defined in the Agreement) for the Mir-21 Product RG-012, notwithstanding the non-achievement of such milestone event. For clarity, if this milestone event is achieved, then the corresponding milestone event shall be payable to

    2.

[***] = Certain Confidential Information Omitted

Regulus regardless of whether or not Sanofi continues the Development of the Mir-21 Product RG-012.

3.MISCELLANEOUS.

3.1Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as of the Second Amendment Date that:

(a)it has the power and authority and the legal right to enter into this Second Amendment and perform its obligations hereunder, and that it has taken all necessary action on its part required to authorize the execution and delivery of this Second Amendment and the performance of its obligations hereunder;

(b)this Second Amendment has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity; and

(c)the execution and delivery of this Second Amendment and the performance of such Party’s obligations hereunder (i) do not conflict with or violate any requirement of Applicable Law or any provision of the certificate of incorporation, bylaws or any similar instrument of such Party, as applicable, in any material way, and (ii) do not conflict with, violate, or breach or constitute a default or require any consent not already obtained under, any Contract or court or administrative order by which such Party is bound.

3.2Notices. All notices and other communications to Regulus under Section 13.5 of the Agreement shall be addressed as follows:

Regulus Therapeutics Inc.

10628 Science Center Drive, Suite 225

San Diego, California 92121

USA

Attention: Chief Scientific Officer

Facsimile: +1 (858) 202-6363

With a copy to:

Attention: General Counsel

Facsimile: +1 (858) 202-6363

or to such other address as Regulus may have furnished to Sanofi in writing in accordance with Section 13.5 of the Agreement.

    3.

3.3Counterparts. This Second Amendment may be executed in two or more counterparts, each of which will be deemed an original, and all of which together will constitute one and the same instrument.

[Signature page follows.]

    4.

IN WITNESS WHEREOF, the Parties hereto have caused this Second Amendment to be executed by their duly authorized representatives as of the Second Amendment Date.

REGULUS THERAPEUTICS INC.	SANOFI
By: /s/ Joseph Hagan	By: /s/ Alban de la Sablière
Name: Joseph Hagan	Name: Alban de la Sablière
Title: President & CEO	Title: Head of Sanofi Partnering
Aug. 24, 2020	Aug. 25, 2020

    5.

SCHEDULES

Amended Schedule 5.5 Additional Mir-21 Fibrosis POC Program-Specific Materials

Amended Schedule 5.5

Additional Mir 21 Fibrosis POC Program-Specific Materials

	Quantity	Value	Comments
[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]
[***]	[***]	[***]	[***]

*To be accepted by Sanofi “as is”

[***] = Certain Confidential Information Omitted

EX-10.2

Exhibit 10.2 TENTH AMENDMENT TO THE LOAN AND SECURITY AGREEMENT THIS TENTH AMENDMENT TO THE LOAN AND SECURITY AGREEMENT (this “Amendment”) is made effective as of August 25, 2020 (the “Amendment Date”) by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and REGULUS THERAPEUTICS INC., a Delaware corporation with offices located at 10628 Science Center Dr., Suite 225, San Diego, California 92121 (“Borrower”). WHEREAS, Collateral Agent, Borrower and Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of June 17, 2016 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein. NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows: 1. Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement. 2. Section 13.1 of the Loan Agreement is hereby further amended by amending and restating the following definitions therein as follows: “Second Amortization Date” means (i) May 1, 2021, if the Principal Paydown Event does not occur and (ii) January 1, 2022, if the Principal Paydown Event occurs. “Minimum Cash Balance” is (i) Five Million Dollars ($5,000,000.00) if Borrower has not as yet made the full Sanofi License Payment related to the License Amendment Payments (described in the clause (ii) of the definition of License Amendment Payments), regardless of whether or not such Sanofi License Payment had become due, and (ii) Three Million Dollars ($3,000,000.00) if Borrower has made the full Sanofi License Payment related to the License Amendment Payments (described in the clause (ii) of the definition of License Amendment Payments). “Principal Paydown Event” means the prepayment by Borrower to the Lenders, after July [_], 2020 and on or before April 30, 2021, of an aggregate principal amount of at least Ten Million Dollars ($10,000,000) in the form of Sanofi License Prepayments in accordance with Section 2.2(d)(iii) of this Agreement. 3. The Amortization Table attached to the Disbursement Letter dated as of the Effective Date is amended and restated as set forth on the Amortization Table attached as Exhibit A hereto effective upon the occurrence of the Principal Paydown Event. 4. Notwithstanding Section 6 of the Eighth Amendment or any other provision of any Loan Document to the contrary, Collateral Agent’s Lien on Intellectual Property of Borrower shall continue regardless of whether or not Borrower’s payment in full of Sanofi License Payment related to the License Amendment Payments (described in the clause (ii) of the definition of License Amendment Payments) has been made and neither Collateral Agent nor any Lender shall be required to take any steps, including, without limitation, entering into any amendments to any Loan Documents to limit or release such Lien and Borrower’s Intellectual ACTIVE 51650193v1 203242840 v2

Property shall continue to be part of Collateral. The parties hereby agree that Section 6 of the Eighth Amendment is hereby made null and void. “Eighth Amendment” is that certain Eighth Amendment to the Loan and Security Agreement, entered into by the Collateral Agent, Lenders and Borrower effective as of May 3, 2019. 5. Limitation of Amendment. a. The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby. b. This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 6. To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows: a. Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; b. Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; c. The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; d. The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower; e. The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; f. This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and 2 ACTIVE 51650193v1 203242840 v2

g. The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent (“Releasees”), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof. 7. Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. 8. Borrower agrees to promptly pay (but in no event in less than 5 Business Days of invoice date) all unpaid Lenders’ Expenses incurred through the date hereof, which may be debited (or ACH’d) from any of Borrower’s accounts. 9. This Amendment shall be deemed effective as of the Amendment Date upon the due execution and delivery to Collateral Agent of this Amendment by each party hereto. 10. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. 11. This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California. [Balance of Page Intentionally Left Blank – Signature Pages to Follow] 3 ACTIVE 51650193v1 203242840 v2

IN WITNESS WHEREOF, the parties hereto have caused this Tenth Amendment to Loan and Security Agreement to be executed as of the date first set forth above. BORROWER: REGULUS THERAPEUTICS INC. By /s/ Joseph Hagan Name: Joseph Hagan Title: CEO COLLATERAL AGENT AND LENDER: OXFORD FINANCE LLC By /s/ Colette H. Featherly Name: Colette H. Featherly Title: Senior Vice President ACTIVE 51650193v1 203242840 v2

EXHIBIT A Amortization Table Please see attached. ACTIVE 51650193v1

Oxford Finance LLC Amortization Table Regulus Total Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $1,007,809.27 5.50% 3rd Amendment Fee: $25,000.00 Fifth Amendment Fee: $25,000.00 Sixth Amendment Fee: $17,000.00 Seventh Amendment Fee: $15,000.00 Eighth Amendment Fee: $650,000.00 Second IO Extension Fee $115,000.00 Amount: 20,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $44,894.25 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $20,000,000.00 1 8/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 2 9/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 3 10/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 4 11/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 5 12/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 6 1/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 7 2/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 8 3/1/17 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 9 4/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 10 5/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 11 6/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 12 7/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 13 8/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 14 9/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 15 10/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 16 11/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 17 12/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 18 1/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 19 2/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 20 3/1/18 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 21 4/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 22 5/1/18 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 23 6/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 24 7/1/18 $20,000,000.00 $982,980.83 $149,647.50 $833,333.33 $19,166,666.67 25 8/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 26 9/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 27 10/1/18 $19,166,666.67 $143,412.19 $143,412.19 $0.00 $19,166,666.67 28 11/1/18 $19,166,666.67 $1,106,525.93 $148,192.59 $958,333.33 $18,208,333.33 29 12/1/18 $18,208,333.33 $1,686,680.17 $136,241.58 $1,550,438.60 $16,657,894.74 30 1/1/19 $16,657,894.74 $1,054,233.90 $128,795.30 $925,438.60 $15,732,456.14 31 2/1/19 $15,732,456.14 $121,640.01 $121,640.01 $0.00 $15,732,456.14 32 3/1/19 $15,732,456.14 $109,868.39 $109,868.39 $0.00 $15,732,456.14 33 4/1/19 $15,732,456.14 $560,335.01 $121,640.01 $438,695.00 $15,293,761.14 34 5/1/19 $15,293,761.14 $726,933.66 $114,433.66 $612,500.00 $14,681,261.14 35 6/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 36 7/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 37 8/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 38 9/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 39 10/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 40 11/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 41 12/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 42 1/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 43 2/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 44 3/1/20 $14,681,261.14 $106,189.01 $106,189.01 $0.00 $14,681,261.14 45 4/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 46 5/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 47 6/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 48 7/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 49 8/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 50 9/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 51 10/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 52 11/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 53 12/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 54 1/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 55 2/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 56 3/1/21 $14,681,261.14 $102,527.32 $102,527.32 $0.00 $14,681,261.14 57 4/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 58 5/1/21 $14,681,261.14 $1,239,178.48 $109,850.70 $1,129,327.78 $13,551,933.36 59 6/1/21 $13,551,933.36 $1,234,108.45 $104,780.67 $1,129,327.78 $12,422,605.58 60 7/1/21 $12,422,605.58 $1,222,278.37 $92,950.59 $1,129,327.78 $11,293,277.80 61 8/1/21 $11,293,277.80 $87,317.22 $87,317.22 $0.00 $11,293,277.80 62 9/1/21 $11,293,277.80 $87,317.22 $87,317.22 $0.00 $11,293,277.80 63 10/1/21 $11,293,277.80 $84,500.54 $84,500.54 $0.00 $11,293,277.80 64 11/1/21 $11,293,277.80 $87,317.22 $87,317.22 $0.00 $11,293,277.80 65 12/1/21 $11,293,277.80 $84,500.54 $84,500.54 $0.00 $11,293,277.80 66 1/1/22 $11,293,277.80 $2,345,972.78 $87,317.22 $2,258,655.56 $9,034,622.24 67 2/1/22 $9,034,622.24 $2,328,509.34 $69,853.78 $2,258,655.56 $6,775,966.68 68 3/1/22 $6,775,966.68 $2,305,975.86 $47,320.30 $2,258,655.56 $4,517,311.12 69 4/1/22 $4,517,311.12 $2,293,582.45 $34,926.89 $2,258,655.56 $2,258,655.56 70 5/1/22 $2,258,655.56 $2,275,555.67 $16,900.11 $2,258,655.56 $0.00 Final 5/1/22 Final Payment $1,854,809.27 $1,854,809.27 $0.00 Totals $30,378,538.42 $10,378,538.42 $20,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 + 7.1.21 payments.xlsx Total 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01a OF ID: 216050 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $352,733.24 5.50% 3rd Amendment Fee: $8,750.00 Fifth Amendment Fee: $8,750.00 Sixth Amendment Fee: $5,950.00 Seventh Amendment Fee: $5,250.00 Eighth Amendment Fee $227,500.00 Second IO Extension Fee $40,250.00 Amount: 7,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $15,712.99 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $7,000,000.00 1 8/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 2 9/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 3 10/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 4 11/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 5 12/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 6 1/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 7 2/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 8 3/1/17 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 9 4/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 10 5/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 11 6/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 12 7/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 13 8/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 14 9/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 15 10/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 16 11/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 17 12/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 18 1/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 19 2/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 20 3/1/18 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 21 4/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 22 5/1/18 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 23 6/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 24 7/1/18 $7,000,000.00 $344,043.29 $52,376.63 $291,666.67 $6,708,333.33 25 8/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 26 9/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 27 10/1/18 $6,708,333.33 $50,194.27 $50,194.27 $0.00 $6,708,333.33 28 11/1/18 $6,708,333.33 $387,284.07 $51,867.41 $335,416.67 $6,372,916.67 29 12/1/18 $6,372,916.67 $590,338.06 $47,684.55 $542,653.51 $5,830,263.16 30 1/1/19 $5,830,263.16 $368,981.86 $45,078.36 $323,903.51 $5,506,359.65 31 2/1/19 $5,506,359.65 $42,574.00 $42,574.00 $0.00 $5,506,359.65 32 3/1/19 $5,506,359.65 $38,453.94 $38,453.94 $0.00 $5,506,359.65 33 4/1/19 $5,506,359.65 $196,117.25 $42,574.00 $153,543.25 $5,352,816.40 34 5/1/19 $5,352,816.40 $254,426.78 $40,051.78 $214,375.00 $5,138,441.40 35 6/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 36 7/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 37 8/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 38 9/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 39 10/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 40 11/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 41 12/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 42 1/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 43 2/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 44 3/1/20 $5,138,441.40 $37,166.15 $37,166.15 $0.00 $5,138,441.40 45 4/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 46 5/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 47 6/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 48 7/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 49 8/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 50 9/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 51 10/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 52 11/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 53 12/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 54 1/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 55 2/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 56 3/1/21 $5,138,441.40 $35,884.56 $35,884.56 $0.00 $5,138,441.40 57 4/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 58 5/1/21 $5,138,441.40 $433,712.47 $38,447.75 $395,264.72 $4,743,176.68 59 6/1/21 $4,743,176.68 $431,937.96 $36,673.23 $395,264.72 $4,347,911.95 60 7/1/21 $4,347,911.95 $427,797.43 $32,532.71 $395,264.72 $3,952,647.23 61 8/1/21 $3,952,647.23 $30,561.03 $30,561.03 $0.00 $3,952,647.23 62 9/1/21 $3,952,647.23 $30,561.03 $30,561.03 $0.00 $3,952,647.23 63 10/1/21 $3,952,647.23 $29,575.19 $29,575.19 $0.00 $3,952,647.23 64 11/1/21 $3,952,647.23 $30,561.03 $30,561.03 $0.00 $3,952,647.23 65 12/1/21 $3,952,647.23 $29,575.19 $29,575.19 $0.00 $3,952,647.23 66 1/1/22 $3,952,647.23 $821,090.47 $30,561.03 $790,529.45 $3,162,117.78 67 2/1/22 $3,162,117.78 $814,978.27 $24,448.82 $790,529.45 $2,371,588.34 68 3/1/22 $2,371,588.34 $807,091.55 $16,562.11 $790,529.45 $1,581,058.89 69 4/1/22 $1,581,058.89 $802,753.86 $12,224.41 $790,529.45 $790,529.45 70 5/1/22 $790,529.45 $796,444.48 $5,915.04 $790,529.45 $0.00 Final 5/1/22 Final Payment $649,183.24 $649,183.24 $0.00 Totals $10,632,488.44 $3,632,488.44 $7,000,000.00 Copy of Regulus - Tab 1a PI 1.1.22 with 5.1.21 + 6.1.21 + 7.1.21 payments.xlsx AA01a 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01c OF ID: 216052 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amendment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $305,569.59 $23,237.65 $282,331.95 $2,823,319.45 61 8/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 62 9/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 63 10/1/21 $2,823,319.45 $21,125.13 $21,125.13 $0.00 $2,823,319.45 64 11/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 65 12/1/21 $2,823,319.45 $21,125.13 $21,125.13 $0.00 $2,823,319.45 66 1/1/22 $2,823,319.45 $586,493.20 $21,829.31 $564,663.89 $2,258,655.56 67 2/1/22 $2,258,655.56 $582,127.33 $17,463.44 $564,663.89 $1,693,991.67 68 3/1/22 $1,693,991.67 $576,493.97 $11,830.08 $564,663.89 $1,129,327.78 69 4/1/22 $1,129,327.78 $573,395.61 $8,731.72 $564,663.89 $564,663.89 70 5/1/22 $564,663.89 $568,888.92 $4,225.03 $564,663.89 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,594,634.60 $2,594,634.60 $5,000,000.00 Copy of Regulus - Tab 1a PI 1.1.22 with 5.1.21 + 6.1.21 + 7.1.21 payments.xlsx AA01c 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01b OF ID: 216051 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amedment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $305,569.59 $23,237.65 $282,331.95 $2,823,319.45 61 8/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 62 9/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 63 10/1/21 $2,823,319.45 $21,125.13 $21,125.13 $0.00 $2,823,319.45 64 11/1/21 $2,823,319.45 $21,829.31 $21,829.31 $0.00 $2,823,319.45 65 12/1/21 $2,823,319.45 $21,125.13 $21,125.13 $0.00 $2,823,319.45 66 1/1/22 $2,823,319.45 $586,493.20 $21,829.31 $564,663.89 $2,258,655.56 67 2/1/22 $2,258,655.56 $582,127.33 $17,463.44 $564,663.89 $1,693,991.67 68 3/1/22 $1,693,991.67 $576,493.97 $11,830.08 $564,663.89 $1,129,327.78 69 4/1/22 $1,129,327.78 $573,395.61 $8,731.72 $564,663.89 $564,663.89 70 5/1/22 $564,663.89 $568,888.92 $4,225.03 $564,663.89 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,594,634.60 $2,594,634.60 $5,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 + 7.1.21 payments.xlsx AA01b 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01d OF ID: 216053 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $151,171.39 5.50% 3rd Amendment Fee: $3,750.00 Fifth Amendment Fee: $3,750.00 Sixth Amendment Fee: $2,550.00 Seventh Amendment Fee: $2,250.00 Eighth Amendment Fee: $97,500.00 Second IO Extension Fee $17,250.00 Amount: 3,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $6,734.14 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $3,000,000.00 1 8/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 2 9/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 3 10/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 4 11/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 5 12/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 6 1/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 7 2/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 8 3/1/17 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 9 4/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 10 5/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 11 6/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 12 7/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 13 8/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 14 9/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 15 10/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 16 11/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 17 12/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 18 1/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 19 2/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 20 3/1/18 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 21 4/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 22 5/1/18 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 23 6/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 24 7/1/18 $3,000,000.00 $147,447.13 $22,447.13 $125,000.00 $2,875,000.00 25 8/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 26 9/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 27 10/1/18 $2,875,000.00 $21,511.83 $21,511.83 $0.00 $2,875,000.00 28 11/1/18 $2,875,000.00 $165,978.89 $22,228.89 $143,750.00 $2,731,250.00 29 12/1/18 $2,731,250.00 $253,002.03 $20,436.24 $232,565.79 $2,498,684.21 30 1/1/19 $2,498,684.21 $158,135.08 $19,319.30 $138,815.79 $2,359,868.42 31 2/1/19 $2,359,868.42 $18,246.00 $18,246.00 $0.00 $2,359,868.42 32 3/1/19 $2,359,868.42 $16,480.26 $16,480.26 $0.00 $2,359,868.42 33 4/1/19 $2,359,868.42 $84,050.25 $18,246.00 $65,804.25 $2,294,064.17 34 5/1/19 $2,294,064.17 $109,040.05 $17,165.05 $91,875.00 $2,202,189.17 35 6/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 36 7/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 37 8/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 38 9/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 39 10/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 40 11/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 41 12/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 42 1/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 43 2/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 44 3/1/20 $2,202,189.17 $15,928.35 $15,928.35 $0.00 $2,202,189.17 45 4/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 46 5/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 47 6/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 48 7/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 49 8/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 50 9/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 51 10/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 52 11/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 53 12/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 54 1/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 55 2/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 56 3/1/21 $2,202,189.17 $15,379.10 $15,379.10 $0.00 $2,202,189.17 57 4/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 58 5/1/21 $2,202,189.17 $185,876.77 $16,477.61 $169,399.17 $2,032,790.00 59 6/1/21 $2,032,790.00 $185,116.27 $15,717.10 $169,399.17 $1,863,390.84 60 7/1/21 $1,863,390.84 $183,341.76 $13,942.59 $169,399.17 $1,693,991.67 61 8/1/21 $1,693,991.67 $13,097.58 $13,097.58 $0.00 $1,693,991.67 62 9/1/21 $1,693,991.67 $13,097.58 $13,097.58 $0.00 $1,693,991.67 63 10/1/21 $1,693,991.67 $12,675.08 $12,675.08 $0.00 $1,693,991.67 64 11/1/21 $1,693,991.67 $13,097.58 $13,097.58 $0.00 $1,693,991.67 65 12/1/21 $1,693,991.67 $12,675.08 $12,675.08 $0.00 $1,693,991.67 66 1/1/22 $1,693,991.67 $351,895.92 $13,097.58 $338,798.33 $1,355,193.34 67 2/1/22 $1,355,193.34 $349,276.40 $10,478.07 $338,798.33 $1,016,395.00 68 3/1/22 $1,016,395.00 $345,896.38 $7,098.05 $338,798.33 $677,596.67 69 4/1/22 $677,596.67 $344,037.37 $5,239.03 $338,798.33 $338,798.33 70 5/1/22 $338,798.33 $341,333.35 $2,535.02 $338,798.33 $0.00 Final 5/1/22 Final Payment $278,221.39 $278,221.39 $0.00 Totals $4,556,780.76 $1,556,780.76 $3,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 + 7.1.21 payments.xlsx AA01d 8/26/2020

Oxford Finance LLC Amortization Table Regulus Total Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $1,007,809.27 5.50% 3rd Amendment Fee: $25,000.00 Fifth Amendment Fee: $25,000.00 Sixth Amendment Fee: $17,000.00 Seventh Amendment Fee: $15,000.00 Eighth Amendment Fee: $650,000.00 Second IO Extension Fee $115,000.00 Amount: 20,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $44,894.25 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $20,000,000.00 1 8/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 2 9/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 3 10/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 4 11/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 5 12/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 6 1/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 7 2/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 8 3/1/17 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 9 4/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 10 5/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 11 6/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 12 7/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 13 8/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 14 9/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 15 10/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 16 11/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 17 12/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 18 1/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 19 2/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 20 3/1/18 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 21 4/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 22 5/1/18 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 23 6/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 24 7/1/18 $20,000,000.00 $982,980.83 $149,647.50 $833,333.33 $19,166,666.67 25 8/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 26 9/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 27 10/1/18 $19,166,666.67 $143,412.19 $143,412.19 $0.00 $19,166,666.67 28 11/1/18 $19,166,666.67 $1,106,525.93 $148,192.59 $958,333.33 $18,208,333.33 29 12/1/18 $18,208,333.33 $1,686,680.17 $136,241.58 $1,550,438.60 $16,657,894.74 30 1/1/19 $16,657,894.74 $1,054,233.90 $128,795.30 $925,438.60 $15,732,456.14 31 2/1/19 $15,732,456.14 $121,640.01 $121,640.01 $0.00 $15,732,456.14 32 3/1/19 $15,732,456.14 $109,868.39 $109,868.39 $0.00 $15,732,456.14 33 4/1/19 $15,732,456.14 $560,335.01 $121,640.01 $438,695.00 $15,293,761.14 34 5/1/19 $15,293,761.14 $726,933.66 $114,433.66 $612,500.00 $14,681,261.14 35 6/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 36 7/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 37 8/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 38 9/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 39 10/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 40 11/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 41 12/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 42 1/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 43 2/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 44 3/1/20 $14,681,261.14 $106,189.01 $106,189.01 $0.00 $14,681,261.14 45 4/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 46 5/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 47 6/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 48 7/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 49 8/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 50 9/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 51 10/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 52 11/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 53 12/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 54 1/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 55 2/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 56 3/1/21 $14,681,261.14 $102,527.32 $102,527.32 $0.00 $14,681,261.14 57 4/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 58 5/1/21 $14,681,261.14 $1,239,178.48 $109,850.70 $1,129,327.78 $13,551,933.36 59 6/1/21 $13,551,933.36 $1,234,108.45 $104,780.67 $1,129,327.78 $12,422,605.58 60 7/1/21 $12,422,605.58 $92,950.59 $92,950.59 $0.00 $12,422,605.58 61 8/1/21 $12,422,605.58 $96,048.95 $96,048.95 $0.00 $12,422,605.58 62 9/1/21 $12,422,605.58 $96,048.95 $96,048.95 $0.00 $12,422,605.58 63 10/1/21 $12,422,605.58 $92,950.59 $92,950.59 $0.00 $12,422,605.58 64 11/1/21 $12,422,605.58 $96,048.95 $96,048.95 $0.00 $12,422,605.58 65 12/1/21 $12,422,605.58 $92,950.59 $92,950.59 $0.00 $12,422,605.58 66 1/1/22 $12,422,605.58 $2,580,570.06 $96,048.95 $2,484,521.12 $9,938,084.46 67 2/1/22 $9,938,084.46 $2,561,360.27 $76,839.16 $2,484,521.12 $7,453,563.35 68 3/1/22 $7,453,563.35 $2,536,573.45 $52,052.33 $2,484,521.12 $4,969,042.23 69 4/1/22 $4,969,042.23 $2,522,940.69 $38,419.58 $2,484,521.12 $2,484,521.12 70 5/1/22 $2,484,521.12 $2,503,111.23 $18,590.12 $2,484,521.12 $0.00 Final 5/1/22 Final Payment $1,854,809.27 $1,854,809.27 $0.00 Totals $30,447,265.53 $10,447,265.53 $20,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 payments.xlsx Total 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01a OF ID: 216050 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $352,733.24 5.50% 3rd Amendment Fee: $8,750.00 Fifth Amendment Fee: $8,750.00 Sixth Amendment Fee: $5,950.00 Seventh Amendment Fee: $5,250.00 Eighth Amendment Fee $227,500.00 Second IO Extension Fee $40,250.00 Amount: 7,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $15,712.99 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $7,000,000.00 1 8/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 2 9/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 3 10/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 4 11/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 5 12/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 6 1/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 7 2/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 8 3/1/17 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 9 4/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 10 5/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 11 6/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 12 7/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 13 8/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 14 9/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 15 10/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 16 11/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 17 12/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 18 1/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 19 2/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 20 3/1/18 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 21 4/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 22 5/1/18 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 23 6/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 24 7/1/18 $7,000,000.00 $344,043.29 $52,376.63 $291,666.67 $6,708,333.33 25 8/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 26 9/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 27 10/1/18 $6,708,333.33 $50,194.27 $50,194.27 $0.00 $6,708,333.33 28 11/1/18 $6,708,333.33 $387,284.07 $51,867.41 $335,416.67 $6,372,916.67 29 12/1/18 $6,372,916.67 $590,338.06 $47,684.55 $542,653.51 $5,830,263.16 30 1/1/19 $5,830,263.16 $368,981.86 $45,078.36 $323,903.51 $5,506,359.65 31 2/1/19 $5,506,359.65 $42,574.00 $42,574.00 $0.00 $5,506,359.65 32 3/1/19 $5,506,359.65 $38,453.94 $38,453.94 $0.00 $5,506,359.65 33 4/1/19 $5,506,359.65 $196,117.25 $42,574.00 $153,543.25 $5,352,816.40 34 5/1/19 $5,352,816.40 $254,426.78 $40,051.78 $214,375.00 $5,138,441.40 35 6/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 36 7/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 37 8/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 38 9/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 39 10/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 40 11/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 41 12/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 42 1/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 43 2/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 44 3/1/20 $5,138,441.40 $37,166.15 $37,166.15 $0.00 $5,138,441.40 45 4/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 46 5/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 47 6/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 48 7/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 49 8/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 50 9/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 51 10/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 52 11/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 53 12/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 54 1/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 55 2/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 56 3/1/21 $5,138,441.40 $35,884.56 $35,884.56 $0.00 $5,138,441.40 57 4/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 58 5/1/21 $5,138,441.40 $433,712.47 $38,447.75 $395,264.72 $4,743,176.68 59 6/1/21 $4,743,176.68 $431,937.96 $36,673.23 $395,264.72 $4,347,911.95 60 7/1/21 $4,347,911.95 $32,532.71 $32,532.71 $0.00 $4,347,911.95 61 8/1/21 $4,347,911.95 $33,617.13 $33,617.13 $0.00 $4,347,911.95 62 9/1/21 $4,347,911.95 $33,617.13 $33,617.13 $0.00 $4,347,911.95 63 10/1/21 $4,347,911.95 $32,532.71 $32,532.71 $0.00 $4,347,911.95 64 11/1/21 $4,347,911.95 $33,617.13 $33,617.13 $0.00 $4,347,911.95 65 12/1/21 $4,347,911.95 $32,532.71 $32,532.71 $0.00 $4,347,911.95 66 1/1/22 $4,347,911.95 $903,199.52 $33,617.13 $869,582.39 $3,478,329.56 67 2/1/22 $3,478,329.56 $896,476.10 $26,893.71 $869,582.39 $2,608,747.17 68 3/1/22 $2,608,747.17 $887,800.71 $18,218.32 $869,582.39 $1,739,164.78 69 4/1/22 $1,739,164.78 $883,029.24 $13,446.85 $869,582.39 $869,582.39 70 5/1/22 $869,582.39 $876,088.93 $6,506.54 $869,582.39 $0.00 Final 5/1/22 Final Payment $649,183.24 $649,183.24 $0.00 Totals $10,656,542.93 $3,656,542.93 $7,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 payments.xlsx AA01a 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01b OF ID: 216051 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amedment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 61 8/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 62 9/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 63 10/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 64 11/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 65 12/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 66 1/1/22 $3,105,651.40 $645,142.52 $24,012.24 $621,130.28 $2,484,521.12 67 2/1/22 $2,484,521.12 $640,340.07 $19,209.79 $621,130.28 $1,863,390.84 68 3/1/22 $1,863,390.84 $634,143.36 $13,013.08 $621,130.28 $1,242,260.56 69 4/1/22 $1,242,260.56 $630,735.17 $9,604.89 $621,130.28 $621,130.28 70 5/1/22 $621,130.28 $625,777.81 $4,647.53 $621,130.28 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,611,816.37 $2,611,816.37 $5,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 payments.xlsx AA01b 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01c OF ID: 216052 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amendment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 61 8/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 62 9/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 63 10/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 64 11/1/21 $3,105,651.40 $24,012.24 $24,012.24 $0.00 $3,105,651.40 65 12/1/21 $3,105,651.40 $23,237.65 $23,237.65 $0.00 $3,105,651.40 66 1/1/22 $3,105,651.40 $645,142.52 $24,012.24 $621,130.28 $2,484,521.12 67 2/1/22 $2,484,521.12 $640,340.07 $19,209.79 $621,130.28 $1,863,390.84 68 3/1/22 $1,863,390.84 $634,143.36 $13,013.08 $621,130.28 $1,242,260.56 69 4/1/22 $1,242,260.56 $630,735.17 $9,604.89 $621,130.28 $621,130.28 70 5/1/22 $621,130.28 $625,777.81 $4,647.53 $621,130.28 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,611,816.37 $2,611,816.37 $5,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 payments.xlsx AA01c 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01d OF ID: 216053 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $151,171.39 5.50% 3rd Amendment Fee: $3,750.00 Fifth Amendment Fee: $3,750.00 Sixth Amendment Fee: $2,550.00 Seventh Amendment Fee: $2,250.00 Eighth Amendment Fee: $97,500.00 Second IO Extension Fee $17,250.00 Amount: 3,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $6,734.14 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $3,000,000.00 1 8/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 2 9/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 3 10/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 4 11/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 5 12/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 6 1/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 7 2/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 8 3/1/17 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 9 4/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 10 5/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 11 6/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 12 7/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 13 8/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 14 9/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 15 10/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 16 11/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 17 12/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 18 1/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 19 2/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 20 3/1/18 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 21 4/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 22 5/1/18 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 23 6/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 24 7/1/18 $3,000,000.00 $147,447.13 $22,447.13 $125,000.00 $2,875,000.00 25 8/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 26 9/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 27 10/1/18 $2,875,000.00 $21,511.83 $21,511.83 $0.00 $2,875,000.00 28 11/1/18 $2,875,000.00 $165,978.89 $22,228.89 $143,750.00 $2,731,250.00 29 12/1/18 $2,731,250.00 $253,002.03 $20,436.24 $232,565.79 $2,498,684.21 30 1/1/19 $2,498,684.21 $158,135.08 $19,319.30 $138,815.79 $2,359,868.42 31 2/1/19 $2,359,868.42 $18,246.00 $18,246.00 $0.00 $2,359,868.42 32 3/1/19 $2,359,868.42 $16,480.26 $16,480.26 $0.00 $2,359,868.42 33 4/1/19 $2,359,868.42 $84,050.25 $18,246.00 $65,804.25 $2,294,064.17 34 5/1/19 $2,294,064.17 $109,040.05 $17,165.05 $91,875.00 $2,202,189.17 35 6/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 36 7/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 37 8/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 38 9/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 39 10/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 40 11/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 41 12/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 42 1/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 43 2/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 44 3/1/20 $2,202,189.17 $15,928.35 $15,928.35 $0.00 $2,202,189.17 45 4/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 46 5/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 47 6/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 48 7/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 49 8/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 50 9/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 51 10/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 52 11/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 53 12/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 54 1/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 55 2/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 56 3/1/21 $2,202,189.17 $15,379.10 $15,379.10 $0.00 $2,202,189.17 57 4/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 58 5/1/21 $2,202,189.17 $185,876.77 $16,477.61 $169,399.17 $2,032,790.00 59 6/1/21 $2,032,790.00 $185,116.27 $15,717.10 $169,399.17 $1,863,390.84 60 7/1/21 $1,863,390.84 $13,942.59 $13,942.59 $0.00 $1,863,390.84 61 8/1/21 $1,863,390.84 $14,407.34 $14,407.34 $0.00 $1,863,390.84 62 9/1/21 $1,863,390.84 $14,407.34 $14,407.34 $0.00 $1,863,390.84 63 10/1/21 $1,863,390.84 $13,942.59 $13,942.59 $0.00 $1,863,390.84 64 11/1/21 $1,863,390.84 $14,407.34 $14,407.34 $0.00 $1,863,390.84 65 12/1/21 $1,863,390.84 $13,942.59 $13,942.59 $0.00 $1,863,390.84 66 1/1/22 $1,863,390.84 $387,085.51 $14,407.34 $372,678.17 $1,490,712.67 67 2/1/22 $1,490,712.67 $384,204.04 $11,525.87 $372,678.17 $1,118,034.50 68 3/1/22 $1,118,034.50 $380,486.02 $7,807.85 $372,678.17 $745,356.33 69 4/1/22 $745,356.33 $378,441.10 $5,762.94 $372,678.17 $372,678.17 70 5/1/22 $372,678.17 $375,466.69 $2,788.52 $372,678.17 $0.00 Final 5/1/22 Final Payment $278,221.39 $278,221.39 $0.00 Totals $4,567,089.83 $1,567,089.83 $3,000,000.00 Regulus - PI 1.1.22 with 5.1.21 + 6.1.21 payments.xlsx AA01d 8/26/2020

Oxford Finance LLC Amortization Table Regulus Total Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $1,007,809.27 5.50% 3rd Amendment Fee: $25,000.00 Fifth Amendment Fee: $25,000.00 Sixth Amendment Fee: $17,000.00 Seventh Amendment Fee: $15,000.00 Eighth Amendment Fee: $650,000.00 Second IO Extension Fee $115,000.00 Amount: 20,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $44,894.25 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $20,000,000.00 1 8/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 2 9/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 3 10/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 4 11/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 5 12/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 6 1/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 7 2/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 8 3/1/17 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 9 4/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 10 5/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 11 6/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 12 7/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 13 8/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 14 9/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 15 10/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 16 11/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 17 12/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 18 1/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 19 2/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 20 3/1/18 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 21 4/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 22 5/1/18 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 23 6/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 24 7/1/18 $20,000,000.00 $982,980.83 $149,647.50 $833,333.33 $19,166,666.67 25 8/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 26 9/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 27 10/1/18 $19,166,666.67 $143,412.19 $143,412.19 $0.00 $19,166,666.67 28 11/1/18 $19,166,666.67 $1,106,525.93 $148,192.59 $958,333.33 $18,208,333.33 29 12/1/18 $18,208,333.33 $1,686,680.17 $136,241.58 $1,550,438.60 $16,657,894.74 30 1/1/19 $16,657,894.74 $1,054,233.90 $128,795.30 $925,438.60 $15,732,456.14 31 2/1/19 $15,732,456.14 $121,640.01 $121,640.01 $0.00 $15,732,456.14 32 3/1/19 $15,732,456.14 $109,868.39 $109,868.39 $0.00 $15,732,456.14 33 4/1/19 $15,732,456.14 $560,335.01 $121,640.01 $438,695.00 $15,293,761.14 34 5/1/19 $15,293,761.14 $726,933.66 $114,433.66 $612,500.00 $14,681,261.14 35 6/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 36 7/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 37 8/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 38 9/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 39 10/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 40 11/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 41 12/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 42 1/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 43 2/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 44 3/1/20 $14,681,261.14 $106,189.01 $106,189.01 $0.00 $14,681,261.14 45 4/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 46 5/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 47 6/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 48 7/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 49 8/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 50 9/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 51 10/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 52 11/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 53 12/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 54 1/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 55 2/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 56 3/1/21 $14,681,261.14 $102,527.32 $102,527.32 $0.00 $14,681,261.14 57 4/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 58 5/1/21 $14,681,261.14 $1,239,178.48 $109,850.70 $1,129,327.78 $13,551,933.36 59 6/1/21 $13,551,933.36 $104,780.67 $104,780.67 $0.00 $13,551,933.36 60 7/1/21 $13,551,933.36 $101,400.65 $101,400.65 $0.00 $13,551,933.36 61 8/1/21 $13,551,933.36 $104,780.67 $104,780.67 $0.00 $13,551,933.36 62 9/1/21 $13,551,933.36 $104,780.67 $104,780.67 $0.00 $13,551,933.36 63 10/1/21 $13,551,933.36 $101,400.65 $101,400.65 $0.00 $13,551,933.36 64 11/1/21 $13,551,933.36 $104,780.67 $104,780.67 $0.00 $13,551,933.36 65 12/1/21 $13,551,933.36 $101,400.65 $101,400.65 $0.00 $13,551,933.36 66 1/1/22 $13,551,933.36 $2,815,167.34 $104,780.67 $2,710,386.67 $10,841,546.69 67 2/1/22 $10,841,546.69 $2,794,211.21 $83,824.54 $2,710,386.67 $8,131,160.02 68 3/1/22 $8,131,160.02 $2,767,171.03 $56,784.36 $2,710,386.67 $5,420,773.34 69 4/1/22 $5,420,773.34 $2,752,298.94 $41,912.27 $2,710,386.67 $2,710,386.67 70 5/1/22 $2,710,386.67 $2,730,666.80 $20,280.13 $2,710,386.67 $0.00 Final 5/1/22 Final Payment $1,854,809.27 $1,854,809.27 $0.00 Totals $30,524,442.69 $10,524,442.69 $20,000,000.00 Regulus - PI 1.1.22 with 5.1.21 payment.xlsx Total 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01a OF ID: 216050 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $352,733.24 5.50% 3rd Amendment Fee: $8,750.00 Fifth Amendment Fee: $8,750.00 Sixth Amendment Fee: $5,950.00 Seventh Amendment Fee: $5,250.00 Eighth Amendment Fee $227,500.00 Second IO Extension Fee $40,250.00 Amount: 7,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $15,712.99 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $7,000,000.00 1 8/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 2 9/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 3 10/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 4 11/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 5 12/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 6 1/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 7 2/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 8 3/1/17 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 9 4/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 10 5/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 11 6/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 12 7/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 13 8/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 14 9/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 15 10/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 16 11/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 17 12/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 18 1/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 19 2/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 20 3/1/18 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 21 4/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 22 5/1/18 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 23 6/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 24 7/1/18 $7,000,000.00 $344,043.29 $52,376.63 $291,666.67 $6,708,333.33 25 8/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 26 9/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 27 10/1/18 $6,708,333.33 $50,194.27 $50,194.27 $0.00 $6,708,333.33 28 11/1/18 $6,708,333.33 $387,284.07 $51,867.41 $335,416.67 $6,372,916.67 29 12/1/18 $6,372,916.67 $590,338.06 $47,684.55 $542,653.51 $5,830,263.16 30 1/1/19 $5,830,263.16 $368,981.86 $45,078.36 $323,903.51 $5,506,359.65 31 2/1/19 $5,506,359.65 $42,574.00 $42,574.00 $0.00 $5,506,359.65 32 3/1/19 $5,506,359.65 $38,453.94 $38,453.94 $0.00 $5,506,359.65 33 4/1/19 $5,506,359.65 $196,117.25 $42,574.00 $153,543.25 $5,352,816.40 34 5/1/19 $5,352,816.40 $254,426.78 $40,051.78 $214,375.00 $5,138,441.40 35 6/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 36 7/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 37 8/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 38 9/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 39 10/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 40 11/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 41 12/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 42 1/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 43 2/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 44 3/1/20 $5,138,441.40 $37,166.15 $37,166.15 $0.00 $5,138,441.40 45 4/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 46 5/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 47 6/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 48 7/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 49 8/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 50 9/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 51 10/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 52 11/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 53 12/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 54 1/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 55 2/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 56 3/1/21 $5,138,441.40 $35,884.56 $35,884.56 $0.00 $5,138,441.40 57 4/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 58 5/1/21 $5,138,441.40 $433,712.47 $38,447.75 $395,264.72 $4,743,176.68 59 6/1/21 $4,743,176.68 $36,673.23 $36,673.23 $0.00 $4,743,176.68 60 7/1/21 $4,743,176.68 $35,490.23 $35,490.23 $0.00 $4,743,176.68 61 8/1/21 $4,743,176.68 $36,673.23 $36,673.23 $0.00 $4,743,176.68 62 9/1/21 $4,743,176.68 $36,673.23 $36,673.23 $0.00 $4,743,176.68 63 10/1/21 $4,743,176.68 $35,490.23 $35,490.23 $0.00 $4,743,176.68 64 11/1/21 $4,743,176.68 $36,673.23 $36,673.23 $0.00 $4,743,176.68 65 12/1/21 $4,743,176.68 $35,490.23 $35,490.23 $0.00 $4,743,176.68 66 1/1/22 $4,743,176.68 $985,308.57 $36,673.23 $948,635.34 $3,794,541.34 67 2/1/22 $3,794,541.34 $977,973.92 $29,338.59 $948,635.34 $2,845,906.01 68 3/1/22 $2,845,906.01 $968,509.86 $19,874.53 $948,635.34 $1,897,270.67 69 4/1/22 $1,897,270.67 $963,304.63 $14,669.29 $948,635.34 $948,635.34 70 5/1/22 $948,635.34 $955,733.38 $7,098.05 $948,635.34 $0.00 Final 5/1/22 Final Payment $649,183.24 $649,183.24 $0.00 Totals $10,683,554.94 $3,683,554.94 $7,000,000.00 Regulus - PI 1.1.22 with 5.1.21 payment.xlsx AA01a 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01b OF ID: 216051 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amedment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 60 7/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 61 8/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 62 9/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 63 10/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 64 11/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 65 12/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 66 1/1/22 $3,387,983.34 $703,791.84 $26,195.17 $677,596.67 $2,710,386.67 67 2/1/22 $2,710,386.67 $698,552.80 $20,956.13 $677,596.67 $2,032,790.00 68 3/1/22 $2,032,790.00 $691,792.76 $14,196.09 $677,596.67 $1,355,193.34 69 4/1/22 $1,355,193.34 $688,074.73 $10,478.07 $677,596.67 $677,596.67 70 5/1/22 $677,596.67 $682,666.70 $5,070.03 $677,596.67 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,631,110.66 $2,631,110.66 $5,000,000.00 Regulus - PI 1.1.22 with 5.1.21 payment.xlsx AA01b 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01c OF ID: 216052 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amendment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 60 7/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 61 8/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 62 9/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 63 10/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 64 11/1/21 $3,387,983.34 $26,195.17 $26,195.17 $0.00 $3,387,983.34 65 12/1/21 $3,387,983.34 $25,350.16 $25,350.16 $0.00 $3,387,983.34 66 1/1/22 $3,387,983.34 $703,791.84 $26,195.17 $677,596.67 $2,710,386.67 67 2/1/22 $2,710,386.67 $698,552.80 $20,956.13 $677,596.67 $2,032,790.00 68 3/1/22 $2,032,790.00 $691,792.76 $14,196.09 $677,596.67 $1,355,193.34 69 4/1/22 $1,355,193.34 $688,074.73 $10,478.07 $677,596.67 $677,596.67 70 5/1/22 $677,596.67 $682,666.70 $5,070.03 $677,596.67 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,631,110.66 $2,631,110.66 $5,000,000.00 Regulus - PI 1.1.22 with 5.1.21 payment.xlsx AA01c 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01d OF ID: 216053 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $151,171.39 5.50% 3rd Amendment Fee: $3,750.00 Fifth Amendment Fee: $3,750.00 Sixth Amendment Fee: $2,550.00 Seventh Amendment Fee: $2,250.00 Eighth Amendment Fee: $97,500.00 Second IO Extension Fee $17,250.00 Amount: 3,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $6,734.14 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $3,000,000.00 1 8/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 2 9/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 3 10/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 4 11/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 5 12/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 6 1/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 7 2/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 8 3/1/17 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 9 4/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 10 5/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 11 6/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 12 7/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 13 8/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 14 9/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 15 10/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 16 11/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 17 12/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 18 1/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 19 2/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 20 3/1/18 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 21 4/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 22 5/1/18 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 23 6/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 24 7/1/18 $3,000,000.00 $147,447.13 $22,447.13 $125,000.00 $2,875,000.00 25 8/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 26 9/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 27 10/1/18 $2,875,000.00 $21,511.83 $21,511.83 $0.00 $2,875,000.00 28 11/1/18 $2,875,000.00 $165,978.89 $22,228.89 $143,750.00 $2,731,250.00 29 12/1/18 $2,731,250.00 $253,002.03 $20,436.24 $232,565.79 $2,498,684.21 30 1/1/19 $2,498,684.21 $158,135.08 $19,319.30 $138,815.79 $2,359,868.42 31 2/1/19 $2,359,868.42 $18,246.00 $18,246.00 $0.00 $2,359,868.42 32 3/1/19 $2,359,868.42 $16,480.26 $16,480.26 $0.00 $2,359,868.42 33 4/1/19 $2,359,868.42 $84,050.25 $18,246.00 $65,804.25 $2,294,064.17 34 5/1/19 $2,294,064.17 $109,040.05 $17,165.05 $91,875.00 $2,202,189.17 35 6/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 36 7/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 37 8/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 38 9/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 39 10/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 40 11/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 41 12/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 42 1/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 43 2/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 44 3/1/20 $2,202,189.17 $15,928.35 $15,928.35 $0.00 $2,202,189.17 45 4/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 46 5/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 47 6/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 48 7/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 49 8/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 50 9/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 51 10/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 52 11/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 53 12/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 54 1/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 55 2/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 56 3/1/21 $2,202,189.17 $15,379.10 $15,379.10 $0.00 $2,202,189.17 57 4/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 58 5/1/21 $2,202,189.17 $185,876.77 $16,477.61 $169,399.17 $2,032,790.00 59 6/1/21 $2,032,790.00 $15,717.10 $15,717.10 $0.00 $2,032,790.00 60 7/1/21 $2,032,790.00 $15,210.10 $15,210.10 $0.00 $2,032,790.00 61 8/1/21 $2,032,790.00 $15,717.10 $15,717.10 $0.00 $2,032,790.00 62 9/1/21 $2,032,790.00 $15,717.10 $15,717.10 $0.00 $2,032,790.00 63 10/1/21 $2,032,790.00 $15,210.10 $15,210.10 $0.00 $2,032,790.00 64 11/1/21 $2,032,790.00 $15,717.10 $15,717.10 $0.00 $2,032,790.00 65 12/1/21 $2,032,790.00 $15,210.10 $15,210.10 $0.00 $2,032,790.00 66 1/1/22 $2,032,790.00 $422,275.10 $15,717.10 $406,558.00 $1,626,232.00 67 2/1/22 $1,626,232.00 $419,131.68 $12,573.68 $406,558.00 $1,219,674.00 68 3/1/22 $1,219,674.00 $415,075.66 $8,517.65 $406,558.00 $813,116.00 69 4/1/22 $813,116.00 $412,844.84 $6,286.84 $406,558.00 $406,558.00 70 5/1/22 $406,558.00 $409,600.02 $3,042.02 $406,558.00 $0.00 Final 5/1/22 Final Payment $278,221.39 $278,221.39 $0.00 Totals $4,578,666.40 $1,578,666.40 $3,000,000.00 Regulus - PI 1.1.22 with 5.1.21 payment.xlsx AA01d 8/26/2020

Oxford Finance LLC Amortization Table Regulus Total Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $1,007,809.27 5.50% 3rd Amendment Fee: $25,000.00 Fifth Amendment Fee: $25,000.00 Sixth Amendment Fee: $17,000.00 Seventh Amendment Fee: $15,000.00 Eighth Amendment Fee: $650,000.00 Second IO Extension Fee $115,000.00 Amount: 20,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $44,894.25 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $20,000,000.00 1 8/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 2 9/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 3 10/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 4 11/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 5 12/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 6 1/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 7 2/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 8 3/1/17 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 9 4/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 10 5/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 11 6/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 12 7/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 13 8/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 14 9/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 15 10/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 16 11/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 17 12/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 18 1/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 19 2/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 20 3/1/18 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 21 4/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 22 5/1/18 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 23 6/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 24 7/1/18 $20,000,000.00 $982,980.83 $149,647.50 $833,333.33 $19,166,666.67 25 8/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 26 9/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 27 10/1/18 $19,166,666.67 $143,412.19 $143,412.19 $0.00 $19,166,666.67 28 11/1/18 $19,166,666.67 $1,106,525.93 $148,192.59 $958,333.33 $18,208,333.33 29 12/1/18 $18,208,333.33 $1,686,680.17 $136,241.58 $1,550,438.60 $16,657,894.74 30 1/1/19 $16,657,894.74 $1,054,233.90 $128,795.30 $925,438.60 $15,732,456.14 31 2/1/19 $15,732,456.14 $121,640.01 $121,640.01 $0.00 $15,732,456.14 32 3/1/19 $15,732,456.14 $109,868.39 $109,868.39 $0.00 $15,732,456.14 33 4/1/19 $15,732,456.14 $560,335.01 $121,640.01 $438,695.00 $15,293,761.14 34 5/1/19 $15,293,761.14 $726,933.66 $114,433.66 $612,500.00 $14,681,261.14 35 6/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 36 7/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 37 8/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 38 9/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 39 10/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 40 11/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 41 12/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 42 1/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 43 2/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 44 3/1/20 $14,681,261.14 $106,189.01 $106,189.01 $0.00 $14,681,261.14 45 4/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 46 5/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 47 6/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 48 7/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 49 8/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 50 9/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 51 10/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 52 11/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 53 12/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 54 1/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 55 2/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 56 3/1/21 $14,681,261.14 $102,527.32 $102,527.32 $0.00 $14,681,261.14 57 4/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 58 5/1/21 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 59 6/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 60 7/1/21 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 61 8/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 62 9/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 63 10/1/21 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 64 11/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 65 12/1/21 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 66 1/1/22 $14,681,261.14 $3,049,764.62 $113,512.39 $2,936,252.23 $11,745,008.91 67 2/1/22 $11,745,008.91 $3,027,062.14 $90,809.91 $2,936,252.23 $8,808,756.68 68 3/1/22 $8,808,756.68 $2,997,768.62 $61,516.39 $2,936,252.23 $5,872,504.46 69 4/1/22 $5,872,504.46 $2,981,657.18 $45,404.96 $2,936,252.23 $2,936,252.23 70 5/1/22 $2,936,252.23 $2,958,222.37 $21,970.14 $2,936,252.23 $0.00 Final 5/1/22 Final Payment $1,854,809.27 $1,854,809.27 $0.00 Totals $30,610,351.57 $10,610,351.57 $20,000,000.00 Regulus - PI 1.1.22.xlsx Total 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01a OF ID: 216050 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $352,733.24 5.50% 3rd Amendment Fee: $8,750.00 Fifth Amendment Fee: $8,750.00 Sixth Amendment Fee: $5,950.00 Seventh Amendment Fee: $5,250.00 Eighth Amendment Fee $227,500.00 Second IO Extension Fee $40,250.00 Amount: 7,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $15,712.99 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $7,000,000.00 1 8/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 2 9/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 3 10/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 4 11/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 5 12/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 6 1/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 7 2/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 8 3/1/17 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 9 4/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 10 5/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 11 6/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 12 7/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 13 8/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 14 9/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 15 10/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 16 11/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 17 12/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 18 1/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 19 2/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 20 3/1/18 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 21 4/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 22 5/1/18 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 23 6/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 24 7/1/18 $7,000,000.00 $344,043.29 $52,376.63 $291,666.67 $6,708,333.33 25 8/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 26 9/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 27 10/1/18 $6,708,333.33 $50,194.27 $50,194.27 $0.00 $6,708,333.33 28 11/1/18 $6,708,333.33 $387,284.07 $51,867.41 $335,416.67 $6,372,916.67 29 12/1/18 $6,372,916.67 $590,338.06 $47,684.55 $542,653.51 $5,830,263.16 30 1/1/19 $5,830,263.16 $368,981.86 $45,078.36 $323,903.51 $5,506,359.65 31 2/1/19 $5,506,359.65 $42,574.00 $42,574.00 $0.00 $5,506,359.65 32 3/1/19 $5,506,359.65 $38,453.94 $38,453.94 $0.00 $5,506,359.65 33 4/1/19 $5,506,359.65 $196,117.25 $42,574.00 $153,543.25 $5,352,816.40 34 5/1/19 $5,352,816.40 $254,426.78 $40,051.78 $214,375.00 $5,138,441.40 35 6/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 36 7/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 37 8/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 38 9/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 39 10/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 40 11/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 41 12/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 42 1/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 43 2/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 44 3/1/20 $5,138,441.40 $37,166.15 $37,166.15 $0.00 $5,138,441.40 45 4/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 46 5/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 47 6/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 48 7/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 49 8/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 50 9/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 51 10/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 52 11/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 53 12/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 54 1/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 55 2/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 56 3/1/21 $5,138,441.40 $35,884.56 $35,884.56 $0.00 $5,138,441.40 57 4/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 58 5/1/21 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 59 6/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 60 7/1/21 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 61 8/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 62 9/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 63 10/1/21 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 64 11/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 65 12/1/21 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 66 1/1/22 $5,138,441.40 $1,067,417.62 $39,729.34 $1,027,688.28 $4,110,753.12 67 2/1/22 $4,110,753.12 $1,059,471.75 $31,783.47 $1,027,688.28 $3,083,064.84 68 3/1/22 $3,083,064.84 $1,049,219.02 $21,530.74 $1,027,688.28 $2,055,376.56 69 4/1/22 $2,055,376.56 $1,043,580.01 $15,891.73 $1,027,688.28 $1,027,688.28 70 5/1/22 $1,027,688.28 $1,035,377.83 $7,689.55 $1,027,688.28 $0.00 Final 5/1/22 Final Payment $649,183.24 $649,183.24 $0.00 Totals $10,713,623.05 $3,713,623.05 $7,000,000.00 Regulus - PI 1.1.22.xlsx AA01a 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01b OF ID: 216051 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amedment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 59 6/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 60 7/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 61 8/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 62 9/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 63 10/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 64 11/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 65 12/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 66 1/1/22 $3,670,315.29 $762,441.15 $28,378.10 $734,063.06 $2,936,252.23 67 2/1/22 $2,936,252.23 $756,765.54 $22,702.48 $734,063.06 $2,202,189.17 68 3/1/22 $2,202,189.17 $749,442.16 $15,379.10 $734,063.06 $1,468,126.11 69 4/1/22 $1,468,126.11 $745,414.30 $11,351.24 $734,063.06 $734,063.06 70 5/1/22 $734,063.06 $739,555.59 $5,492.54 $734,063.06 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,652,587.89 $2,652,587.89 $5,000,000.00 Regulus - PI 1.1.22.xlsx AA01b 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01c OF ID: 216052 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amendment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 59 6/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 60 7/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 61 8/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 62 9/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 63 10/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 64 11/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 65 12/1/21 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 66 1/1/22 $3,670,315.29 $762,441.15 $28,378.10 $734,063.06 $2,936,252.23 67 2/1/22 $2,936,252.23 $756,765.54 $22,702.48 $734,063.06 $2,202,189.17 68 3/1/22 $2,202,189.17 $749,442.16 $15,379.10 $734,063.06 $1,468,126.11 69 4/1/22 $1,468,126.11 $745,414.30 $11,351.24 $734,063.06 $734,063.06 70 5/1/22 $734,063.06 $739,555.59 $5,492.54 $734,063.06 $0.00 Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,652,587.89 $2,652,587.89 $5,000,000.00 Regulus - PI 1.1.22.xlsx AA01c 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01d OF ID: 216053 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $151,171.39 5.50% 3rd Amendment Fee: $3,750.00 Fifth Amendment Fee: $3,750.00 Sixth Amendment Fee: $2,550.00 Seventh Amendment Fee: $2,250.00 Eighth Amendment Fee: $97,500.00 Second IO Extension Fee $17,250.00 Amount: 3,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $6,734.14 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $3,000,000.00 1 8/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 2 9/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 3 10/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 4 11/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 5 12/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 6 1/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 7 2/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 8 3/1/17 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 9 4/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 10 5/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 11 6/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 12 7/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 13 8/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 14 9/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 15 10/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 16 11/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 17 12/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 18 1/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 19 2/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 20 3/1/18 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 21 4/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 22 5/1/18 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 23 6/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 24 7/1/18 $3,000,000.00 $147,447.13 $22,447.13 $125,000.00 $2,875,000.00 25 8/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 26 9/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 27 10/1/18 $2,875,000.00 $21,511.83 $21,511.83 $0.00 $2,875,000.00 28 11/1/18 $2,875,000.00 $165,978.89 $22,228.89 $143,750.00 $2,731,250.00 29 12/1/18 $2,731,250.00 $253,002.03 $20,436.24 $232,565.79 $2,498,684.21 30 1/1/19 $2,498,684.21 $158,135.08 $19,319.30 $138,815.79 $2,359,868.42 31 2/1/19 $2,359,868.42 $18,246.00 $18,246.00 $0.00 $2,359,868.42 32 3/1/19 $2,359,868.42 $16,480.26 $16,480.26 $0.00 $2,359,868.42 33 4/1/19 $2,359,868.42 $84,050.25 $18,246.00 $65,804.25 $2,294,064.17 34 5/1/19 $2,294,064.17 $109,040.05 $17,165.05 $91,875.00 $2,202,189.17 35 6/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 36 7/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 37 8/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 38 9/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 39 10/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 40 11/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 41 12/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 42 1/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 43 2/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 44 3/1/20 $2,202,189.17 $15,928.35 $15,928.35 $0.00 $2,202,189.17 45 4/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 46 5/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 47 6/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 48 7/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 49 8/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 50 9/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 51 10/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 52 11/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 53 12/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 54 1/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 55 2/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 56 3/1/21 $2,202,189.17 $15,379.10 $15,379.10 $0.00 $2,202,189.17 57 4/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 58 5/1/21 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 59 6/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 60 7/1/21 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 61 8/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 62 9/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 63 10/1/21 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 64 11/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 65 12/1/21 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 66 1/1/22 $2,202,189.17 $457,464.69 $17,026.86 $440,437.83 $1,761,751.34 67 2/1/22 $1,761,751.34 $454,059.32 $13,621.49 $440,437.83 $1,321,313.50 68 3/1/22 $1,321,313.50 $449,665.29 $9,227.46 $440,437.83 $880,875.67 69 4/1/22 $880,875.67 $447,248.58 $6,810.74 $440,437.83 $440,437.83 70 5/1/22 $440,437.83 $443,733.36 $3,295.52 $440,437.83 $0.00 Final 5/1/22 Final Payment $278,221.39 $278,221.39 $0.00 Totals $4,591,552.74 $1,591,552.74 $3,000,000.00 Regulus - PI 1.1.22.xlsx AA01d 8/26/2020

Oxford Finance LLC Amortization Table Regulus Total Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $1,007,809.27 5.50% 3rd Amendment Fee: $25,000.00 Fifth Amendment Fee: $25,000.00 Sixth Amendment Fee: $17,000.00 Seventh Amendment Fee: $15,000.00 Eighth Amendment Fee: $650,000.00 Second IO Extension Fee $115,000.00 Amount: 20,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $44,894.25 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $20,000,000.00 1 8/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 2 9/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 3 10/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 4 11/1/16 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 5 12/1/16 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 6 1/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 7 2/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 8 3/1/17 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 9 4/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 10 5/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 11 6/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 12 7/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 13 8/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 14 9/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 15 10/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 16 11/1/17 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 17 12/1/17 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 18 1/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 19 2/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 20 3/1/18 $20,000,000.00 $139,671.00 $139,671.00 $0.00 $20,000,000.00 21 4/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 22 5/1/18 $20,000,000.00 $149,647.50 $149,647.50 $0.00 $20,000,000.00 23 6/1/18 $20,000,000.00 $154,635.75 $154,635.75 $0.00 $20,000,000.00 24 7/1/18 $20,000,000.00 $982,980.83 $149,647.50 $833,333.33 $19,166,666.67 25 8/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 26 9/1/18 $19,166,666.67 $148,192.59 $148,192.59 $0.00 $19,166,666.67 27 10/1/18 $19,166,666.67 $143,412.19 $143,412.19 $0.00 $19,166,666.67 28 11/1/18 $19,166,666.67 $1,106,525.93 $148,192.59 $958,333.33 $18,208,333.33 29 12/1/18 $18,208,333.33 $1,686,680.17 $136,241.58 $1,550,438.60 $16,657,894.74 30 1/1/19 $16,657,894.74 $1,054,233.90 $128,795.30 $925,438.60 $15,732,456.14 31 2/1/19 $15,732,456.14 $121,640.01 $121,640.01 $0.00 $15,732,456.14 32 3/1/19 $15,732,456.14 $109,868.39 $109,868.39 $0.00 $15,732,456.14 33 4/1/19 $15,732,456.14 $560,335.01 $121,640.01 $438,695.00 $15,293,761.14 34 5/1/19 $15,293,761.14 $726,933.66 $114,433.66 $612,500.00 $14,681,261.14 35 6/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 36 7/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 37 8/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 38 9/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 39 10/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 40 11/1/19 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 41 12/1/19 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 42 1/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 43 2/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 44 3/1/20 $14,681,261.14 $106,189.01 $106,189.01 $0.00 $14,681,261.14 45 4/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 46 5/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 47 6/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 48 7/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 49 8/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 50 9/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 51 10/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 52 11/1/20 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 53 12/1/20 $14,681,261.14 $109,850.70 $109,850.70 $0.00 $14,681,261.14 54 1/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 55 2/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 56 3/1/21 $14,681,261.14 $102,527.32 $102,527.32 $0.00 $14,681,261.14 57 4/1/21 $14,681,261.14 $113,512.39 $113,512.39 $0.00 $14,681,261.14 58 5/1/21 $14,681,261.14 $1,239,178.48 $109,850.70 $1,129,327.78 $13,551,933.36 59 6/1/21 $13,551,933.36 $1,234,108.45 $104,780.67 $1,129,327.78 $12,422,605.58 60 7/1/21 $12,422,605.58 $1,222,278.37 $92,950.59 $1,129,327.78 $11,293,277.80 61 8/1/21 $11,293,277.80 $1,216,645.00 $87,317.22 $1,129,327.78 $10,163,950.02 62 9/1/21 $10,163,950.02 $1,207,913.28 $78,585.50 $1,129,327.78 $9,034,622.24 63 10/1/21 $9,034,622.24 $1,196,928.21 $67,600.43 $1,129,327.78 $7,905,294.46 64 11/1/21 $7,905,294.46 $1,190,449.84 $61,122.06 $1,129,327.78 $6,775,966.68 65 12/1/21 $6,775,966.68 $1,180,028.10 $50,700.32 $1,129,327.78 $5,646,638.90 66 1/1/22 $5,646,638.90 $1,172,986.39 $43,658.61 $1,129,327.78 $4,517,311.12 67 2/1/22 $4,517,311.12 $1,164,254.67 $34,926.89 $1,129,327.78 $3,387,983.34 68 3/1/22 $3,387,983.34 $1,152,987.93 $23,660.15 $1,129,327.78 $2,258,655.56 69 4/1/22 $2,258,655.56 $1,146,791.22 $17,463.44 $1,129,327.78 $1,129,327.78 70 5/1/22 $1,129,327.78 $1,137,777.83 $8,450.05 $1,129,327.78 ($0.00) Final 5/1/22 Final Payment $1,854,809.27 $1,854,809.27 $0.00 Totals $30,164,752.06 $10,164,752.06 $20,000,000.00 Regulus - PI 5.1.21.xlsx Total 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01a OF ID: 216050 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $352,733.24 5.50% 3rd Amendment Fee: $8,750.00 Fifth Amendment Fee: $8,750.00 Sixth Amendment Fee: $5,950.00 Seventh Amendment Fee: $5,250.00 Eighth Amendment Fee $227,500.00 Second IO Extension Fee $40,250.00 Amount: 7,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $15,712.99 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $7,000,000.00 1 8/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 2 9/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 3 10/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 4 11/1/16 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 5 12/1/16 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 6 1/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 7 2/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 8 3/1/17 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 9 4/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 10 5/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 11 6/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 12 7/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 13 8/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 14 9/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 15 10/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 16 11/1/17 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 17 12/1/17 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 18 1/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 19 2/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 20 3/1/18 $7,000,000.00 $48,884.85 $48,884.85 $0.00 $7,000,000.00 21 4/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 22 5/1/18 $7,000,000.00 $52,376.63 $52,376.63 $0.00 $7,000,000.00 23 6/1/18 $7,000,000.00 $54,122.51 $54,122.51 $0.00 $7,000,000.00 24 7/1/18 $7,000,000.00 $344,043.29 $52,376.63 $291,666.67 $6,708,333.33 25 8/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 26 9/1/18 $6,708,333.33 $51,867.41 $51,867.41 $0.00 $6,708,333.33 27 10/1/18 $6,708,333.33 $50,194.27 $50,194.27 $0.00 $6,708,333.33 28 11/1/18 $6,708,333.33 $387,284.07 $51,867.41 $335,416.67 $6,372,916.67 29 12/1/18 $6,372,916.67 $590,338.06 $47,684.55 $542,653.51 $5,830,263.16 30 1/1/19 $5,830,263.16 $368,981.86 $45,078.36 $323,903.51 $5,506,359.65 31 2/1/19 $5,506,359.65 $42,574.00 $42,574.00 $0.00 $5,506,359.65 32 3/1/19 $5,506,359.65 $38,453.94 $38,453.94 $0.00 $5,506,359.65 33 4/1/19 $5,506,359.65 $196,117.25 $42,574.00 $153,543.25 $5,352,816.40 34 5/1/19 $5,352,816.40 $254,426.78 $40,051.78 $214,375.00 $5,138,441.40 35 6/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 36 7/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 37 8/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 38 9/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 39 10/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 40 11/1/19 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 41 12/1/19 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 42 1/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 43 2/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 44 3/1/20 $5,138,441.40 $37,166.15 $37,166.15 $0.00 $5,138,441.40 45 4/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 46 5/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 47 6/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 48 7/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 49 8/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 50 9/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 51 10/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 52 11/1/20 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 53 12/1/20 $5,138,441.40 $38,447.75 $38,447.75 $0.00 $5,138,441.40 54 1/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 55 2/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 56 3/1/21 $5,138,441.40 $35,884.56 $35,884.56 $0.00 $5,138,441.40 57 4/1/21 $5,138,441.40 $39,729.34 $39,729.34 $0.00 $5,138,441.40 58 5/1/21 $5,138,441.40 $433,712.47 $38,447.75 $395,264.72 $4,743,176.68 59 6/1/21 $4,743,176.68 $431,937.96 $36,673.23 $395,264.72 $4,347,911.95 60 7/1/21 $4,347,911.95 $427,797.43 $32,532.71 $395,264.72 $3,952,647.23 61 8/1/21 $3,952,647.23 $425,825.75 $30,561.03 $395,264.72 $3,557,382.51 62 9/1/21 $3,557,382.51 $422,769.65 $27,504.93 $395,264.72 $3,162,117.78 63 10/1/21 $3,162,117.78 $418,924.87 $23,660.15 $395,264.72 $2,766,853.06 64 11/1/21 $2,766,853.06 $416,657.44 $21,392.72 $395,264.72 $2,371,588.34 65 12/1/21 $2,371,588.34 $413,009.84 $17,745.11 $395,264.72 $1,976,323.62 66 1/1/22 $1,976,323.62 $410,545.24 $15,280.51 $395,264.72 $1,581,058.89 67 2/1/22 $1,581,058.89 $407,489.13 $12,224.41 $395,264.72 $1,185,794.17 68 3/1/22 $1,185,794.17 $403,545.78 $8,281.05 $395,264.72 $790,529.45 69 4/1/22 $790,529.45 $401,376.93 $6,112.21 $395,264.72 $395,264.72 70 5/1/22 $395,264.72 $398,222.24 $2,957.52 $395,264.72 $0.00 Final 5/1/22 Final Payment $649,183.24 $649,183.24 $0.00 Totals $10,557,663.22 $3,557,663.22 $7,000,000.00 Regulus - PI 5.1.21.xlsx AA01a 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01b OF ID: 216051 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amedment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $305,569.59 $23,237.65 $282,331.95 $2,823,319.45 61 8/1/21 $2,823,319.45 $304,161.25 $21,829.31 $282,331.95 $2,540,987.51 62 9/1/21 $2,540,987.51 $301,978.32 $19,646.38 $282,331.95 $2,258,655.56 63 10/1/21 $2,258,655.56 $299,232.05 $16,900.11 $282,331.95 $1,976,323.62 64 11/1/21 $1,976,323.62 $297,612.46 $15,280.51 $282,331.95 $1,693,991.67 65 12/1/21 $1,693,991.67 $295,007.03 $12,675.08 $282,331.95 $1,411,659.73 66 1/1/22 $1,411,659.73 $293,246.60 $10,914.65 $282,331.95 $1,129,327.78 67 2/1/22 $1,129,327.78 $291,063.67 $8,731.72 $282,331.95 $846,995.84 68 3/1/22 $846,995.84 $288,246.98 $5,915.04 $282,331.95 $564,663.89 69 4/1/22 $564,663.89 $286,697.81 $4,365.86 $282,331.95 $282,331.95 70 5/1/22 $282,331.95 $284,444.46 $2,112.51 $282,331.95 ($0.00) Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,541,188.01 $2,541,188.01 $5,000,000.00 Regulus - PI 5.1.21.xlsx AA01b 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01c OF ID: 216052 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $251,952.31 5.50% 3rd Amendment Fee: $6,250.00 Fifth Amendment Fee: $6,250.00 Sixth Amendment Fee: $4,250.00 Seventh Amendment Fee: $3,750.00 Eighth Amendment Fee: $162,500.00 Second IO Extension Fee $28,750.00 Amount: 5,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $11,223.56 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $5,000,000.00 1 8/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 2 9/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 3 10/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 4 11/1/16 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 5 12/1/16 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 6 1/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 7 2/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 8 3/1/17 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 9 4/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 10 5/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 11 6/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 12 7/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 13 8/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 14 9/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 15 10/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 16 11/1/17 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 17 12/1/17 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 18 1/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 19 2/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 20 3/1/18 $5,000,000.00 $34,917.75 $34,917.75 $0.00 $5,000,000.00 21 4/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 22 5/1/18 $5,000,000.00 $37,411.88 $37,411.88 $0.00 $5,000,000.00 23 6/1/18 $5,000,000.00 $38,658.94 $38,658.94 $0.00 $5,000,000.00 24 7/1/18 $5,000,000.00 $245,745.21 $37,411.88 $208,333.33 $4,791,666.67 25 8/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 26 9/1/18 $4,791,666.67 $37,048.15 $37,048.15 $0.00 $4,791,666.67 27 10/1/18 $4,791,666.67 $35,853.05 $35,853.05 $0.00 $4,791,666.67 28 11/1/18 $4,791,666.67 $276,631.48 $37,048.15 $239,583.33 $4,552,083.33 29 12/1/18 $4,552,083.33 $421,670.04 $34,060.39 $387,609.65 $4,164,473.68 30 1/1/19 $4,164,473.68 $263,558.47 $32,198.83 $231,359.65 $3,933,114.04 31 2/1/19 $3,933,114.04 $30,410.00 $30,410.00 $0.00 $3,933,114.04 32 3/1/19 $3,933,114.04 $27,467.10 $27,467.10 $0.00 $3,933,114.04 33 4/1/19 $3,933,114.04 $140,083.75 $30,410.00 $109,673.75 $3,823,440.29 34 5/1/19 $3,823,440.29 $181,733.41 $28,608.41 $153,125.00 $3,670,315.29 35 6/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 36 7/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 37 8/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 38 9/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 39 10/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 40 11/1/19 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 41 12/1/19 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 42 1/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 43 2/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 44 3/1/20 $3,670,315.29 $26,547.25 $26,547.25 $0.00 $3,670,315.29 45 4/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 46 5/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 47 6/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 48 7/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 49 8/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 50 9/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 51 10/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 52 11/1/20 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 53 12/1/20 $3,670,315.29 $27,462.68 $27,462.68 $0.00 $3,670,315.29 54 1/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 55 2/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 56 3/1/21 $3,670,315.29 $25,631.83 $25,631.83 $0.00 $3,670,315.29 57 4/1/21 $3,670,315.29 $28,378.10 $28,378.10 $0.00 $3,670,315.29 58 5/1/21 $3,670,315.29 $309,794.62 $27,462.68 $282,331.95 $3,387,983.34 59 6/1/21 $3,387,983.34 $308,527.11 $26,195.17 $282,331.95 $3,105,651.40 60 7/1/21 $3,105,651.40 $305,569.59 $23,237.65 $282,331.95 $2,823,319.45 61 8/1/21 $2,823,319.45 $304,161.25 $21,829.31 $282,331.95 $2,540,987.51 62 9/1/21 $2,540,987.51 $301,978.32 $19,646.38 $282,331.95 $2,258,655.56 63 10/1/21 $2,258,655.56 $299,232.05 $16,900.11 $282,331.95 $1,976,323.62 64 11/1/21 $1,976,323.62 $297,612.46 $15,280.51 $282,331.95 $1,693,991.67 65 12/1/21 $1,693,991.67 $295,007.03 $12,675.08 $282,331.95 $1,411,659.73 66 1/1/22 $1,411,659.73 $293,246.60 $10,914.65 $282,331.95 $1,129,327.78 67 2/1/22 $1,129,327.78 $291,063.67 $8,731.72 $282,331.95 $846,995.84 68 3/1/22 $846,995.84 $288,246.98 $5,915.04 $282,331.95 $564,663.89 69 4/1/22 $564,663.89 $286,697.81 $4,365.86 $282,331.95 $282,331.95 70 5/1/22 $282,331.95 $284,444.46 $2,112.51 $282,331.95 ($0.00) Final 5/1/22 Final Payment $463,702.31 $463,702.31 $0.00 Totals $7,541,188.01 $2,541,188.01 $5,000,000.00 Regulus - PI 5.1.21.xlsx AA01c 8/26/2020

Oxford Finance LLC Amortization Table Regulus AA01d OF ID: 216053 Start Date: 6/22/2016 Disclaimer: Interest Rate: 8.97885% THIS IS A STANDARD AMORTIZATION Term: 47 23 IO + 24 PI SCHEDULE. IT IS NOT INTENDED TO BE Payment: Varies USED FOR PAYOFF PURPOSES. Final Payment: $151,171.39 5.50% 3rd Amendment Fee: $3,750.00 Fifth Amendment Fee: $3,750.00 Sixth Amendment Fee: $2,550.00 Seventh Amendment Fee: $2,250.00 Eighth Amendment Fee: $97,500.00 Second IO Extension Fee $17,250.00 Amount: 3,000,000.00 THIS AMORTIZATION SCHEDULE REPRESENTS A Interim Interest Days: 9 FLOATING INTEREST RATE LOAN. INTEREST RATE Interim Interest: $6,734.14 CHARGED MAY DIFFER FROM RATE PER THIS SCHEDULE BASED ON THE TERMS OF THE LOAN AGREEMENT PMT Payment Beginning Monthly Ending No. Date Balance Payment Interest Principal Balance 7/1/16 Interim Interest Due $3,000,000.00 1 8/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 2 9/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 3 10/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 4 11/1/16 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 5 12/1/16 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 6 1/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 7 2/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 8 3/1/17 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 9 4/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 10 5/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 11 6/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 12 7/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 13 8/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 14 9/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 15 10/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 16 11/1/17 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 17 12/1/17 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 18 1/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 19 2/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 20 3/1/18 $3,000,000.00 $20,950.65 $20,950.65 $0.00 $3,000,000.00 21 4/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 22 5/1/18 $3,000,000.00 $22,447.13 $22,447.13 $0.00 $3,000,000.00 23 6/1/18 $3,000,000.00 $23,195.36 $23,195.36 $0.00 $3,000,000.00 24 7/1/18 $3,000,000.00 $147,447.13 $22,447.13 $125,000.00 $2,875,000.00 25 8/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 26 9/1/18 $2,875,000.00 $22,228.89 $22,228.89 $0.00 $2,875,000.00 27 10/1/18 $2,875,000.00 $21,511.83 $21,511.83 $0.00 $2,875,000.00 28 11/1/18 $2,875,000.00 $165,978.89 $22,228.89 $143,750.00 $2,731,250.00 29 12/1/18 $2,731,250.00 $253,002.03 $20,436.24 $232,565.79 $2,498,684.21 30 1/1/19 $2,498,684.21 $158,135.08 $19,319.30 $138,815.79 $2,359,868.42 31 2/1/19 $2,359,868.42 $18,246.00 $18,246.00 $0.00 $2,359,868.42 32 3/1/19 $2,359,868.42 $16,480.26 $16,480.26 $0.00 $2,359,868.42 33 4/1/19 $2,359,868.42 $84,050.25 $18,246.00 $65,804.25 $2,294,064.17 34 5/1/19 $2,294,064.17 $109,040.05 $17,165.05 $91,875.00 $2,202,189.17 35 6/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 36 7/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 37 8/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 38 9/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 39 10/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 40 11/1/19 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 41 12/1/19 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 42 1/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 43 2/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 44 3/1/20 $2,202,189.17 $15,928.35 $15,928.35 $0.00 $2,202,189.17 45 4/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 46 5/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 47 6/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 48 7/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 49 8/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 50 9/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 51 10/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 52 11/1/20 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 53 12/1/20 $2,202,189.17 $16,477.61 $16,477.61 $0.00 $2,202,189.17 54 1/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 55 2/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 56 3/1/21 $2,202,189.17 $15,379.10 $15,379.10 $0.00 $2,202,189.17 57 4/1/21 $2,202,189.17 $17,026.86 $17,026.86 $0.00 $2,202,189.17 58 5/1/21 $2,202,189.17 $185,876.77 $16,477.61 $169,399.17 $2,032,790.00 59 6/1/21 $2,032,790.00 $185,116.27 $15,717.10 $169,399.17 $1,863,390.84 60 7/1/21 $1,863,390.84 $183,341.76 $13,942.59 $169,399.17 $1,693,991.67 61 8/1/21 $1,693,991.67 $182,496.75 $13,097.58 $169,399.17 $1,524,592.50 62 9/1/21 $1,524,592.50 $181,186.99 $11,787.83 $169,399.17 $1,355,193.34 63 10/1/21 $1,355,193.34 $179,539.23 $10,140.06 $169,399.17 $1,185,794.17 64 11/1/21 $1,185,794.17 $178,567.48 $9,168.31 $169,399.17 $1,016,395.00 65 12/1/21 $1,016,395.00 $177,004.22 $7,605.05 $169,399.17 $846,995.84 66 1/1/22 $846,995.84 $175,947.96 $6,548.79 $169,399.17 $677,596.67 67 2/1/22 $677,596.67 $174,638.20 $5,239.03 $169,399.17 $508,197.50 68 3/1/22 $508,197.50 $172,948.19 $3,549.02 $169,399.17 $338,798.33 69 4/1/22 $338,798.33 $172,018.68 $2,619.52 $169,399.17 $169,399.17 70 5/1/22 $169,399.17 $170,666.68 $1,267.51 $169,399.17 $0.00 Final 5/1/22 Final Payment $278,221.39 $278,221.39 $0.00 Totals $4,524,712.81 $1,524,712.81 $3,000,000.00 Regulus - PI 5.1.21.xlsx AA01d 8/26/2020

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph P. Hagan, certify that:

    1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.;

    2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:

        a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

        b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

        c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

        d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

    5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

        a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

        b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 5, 2020	/s/ Joseph P. Hagan
	Joseph P. Hagan
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Cris Calsada, certify that:

    1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.;

    2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:

        a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

        b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

        c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

        d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

    5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

        a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

        b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 5, 2020	/s/ Cris Calsada
	Cris Calsada
	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the quarterly report of Regulus Therapeutics Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph P. Hagan, President and Chief Executive Officer of the Company, and I, Cris Calsada, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

        (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

        (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 5, 2020	/s/ Joseph P. Hagan
	Joseph P. Hagan
	President and Chief Executive Officer
	(Principal Executive Officer)
November 5, 2020	/s/ Cris Calsada
	Cris Calsada
	Chief Financial Officer
	(Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

XML

Cover - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-35670
Entity Registrant Name	REGULUS THERAPEUTICS INC.
Entity Central Index Key	0001505512
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4738379
Entity Address, Address Line One	10628 Science Center Drive, Suite 225
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	202-6300
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	RGLS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,163,096

XML

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 17,843	$ 34,121
Contract and other receivables	4,000	1,141
Prepaid materials, net	3,388	3,924
Prepaid expenses and other current assets	1,076	1,221
Total current assets	26,307	40,407
Property and equipment, net	574	921
Intangibles, net	129	266
Other assets	333	487
Total assets	27,343	42,081
Current liabilities:
Accounts payable	1,102	1,321
Accrued liabilities	1,089	917
Accrued compensation	1,260	1,676
Current portion of term loan, less debt issuance costs	13,647	14,631
Current portion of contract liabilities	0	6
Other current liabilities	2,381	3,047
Total current liabilities	19,479	21,598
Other long-term liabilities	110	468
Total liabilities	19,589	22,066
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 39,163,096 and 21,018,663 shares issued and outstanding at September 30, 2020 (unaudited) and December 31, 2019, respectively	39	21
Additional paid-in capital	433,436	431,305
Accumulated deficit	(425,723)	(411,315)
Total stockholders’ equity	7,754	20,015
Total liabilities and stockholders’ equity	27,343	42,081
Class A-1 Convertible Preferred Stock
Stockholders’ equity:
Preferred stock	0	1
Class A-2 Convertible Preferred Stock
Stockholders’ equity:
Preferred stock	$ 2	$ 3

XML

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, shares authorized (in shares)	1,639,515
Preferred stock, shares issued (in shares)	1,639,515
Common stock par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (shares)	39,163,096	21,018,663
Common stock, shares outstanding (in shares)	39,163,096	21,018,663
Class A-1 Convertible Preferred Stock
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	256,700	415,898
Preferred stock, shares issued (in shares)	256,700	415,898
Preferred stock, shares outstanding (in shares)	256,700	415,898
Class A-2 Convertible Preferred Stock
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)		3,288,390
Preferred stock, shares issued (in shares)		3,288,390
Preferred stock, shares outstanding (in shares)	1,639,515	3,288,390

XML

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 5,000	$ 18	$ 5,006	$ 6,814
Operating expenses:
Research and development	4,036	2,440	11,396	10,259
General and administrative	2,059	2,571	6,736	8,954
Total operating expenses	6,095	5,011	18,132	19,213
Loss from operations	(1,095)	(4,993)	(13,126)	(12,399)
Other income (expense):
Interest and other income	38	87	127	332
Interest and other expense	(466)	(517)	(1,416)	(1,631)
Loss before income taxes	(1,523)	(5,423)	(14,415)	(13,698)
Income tax (expense) benefit	(1)	0	7	(1)
Net loss and comprehensive loss	$ (1,524)	$ (5,423)	$ (14,408)	$ (13,699)
Net loss per share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.26)	$ (0.47)	$ (0.86)
Weighted average shares used to compute basic and diluted net loss per share (in shares)	38,137,281	20,849,083	30,695,137	16,016,515
Revenue, Product and Service [Extensible List]			us-gaap:RevenueUnderCollaborationsMember

XML

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated deficit	Convertible preferred stock	ATM	ATM Common stock	ATM Additional paid-in capital	Preferred Stock and Warrants from Private Placement	Preferred Stock and Warrants from Private Placement Common stock	Preferred Stock and Warrants from Private Placement Additional paid-in capital
Beginning balance (in shares) at Dec. 31, 2018		8,818,019			0
Beginning balance at Dec. 31, 2018	$ (5,854)	$ 9	$ 386,860	$ (392,723)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		93,648
Issuance of new shares (in shares)							1,903,880
Issuance of new shares						$ 2,084	$ 2	$ 2,082
Issuance of common stock under Employee Stock Purchase Plan (in shares)		2,369
Issuance of common stock under Employee Stock Purchase Plan	2		2
Stock-based compensation expense	959		959
Net loss	(3,260)			(3,260)
Ending balance (in shares) at Mar. 31, 2019		10,817,916			0
Ending balance at Mar. 31, 2019	(6,069)	$ 11	389,903	(395,983)	$ 0
Beginning balance (in shares) at Dec. 31, 2018		8,818,019			0
Beginning balance at Dec. 31, 2018	(5,854)	$ 9	386,860	(392,723)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(13,699)
Ending balance (in shares) at Sep. 30, 2019		20,927,053			415,898
Ending balance at Sep. 30, 2019	(143)	$ 21	406,258	(406,422)	$ 0
Beginning balance (in shares) at Mar. 31, 2019		10,817,916			0
Beginning balance at Mar. 31, 2019	(6,069)	$ 11	389,903	(395,983)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		273,438
Issuance of common stock upon exercise of options (in shares)		2,500
Issuance of common stock upon exercise of stock options	2		2
Issuance of new shares (in shares)									415,898	9,730,534
Issuance of new shares									$ 15,505	$ 10	$ 15,495
Stock-based compensation expense	321		321
Net loss	(5,016)			(5,016)
Ending balance (in shares) at Jun. 30, 2019		20,824,388			415,898
Ending balance at Jun. 30, 2019	4,743	$ 21	405,721	(400,999)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		100,749
Issuance of common stock upon exercise of options (in shares)		250
Issuance of common stock under Employee Stock Purchase Plan (in shares)		1,666
Issuance of common stock under Employee Stock Purchase Plan	1		1
Stock-based compensation expense	536		536
Net loss	(5,423)			(5,423)
Ending balance (in shares) at Sep. 30, 2019		20,927,053			415,898
Ending balance at Sep. 30, 2019	(143)	$ 21	406,258	(406,422)	$ 0
Beginning balance (in shares) at Dec. 31, 2019		21,018,663			3,704,288
Beginning balance at Dec. 31, 2019	20,015	$ 21	431,305	(411,315)	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		21,166
Issuance of common stock upon exercise of options (in shares)		468
Issuance of common stock under Employee Stock Purchase Plan (in shares)		1,666
Issuance of common stock under Employee Stock Purchase Plan	1		1
Conversions of convertible preferred stock (in shares)		6,566,820			(656,682)
Conversions of convertible preferred stock		$ 7	(6)		$ (1)
Stock-based compensation expense	823		823
Net loss	(5,937)			(5,937)
Ending balance (in shares) at Mar. 31, 2020		27,608,783			3,047,606
Ending balance at Mar. 31, 2020	14,902	$ 28	432,123	(417,252)	$ 3
Beginning balance (in shares) at Dec. 31, 2019		21,018,663			3,704,288
Beginning balance at Dec. 31, 2019	20,015	$ 21	431,305	(411,315)	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(14,408)
Ending balance (in shares) at Sep. 30, 2020		39,163,096			1,896,215
Ending balance at Sep. 30, 2020	7,754	$ 39	433,436	(425,723)	$ 2
Beginning balance (in shares) at Mar. 31, 2020		27,608,783			3,047,606
Beginning balance at Mar. 31, 2020	14,902	$ 28	432,123	(417,252)	$ 3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		17,703
Conversions of convertible preferred stock (in shares)		8,296,430			(829,643)
Conversions of convertible preferred stock		$ 8	(7)		$ (1)
Stock-based compensation expense	629		629
Net loss	(6,947)			(6,947)
Ending balance (in shares) at Jun. 30, 2020		35,922,916			2,217,963
Ending balance at Jun. 30, 2020	8,584	$ 36	432,745	(424,199)	$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of restricted stock units (in shares)		19,368
Issuance of common stock under Employee Stock Purchase Plan (in shares)		3,332
Issuance of common stock under Employee Stock Purchase Plan	2		2
Conversions of convertible preferred stock (in shares)		3,217,480			(321,748)
Conversions of convertible preferred stock		$ 3	(3)		$ 0
Stock-based compensation expense	692		692
Net loss	(1,524)			(1,524)
Ending balance (in shares) at Sep. 30, 2020		39,163,096			1,896,215
Ending balance at Sep. 30, 2020	$ 7,754	$ 39	$ 433,436	$ (425,723)	$ 2

XML

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (14,408)	$ (13,699)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	362	800
Stock-based compensation	2,144	1,816
Gain on reduction of lease liability	0	1,839
Other	148	262
Change in operating assets and liabilities:
Contracts and other receivables	(2,859)	(673)
Prepaid materials	536	368
Prepaid expenses and other assets	299	572
Accounts payable	(219)	(193)
Accrued liabilities	172	(473)
Accrued compensation	(416)	(676)
Contract liabilities	(6)	(2,554)
Other liabilities	(1,478)	(2,233)
Net cash used in operating activities	(15,725)	(14,844)
Investing activities
Purchases of property and equipment	0	(162)
Sales of property and equipment	0	318
Acquisition of intangibles	(11)	(23)
Net cash (used in) provided by investing activities	(11)	133
Financing activities
Proceeds from borrowing under Paycheck Protection Program	662	0
Proceeds from issuance of securities through private placement, net of issuance costs	0	15,505
Proceeds from issuance of common stock, net	3	2,087
Proceeds from exercise of common stock options	0	3
Principal payments on term loan	(1,000)	(1,977)
Payments on financing leases	(207)	(196)
Net cash (used in) provided by financing activities	(542)	15,422
Net (decrease) increase in cash and cash equivalents	(16,278)	711
Cash and cash equivalents at beginning of period	34,121	13,935
Cash and cash equivalents at end of period	17,843	14,646
Supplemental disclosure of cash flow information
Interest paid	(1,066)	(1,263)
Income taxes paid	(1)	(1)
Supplemental disclosure of non-cash investing and financing activities
Non-cash acquisition of property and equipment	$ 0	$ 61

XML

Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2019, from which the balance sheet information herein was derived.

Liquidity

The accompanying financial statements have been prepared on a basis which assumes we are a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to our ability to continue as a going concern. Through the date of the issuance of these financial statements, we have principally been financed through proceeds received from the sale of our common stock and other equity securities, debt financings, up-front payments and milestones received from collaboration agreements, totaling $455.1 million. As of September 30, 2020, we had approximately $17.8 million of cash and cash equivalents. Based on our operating plans, we believe our cash and cash equivalents may not be sufficient to fund our operations for the period one year following the issuance of these financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. All amounts due under the Term Loan (see note 5) have been classified as a current liability as of September 30, 2020 and December 31, 2019, due to the considerations discussed above and the assessment that the material adverse change clause under the Term Loan is not within our control. We have not been notified, by the Lender, of an event of default as of the date of the filing of this Form 10-Q.

We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. In addition, the COVID-19 pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could negatively affect our liquidity. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity, or cease operations.

If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock.

Use of Estimates

Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.

Revenue Recognition

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements.

We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Collaborative Arrangements

We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.

As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

License Fees

If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments

At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.

Clinical Trial and Preclinical Study Accruals

We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.

Prepaid Materials

We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements, which clarifies the interaction between Topic 808, Collaborative Arrangements and Topic 606, including clarification around certain transactions between

collaborative arrangement participants and adding unit-of-account guidance to Topic 808. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The adoption of this guidance on January 1, 2020 had no impact on our financial statements.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on its financial statements and disclosures.

XML

Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per ShareBasic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of options outstanding under our stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.Dilutive common stock equivalents were 25,813,032 for the three and nine months ended September 30, 2020, consisting of convertible preferred stock, stock options and restricted stock units, and 4,908,289 and 2,973,525 for the three and nine months ended September 30, 2019, respectively, consisting of convertible preferred stock, stock options and restricted stock units.

XML

Investments	9 Months Ended
	Sep. 30, 2020
Debt Securities, Available-for-sale [Abstract]
Investments	InvestmentsWe have historically invested our excess cash primarily in debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. We generally hold our investments to maturity and do not sell our investments before we have recovered our amortized cost basis. As of September 30, 2020 and December 31, 2019, our cash balance was comprised entirely of cash and cash equivalents and there was no unrealized gain or loss in either period.

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:

•Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

•Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

•Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

Financial Assets Measured at Fair Value

The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands):

	Fair value as of September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	14,900	$	14,900	$	—	$	—
	$	14,900	$	14,900	$	—	$	—

	Fair value as of December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,909	$	8,909	$	—	$	—
	$	8,909	$	8,909	$	—	$	—

We obtain pricing information from quoted market prices or quotes from brokers/dealers. We have historically determined the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.

XML

Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

Debt

Term Loan

On June 17, 2016, we entered into a loan and security agreement ("Loan Agreement") with Oxford Finance, LLC, ("Oxford", or sometimes referred to as the “Lender”), pursuant to which we received $20.0 million in proceeds, net of debt issuance costs, on June 22, 2016 (the "Term Loan").

The outstanding Term Loan will mature on May 1, 2022 (the “Maturity Date”) and bears interest at a floating per annum rate equal to (i) 8.51% plus (ii) the greater of (a) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (b) 0.44%. Under the original Loan Agreement, we were required to make interest-only payments through June 1, 2018, followed by 24 equal monthly payments of principal and unpaid accrued interest.

In August 2018, we and Oxford entered into an amendment to our Loan Agreement, providing for a modification of the loan amortization period. Under the terms of the amendment, principal amortization and repayment was deferred between August 2018 through October 2018, and during this period, we were required to make payments of interest-only. Amortization payments recommenced in November 2018. Pursuant to the amendment, we granted the Lender a security interest in our intellectual property as additional collateral for the repayment of the Term Loan.

In November 2018, and in connection with the 2018 Sanofi Amendment, we entered into a fourth amendment to the Loan Agreement with the Lender (the "Fourth Amendment"). Under the terms of the Fourth Amendment, the Lender consented to the 2018 Sanofi Amendment and our license, assignment and transfer to Sanofi of certain of our intellectual property, as required to be delivered to Sanofi under the 2018 Sanofi Amendment (the “Assigned Assets”), which previously served as collateral under the Loan Agreement, and released its liens in the Assigned Assets, provided that the Lender will continue to have liens on all proceeds received by us pursuant to our collaboration and license agreement with Sanofi dated February 4, 2014 (the “Sanofi License Agreement”). Under the terms of the Fourth Amendment, we have the option to prepay part of the Term Loan at any

time and in any amount after 10 days’ prior written notice. We are also required to prepay a portion of the Term Loan with 25% of certain payments we receive under the 2018 Sanofi Amendment, which payments consist of the Upfront Amendment Payments and the first development milestone payment in the amount of $10.0 million. In accordance with this term, we prepaid $0.6 million pursuant to our receipt of $2.5 million in Upfront Amendment Payments in November 2018. Additionally, we prepaid $0.4 million pursuant to our receipt of $1.8 million in Upfront Amendment Payments in March 2019. We are required to pay the applicable 5.5% final payment fee related to each such 2018 Sanofi Amendment prepayment.

On January 31, 2019, we entered into a fifth amendment to the Loan Agreement with the Lender (the "Fifth Amendment"). Under the terms of the Fifth Amendment, our required monthly payment to the Lender for the month of February 2019 was comprised of interest only. On March 7, 2019, we entered into a sixth amendment to the Loan Agreement with the Lender (the "Sixth Amendment"). Under the terms of the Sixth Amendment, our required monthly payment to the Lender for the month of March 2019 was comprised of interest only.

On April 9, 2019 we entered into a seventh amendment to the Loan Agreement with the Lender (the "Seventh Amendment"). Under the terms of the Seventh Amendment, our required monthly payments to the Lender were to be comprised of interest only through and including the payment date immediately preceding the following date (the “Second Amortization Date”): (i) April 1, 2019, if we did not receive unrestricted gross cash proceeds of not less than $10 million on or before April 30, 2019 from (a) the issuance and sale of our unsecured subordinated convertible debt and/or equity securities and/or (b) “up front” or milestone payments in connection with a joint venture, collaboration or other partnering transaction other than pursuant to the Sanofi License Agreement (the receipt of such net proceeds, the “ Seventh Amendment Capital Event”), and (ii) May 1, 2019, if the Seventh Amendment Capital Event occurs. The Seventh Amendment Capital event did not occur on or before April 30, 2019.

Commencing on the Second Amortization Date, and continuing on each successive payment date thereafter, we were to be required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender; provided, however, that we were required to make the monthly principal payment due April 1, 2019 on May 1, 2019 (in addition to all other payments due on May 1, 2019) if the Seventh Amendment Capital Event did not occur. The Seventh Amendment also provided that we can irrevocably elect to increase the prepayment percentage for the funds that we are required to prepay under the Term Loan in the event we receive $10.0 million from the first development milestone under the 2018 Sanofi Amendment (the "Milestone Payment") from 25% to 75% (the “Applicable Sanofi Percentage”). Under the Seventh Amendment, we are required to maintain cash in a collateral account controlled by the Lender of (i) $10.0 million if the Applicable Sanofi Percentage is 25% and if we had not prepaid an aggregate of $5 million under the Term Loan (which amount shall not include any Sanofi License Agreement prepayments) on or before April 30, 2019 (such prepayment, the “Principal Paydown Event”), (ii) $5.0 million if the Applicable Sanofi Percentage is 75% and the Principal Paydown Event had not occurred and (iii) zero if the Principal Paydown Event had occurred.

On May 3, 2019, concurrently with our Securities Purchase Agreement dated May 2019 (the "May 2019 SPA") (as described in further detail in Note 10), we entered into an eighth amendment to the Loan Agreement with the Lender (the "Eighth Amendment"). Pursuant to the terms of the Eighth Amendment and as a result of the completion of the initial closing under the May 2019 SPA, our required monthly payments to the Lender were comprised of interest only from May 2019 through and including the payment to be made in April 2020, in exchange for an interest-only period extension fee of $0.1 million. Additionally, under the Eighth Amendment, the Term Loan maturity date was extended from June 2020 to May 2022, in exchange for a maturity date extension fee of $0.7 million. Pursuant to the Eighth Amendment, as a result of our receipt of over $20.0 million in capital in December 2019 under the second and final closing under the May 2019 SPA, our required monthly payments to the Lender are comprised of interest only through and including the payment to be made in April 2021. Commencing in May 2021, and continuing on each successive payment date thereafter, we are required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to the Lender. The Eighth Amendment also provides for an increase in the prepayment percentage for the funds that we are required to prepay under the Term Loan, in the event that we receive the $10.0 million Milestone Payment, from 75% to 100% of the Milestone Payment. Upon payment of the Milestone Payment to the Lender, we will no longer be required to maintain cash in a collateral account controlled by Lender and the positive lien on our intellectual property will be released.

On May 1, 2020 we entered into a ninth amendment to the Term Loan with the Lender (the “Ninth Amendment”). Pursuant to the terms of the Ninth Amendment, (i) the approximately $0.7 million of loan proceeds (the "PPP Loan") we received under the Paycheck Protection Program ("PPP") was included as permitted indebtedness under the terms of the Term Loan, (ii) we agreed to apply for forgiveness of the maximum amount of PPP Loan permissible in accordance with the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and use best efforts to cause not less than $0.5 million of the PPP Loan to be forgiven by the PPP Loan lender on or before September 30, 2020 and (iii) we agreed not to amend any material provision in any document relating to the PPP Loan nor make any prepayment of the PPP Loan unless such

prepayment is necessary or advisable due to change in the applicable law or guidance issued by the U.S. Small Business Administration (“SBA”).

On August 25, 2020 we entered into a tenth amendment to the Term Loan with the Lender (the "Tenth Amendment"). Pursuant to the terms of the Tenth Amendment, we are eligible for up to an additional seven months of interest only payments in the event the we pay down $10 million in loan principal before April 30, 2021 (the "Principal Paydown Event"). In the event the Principal Paydown Event does not occur by April 30, 2021, we will make principal and accrued interest payments, in arrears, commencing May 1, 2021, in accordance with the terms of the Eighth Amendment. If the Principal Paydown Event occurs after April 30, 2021 but on or before July 31, 2021, we will recommence an extended interest only payment period through December 31, 2021. In the event we receive the additional interest only period, principal and accrued interest payments will recommence on January 1, 2022.

On September 30, 2020, upon our receipt of $1.0 million in proceeds from Sanofi (see Note 7) and under the terms of the Tenth Amendment, we prepaid $1.0 million of outstanding principal to the Lender. We also paid the applicable 5.5% final payment fee related to the $1.0 million prepayment to the Lender. On October 8, 2020, upon receipt of $4.0 million in proceeds from Sanofi (see note 7) and under the terms of the Tenth Amendment, we prepaid $4.0 million of outstanding principal to the Lender. We also paid the applicable 5.5% final payment fee related to the $4.0 million prepayment to the Lender.

We used the proceeds from the Term Loan solely for working capital and to fund our general business requirements. Our obligations under the Loan Agreement are secured by a first priority security interest in substantially all of our current and future assets, other than our intellectual property, for which Oxford currently has a positive lien, and certain assets under finance lease obligations. We have also agreed not to encumber our intellectual property assets, except as permitted by the Loan Agreement. The Loan Agreement includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding Term Loan. As of September 30, 2020 we were in compliance with all covenants under the Loan Agreement.      

As of September 30, 2020, $13.7 million was outstanding under the Term Loan, with an additional $1.8 million payable at the conclusion of the Term Loan. We had less than $0.1 million of debt issuance costs outstanding as of September 30, 2020, which are being accreted to interest expense over the life of the Term Loan using an effective interest rate of 8.98%. The exit fees are being accrued over the life of the Term Loan through interest expense.

As of September 30, 2020, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):

2020	$	—
2021	8,419
2022	5,262
	$	13,681

Paycheck Protection Program Loan

On April 23, 2020, we received the proceeds from the PPP Loan in the amount of approximately $0.7 million from Silicon Valley Bank, as lender, pursuant to the PPP of the CARES Act. The PPP Loan matures on April 23, 2022 and bears interest at a rate of 1.0% per annum. The PPP Loan is evidenced by a promissory note dated April 23, 2020, which contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan may be prepaid by us at any time prior to maturity with no prepayment penalties.

All or a portion of the PPP Loan may be forgiven by the SBA upon our application and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered mortgage interest, covered rent payments and covered utilities during the 24 week period beginning on the date of loan disbursement. For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, annualized, prorated for the covered period. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines during the covered period as compared to specified reference periods, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and includes accrued interest.

We have used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments, and are seeking forgiveness in accordance with the program.

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Stockholders' Equity

Stockholders’ Equity

2019 Equity Incentive Plan

On June 15, 2019 our board of directors approved, and on August 1, 2019 our stockholders approved, our 2019 Equity Incentive Plan (the "2019 Plan"). The 2019 Plan is intended as the successor to and continuation of our 2012 Equity Incentive Plan. The number of shares authorized for issuance under the 2019 Plan may be increased by (a) the shares subject to outstanding stock awards granted under our 2009 Equity Incentive Plan (the “2009 Plan”) and our 2012 Equity Incentive Plan (together the with 2009 Plan, the “Prior Plans”) that on or after the effective date of the 2019 Plan (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to us, or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. No further grants will be made under the Prior Plans. In addition, on January 22, 2020, an additional 4,166,860 shares of common stock became available for issuance under the 2019 Plan pursuant to the second and final closing under the May 2019 SPA. Further, on January 1st of each year, for a period of not more than ten years, beginning on January 1, 2021 and continuing through January 1, 2029, the number of shares authorized for issuance under the 2019 Plan will increase by 5.0% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by our Board of Directors.

As of September 30, 2020, 888,432 shares of common stock were available for new equity award grants under the 2019 Plan and 6,850,882 shares of common stock are reserved for issuance pursuant to equity awards outstanding as of September 30, 2020.

Private Placement of Common Stock, Non-Voting Convertible Preferred Stock and Warrants

On May 3, 2019, we entered into the May 2019 SPA with certain institutional and other accredited investors, including certain of our directors, executive officers and employees (the “Purchasers”), pursuant to which we agreed to sell and issue shares of our common stock, shares of our newly designated non-voting convertible preferred stock, and warrants to purchase common stock, in up to two closings, in a private placement transaction (the “Private Placement”).

At an initial closing under the May 2019 SPA that occurred on May 7, 2019 (the “Initial Closing”), we sold and issued to the Purchasers (i) 9,730,534 shares of common stock and accompanying warrants to purchase up to an aggregate of 9,730,534 shares of common stock at a combined purchase price of $1.205 per share, and (ii) 415,898 shares of non-voting Class A-1 convertible preferred stock, in lieu of shares of common stock, at a price of $10.80 per share, and accompanying warrants to purchase an aggregate of 4,158,980 shares of common stock at a price of $0.125 for each share of common stock underlying such warrants. Total gross proceeds from the Initial Closing were approximately $16.7 million, which does not include any proceeds that may be received upon exercise of the warrants. Each share of non-voting Class A-1 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants are exercisable for a period of five years following the date of issuance and have an exercise price of $1.08 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise "cashless" basis. An aggregate of 526,083 shares of common stock and warrants to purchase up to 526,083 shares of common stock were purchased for $0.6 million by certain of our directors and executive officers under the Initial Closing.

Pursuant to the May 2019 SPA, in the event our Board of Directors unanimously resolved to recommence our Phase 1 multiple ascending dose clinical trial of our RGLS4326 product candidate for the treatment of ADPKD (the “Phase 1 Trial”) based on correspondence from the U.S. Food and Drug Administration’s Division of Cardiovascular and Renal Products, and thereafter but on or before December 31, 2019, we made a public announcement of our plan to recommence the Phase 1 Trial (the “Public Announcement”), we were able to sell and the Purchasers were able to purchase, at a second closing under the May 2019 SPA (“Milestone Closing”), shares of our non-voting convertible preferred stock and accompanying warrants to purchase shares of Common Stock. On December 15, 2019, our Board of Directors unanimously resolved to recommence the Phase 1 Trial based on correspondence from the U.S. Food & Drug Administration’s Division of Cardiovascular and Renal Products and on December 16, 2019, we made the related Public Announcement, triggering the Milestone Closing, which occurred on December 24, 2019. At the Milestone Closing, we sold and issued to the Purchasers 3,288,390 shares of non-voting Class A-2 convertible preferred stock and accompanying warrants to purchase an aggregate of 32,883,900 shares of common stock for an aggregate purchase price of approximately $26.0 million. Net proceeds to us from the Milestone Closing

were approximately $24.6 million. Each share of non-voting Class A-2 convertible preferred stock is convertible into 10 shares of Common Stock, subject to certain beneficial ownership conversion limitations. The warrants will be exercisable for a period of five years following the date of issuance and have an exercise price of $0.666 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events. The warrants are exercisable on a net exercise “cashless” basis. An aggregate of 121,581 shares of Class A-2 convertible preferred stock and warrants to purchase up to 1,215,810 shares of common stock were purchased for approximately $1.0 million by certain of our directors and executive officers under the Milestone Closing.

We evaluated the non-voting Class A-1 convertible preferred stock and common stock warrants sold in the Initial Closing and the Class A-2 convertible preferred stock and common stock warrants sold in the Milestone Closing under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, and determined permanent equity treatment was appropriate for these freestanding financial instruments. The Initial Closing and Milestone Closing did not include any embedded features that required bifurcation. The non-voting Class A-2 convertible preferred stock and warrants issuable under the Milestone Closing were not subject to accounting recognition until the Milestone Closing occurred, as the terms of the Milestone Closing did not provide a right or an obligation on either us nor the Purchasers.

A total of 321,748 and 1,648,875 shares of Class A-2 convertible preferred stock were converted into 3,217,480 and 16,488,750 shares of common stock, respectively, during the three and nine months ended September 30, 2020. A total of 159,198 shares of Class A-1 convertible preferred stock were converted into 1,591,980 shares of common stock during the nine months ended September 30, 2020. No shares of Class A-1 convertible preferred stock were converted into common stock during the three months ended September 30, 2020. No warrants were exercised during the three months and nine months ended September 30, 2020 or 2019.

ATM Offering

On December 12, 2018, we entered into a Common Stock Sales Agreement (the “Stock Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”), pursuant to which we may sell and issue shares of our common stock from time to time through HCW, as our sales agent (the “ATM Offering”). We have no obligation to sell any shares of common stock in the ATM Offering, and may at any time suspend offers under the Stock Sales Agreement or terminate the Stock Sales Agreement. Subject to the terms and conditions of the Stock Sales Agreement, HCW will use its commercially reasonable efforts to sell shares of our common stock from time to time based upon our instructions (including any price, time or size limits or other parameters or conditions the we may impose). We will pay HCW a commission of 3.0% of the gross sales price of any shares sold under the Stock Sales Agreement. No shares were sold under the Stock Sales Agreement during the three and nine months ended September 30, 2020. No shares were sold under the Stock Sales Agreement during the three months ended September 30, 2019. A total of 1,903,880 shares were sold for proceeds of $2.1 million (net of approximately $0.1 million in commissions) under the Stock Sales Agreement during the nine months ended September 30, 2019.

Shares Reserved for Future Issuance

The following shares of common stock were reserved for future issuance as of September 30, 2020 (in thousands):

Class A-1 convertible preferred stock outstanding (as-converted)	2,567
Class A-2 convertible preferred stock outstanding (as-converted)	16,395
Initial Closing warrants	13,890
Milestone Closing warrants	32,884
Common stock options outstanding	6,800
RSUs outstanding	51
Common stock available for future grant under 2019 Equity Incentive Plan	888
Employee Stock Purchase Plan	188
Total common shares reserved for future issuance	73,663

The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2020 (shares in thousands): 

	Number of options	Weighted average exercise price		Number of RSUs	Weighted average grant date fair value
Stock Awards outstanding at December 31, 2019	3,098	$	1.17	129	$	1.50
Granted	3,861	$	1.20	—	$	—
Exercised (options) or Vested (RSUs)	(1)	$	0.95	(59)	$	1.50
Canceled/forfeited/expired	(158)	$	4.82	(19)	$	1.50
Stock Awards outstanding at September 30, 2020	6,800	$	1.10	51	$	1.50

Stock-Based Compensation

The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan and 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Stock options
Risk-free interest rate	0.4	%	1.5	%	1.1	%	2.1	%
Volatility	95.3	%	95.1	%	95.4	%	94.4	%
Dividend yield	—		—		—		—
Expected term (years)	6.1		6.1		6.1		6.1
Performance stock options
Risk-free interest rate	—		—		1.4	%	2.6	%
Volatility	—		—		95.4	%	93.8	%
Dividend yield	—		—		—		—
Expected term (years)	0		0		6.1		6.1
Employee stock purchase plan shares
Risk-free interest rate	0.3	%	2.3	%	0.7	%	2.4	%
Volatility	94.9	%	106.7	%	98.2	%	110.1	%
Dividend yield	—		—		—		—
Expected term (years)	0.5		0.5		0.5		0.5

The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands): 

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Research and development	$	255	$	45	$	571	$	240
General and administrative	437		491		1,573		1,576
Total	$	692	$	536	$	2,144	$	1,816

XML

Collaborations

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations

Collaborations

Revenue recognized from our strategic collaborations was $5.0 million for the three and nine months ended September 30, 2020, compared to less than $0.1 million and $6.8 million for the three and nine months ended September 30, 2019, respectively.

Sanofi

In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. We determined that the elements within the strategic collaboration agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic collaboration with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology collaboration.

In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. Revenue associated with the creditable portion of this option payment was deferred as of December 31, 2017 and recorded as an adjustment to accumulated deficit upon our adoption of Topic 606 on January 1, 2018. The non-creditable portion of this payment, $1.25 million, was recognized as revenue over the option period from the effective date of the option agreement in June 2013 through the expiration of the option period in January 2014.

In February 2014, we and Sanofi entered into the 2014 Sanofi Amendment to renew our strategic collaboration to discover, develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Under the terms of the 2014 Sanofi Amendment, Sanofi had opt-in rights to our clinical fibrosis program targeting miR-21 for the treatment of Alport syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical program targeting miR-221/222 for hepatocellular carcinoma (“HCC”). We were responsible for developing each of these programs to proof-of-concept, at which time Sanofi had an exclusive option on each program. If Sanofi chooses to exercise its option on any of these programs, Sanofi would reimburse us for a significant portion of our preclinical and clinical development costs and would also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. We are eligible to receive royalties on microRNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products relating to our preclinical program targeting miR-221/222. As indicated below, we entered into an additional amendment with Sanofi in November 2018, under which Sanofi's opt-in rights to our miR-21 programs under the 2014 Sanofi Amendment were relinquished. Sanofi's opt-in rights with regard to our miR-221/222 preclinical program under the 2014 Sanofi Amendment remained unchanged.

In connection with the 2014 Sanofi Amendment, we entered into a Common Stock Purchase Agreement (the “Sanofi Purchase Agreement”), pursuant to which we sold 1,303,780 shares of our common stock to Aventisub LLC (“Aventis”), an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. Under the terms of the Sanofi Purchase Agreement, Aventis was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of any common stock for the 12-month period following its effective date. The Sanofi Purchase Agreement and the 2014 Sanofi Amendment were negotiated concurrently and were therefore evaluated as a single agreement. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the discount for

lack of marketability, approximately $0.4 million of the proceeds from the Sanofi Purchase Agreement was attributed to the 2014 Sanofi Amendment, and represents consideration for the value of the program targeting miR-221/222 for HCC. We recognized the $0.4 million allocated consideration into revenue ratably over the estimated period of performance of the miR-221/222 program, though January 2020.

We are eligible to receive milestone payments related to the development and commercialization of miR-221/222 for HCC of up to $38.8 million for proof-of-concept option exercise fees (net of $1.25 million creditable, as noted above), $34.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales of any products from the miR-221/222 program which, in the case of sales in the United States, will be in the middle of the 10% to 20% range, and, in the case of sales outside of the United States, will range from the low end to the middle of the 10% to 20% range, depending upon the volume of sales. If we exercise our option to co-promote a miR-221/222 product, we will continue to be eligible to receive royalties on net sales of each product in the United States at the same rate, unless we elect to share a portion of Sanofi’s profits from sales of such product in the United States in lieu of royalties.

In November 2018, we entered into an amendment to the 2014 Sanofi Amendment with Sanofi to modify the parties’ rights and obligations with respect to our miR-21 programs, including our RG-012 program (the “2018 Sanofi Amendment”). Under the terms of the 2018 Sanofi Amendment, we have granted Sanofi a worldwide, royalty-free, fee-bearing, exclusive license, with the right to grant sublicenses, under our know-how and patents to develop and commercialize miR-21 compounds and products for all indications, including Alport Syndrome. Sanofi will control and will assume all responsibilities and obligations for developing and commercializing each of our miR-21 programs, including our obligations regarding the administration and expense of clinical trials and all other costs, including in-license royalties and other in-license payments, related to our miR-21 programs. Under the terms of the 2018 Sanofi Amendment, we have assigned to Sanofi certain agreements, product-specific patents and all materials directed to miR-21 or to any miR-21 compound or product and are required to provide reasonable technical assistance to Sanofi for a period of 24 months after the date of the 2018 Sanofi Amendment. Under the terms of the 2018 Sanofi Amendment, we were eligible to receive approximately $6.8 million in upfront payments for the license and for miR-21 program-related materials (collectively, the “Upfront Amendment Payments”). We were also eligible to receive up to $40.0 million in development milestone payments, including a $10.0 million payment for an interim enrollment milestone (the "Enrollment Milestone"). In addition, Sanofi has agreed to reimburse us for certain out-of-pocket transition activities and assume our upstream license royalty obligations. We and Sanofi also agreed to a general release of claims against each other for any claims that arose at any time prior to the date of the 2018 Sanofi Amendment, or that thereafter could arise based on anything that occurred prior to the date of the 2018 Sanofi Amendment. We received $2.5 million and $1.8 million in Upfront Amendment Payments under the 2018 Sanofi Amendment in November 2018 and March 2019, respectively. As the performance obligations associated with these Upfront Amendment Payments had been satisfied under Topic 606 as of March 31, 2019, both amounts were recognized as revenue in the first quarter of 2019. Additionally, we recognized an additional $2.5 million as revenue in the first quarter of 2019 for the final Upfront Amendment Payment allowable under the 2018 Sanofi Amendment, as the performance obligations associated with the final Upfront Amendment Payment were also satisfied under Topic 606 as of March 31, 2019. We received the final $2.5 million Upfront Amendment Payment in April 2019.

In August 2020, we entered into an amendment to the 2018 Sanofi Amendment (the "2020 Sanofi Amendment"). Under the terms of the 2020 Sanofi Amendment, we agreed to transfer to Sanofi additional RG-012 development program materials (the “Materials”) in exchange for a payment from Sanofi of $1.0 million (the “Transfer Payment”). In addition, in lieu of the $10.0 million Enrollment Milestone under the 2018 Sanofi Amendment, Sanofi agreed to pay us a $4.0 million milestone upon the completion of the transfer and verification of the Materials, and $5.0 million upon achievement of the Enrollment Milestone. Additionally, we are eligible to receive $25.0 million upon achievement of an additional development milestone related to Sanofi's development of the miR-21 compounds. In September 2020, we received $1.0 million in exchange for the transfer of the Materials to Sanofi, and received an additional $4.0 million in October 2020 as a result of Sanofi's completion and verification of the Materials in September 2020. As the performance obligations associated with both of these payments had been satisfied under Topic 606 as of September 30, 2020, both amounts were recognized as revenue in the third quarter of 2020. As the $4.0 million payment was received in October 2020, it was recorded in accounts receivable on our balance sheet at September 30, 2020.

As of September 30, 2020, the $30.0 million in development milestone payments (variable consideration) are fully constrained and therefore, do not meet the criteria for revenue recognition.

XML

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

Leases

At the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.

In July 2015, we entered into an operating lease agreement (the "Prior Lease") for approximately 59,248 square feet of office and laboratory facility space located at 10614 Science Center Drive, San Diego, California 92121. The lease term was 96 months from the lease commencement date, and we moved our headquarters into this facility in May 2016. In conjunction with the lease, we received $1.4 million of lease incentives and $8.2 million of tenant improvement allowance, which was to be used for non-structural leasehold improvements. The lease incentives and tenant improvement allowance were included within deferred rent. Our deferred rent balance as of December 31, 2018 was $8.0 million. The Prior Lease agreement was with ARE SD Region No. 44 LLC (“Landlord”).

On February 19, 2019, we entered into an agreement, the (“Space Swap Agreement"), with Nitto Biopharma, Inc. ("Nitto"), pursuant to which we agreed, contingent upon the execution of a new lease agreement (the "February Lease") for Nitto's space with Landlord and the termination of the Prior Lease, to, among other things, (i) swap buildings with Nitto, and (ii) sell, convey and transfer all right, title and interest in certain furniture, fixtures and equipment to Nitto, as set forth in the Space Swap Agreement. Under the Space Swap Agreement, we paid Nitto (a) a relocation assistance payment in the amount of $0.1 million; (b) $0.2 million representing the difference between the security deposits under the Prior Lease and Nitto’s prior lease, and (c) $1.3 million as reimbursement for the six monthly installments of base monthly rent due pursuant to the new lease between Nitto and Landlord, subject to certain adjustments, which reimbursements are to be paid as rent comes due for Nitto under its new lease.

On February 25, 2019, we and Landlord entered into a second amendment (the “Prior Lease Amendment”) to the Prior Lease. Under the terms of the Prior Lease Amendment, the expiration date of the Prior Lease was accelerated from April 30, 2024 to March 31, 2019 and the Prior Lease terminated on April 1, 2019. The Prior Lease Amendment eliminated all further cash payments due under the Prior Lease, including aggregate base rent over its remaining term of approximately $14.4 million.

On February 25, 2019, we entered into an operating lease agreement with Landlord (the "February Lease"), for the lease of approximately 24,562 square feet of rentable area of the building located at 10628 Science Center Drive, San Diego, California, 92121 (the "Premises"), which Premises were previously occupied by Nitto. The commencement date of the February Lease was April 1, 2019 (the “Commencement Date”). The Premises served as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the February Lease (“Initial Term”) was 51 months, ending June 30, 2023. The aggregate base rent due over the Initial Term was approximately $4.8 million. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses, the annual tax expenses and the annual utilities costs related to the February Lease.

The execution of the February Lease and Prior Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. The leasehold improvements under the Prior Lease were accounted for as non-cash consideration of $5.6 million paid by us upon termination of the Prior Lease to the Landlord. We accounted for a $1.3 million portion of the reduction in the lease liability for the Prior Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.9 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the Lease. The $1.6 million obligation to reimburse Nitto for six monthly installments of base rent of the Prior Lease and certain other costs were accounted for as cost of terminating the Prior Lease in the unaudited condensed statement of operations. The net impact of the modification was a $0.4 million charge in the unaudited condensed statement of operations. Our payment obligations to Nitto under the Space Swap Agreement were fully satisfied as of September 30, 2019 and no assets

or liabilities remained with respect to the Prior Lease as of March 31, 2020. The commencement date of the February Lease did not occur until April 1, 2019 and therefore, as of March 31, 2019, the lease liability for the February Lease was zero. On April 1, 2019, we recorded a $3.8 million lease liability for the February Lease, which was calculated as the present value of future lease payments to be made under the February Lease. A $2.9 million ROU asset was also recorded on April 1, 2019, which represents the difference between the lease liability and the $0.9 million deferred credit for the reduction of the lease liability under the Prior Lease.

On June 19, 2019, we entered into a lease agreement (the “New Lease”) with Landlord for the lease of approximately 8,727 square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the “New Premises”). The commencement date of the New Lease was July 1, 2019 (the “New Commencement Date”). We are using the New Premises as our new principal executive offices and as a laboratory for research and development and other related uses. The term of the New Lease (the “New Initial Term”) is two years, six months, ending December 31, 2021. The base rent payments due for the New Premises are $0.4 million in 2020 and $0.4 million in 2021, net of certain rent abatement terms. We will also be responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.

On June 19, 2019, we entered into a first amendment to the February Lease with Landlord (the “February Lease Amendment”). Under the terms of the February Lease Amendment, the expiration date of the February Lease was accelerated from June 30, 2023 to June 30, 2019 and the February Lease terminated upon the Commencement Date of the New Lease. The February Lease Amendment eliminated all further rents due under the February Lease, including aggregate base rent over its remaining term of approximately $4.8 million.

The execution of the New Lease and February Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $0.5 million portion of the reduction in the lease liability for the February Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.2 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the New Lease. No other assets or liabilities remained with respect to the February Lease as of June 30, 2019. The commencement date of the New Lease did not occur until July 1, 2019 and therefore, as of June 30, 2019, the lease liability for the New Lease was zero. On July 1, 2019, we recorded a $0.8 million lease liability for the New Lease, which was calculated as the present value of future lease payments to be made under the New Lease. A $0.6 million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $0.2 million deferred credit for the reduction of the lease liability under the February Lease.

Our future lease payments under operating and finance leases at September 30, 2020 are as follows (in thousands):

	Operating Leases		Finance Leases
Remaining 2020	$	109	$	72
2021	442		57
Total lease payments	$	551	$	129
Less: amount representing interest	(38)		(2)
Present value of obligations under leases	513		127
Less: current portion	(403)		(127)
Long-term lease obligations	$	110	$	—

Leases

Leases

At the inception of a contractual arrangement, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. For operating leases with an initial term greater than 12 months, we recognize operating lease right of use assets ("ROU assets") and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease ROU assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when we are reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For our operating leases, we generally cannot determine the interest rate implicit in the lease, in which case we use our incremental borrowing rate as the discount rate for the lease. We estimate our incremental borrowing rate for our operating leases based on what we would normally pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not recorded on the unaudited condensed balance sheet. Instead, we recognize lease expense for these leases on a straight-line basis over the lease term. Our lease agreements do not contain any material variable lease payments, residual value guarantees or restrictive covenants. Certain leases require us to pay taxes, insurance, utilities, and maintenance costs for the building, which do not represent lease components. We elected to not separate lease and non-lease components.

In July 2015, we entered into an operating lease agreement (the "Prior Lease") for approximately 59,248 square feet of office and laboratory facility space located at 10614 Science Center Drive, San Diego, California 92121. The lease term was 96 months from the lease commencement date, and we moved our headquarters into this facility in May 2016. In conjunction with the lease, we received $1.4 million of lease incentives and $8.2 million of tenant improvement allowance, which was to be used for non-structural leasehold improvements. The lease incentives and tenant improvement allowance were included within deferred rent. Our deferred rent balance as of December 31, 2018 was $8.0 million. The Prior Lease agreement was with ARE SD Region No. 44 LLC (“Landlord”).

On February 19, 2019, we entered into an agreement, the (“Space Swap Agreement"), with Nitto Biopharma, Inc. ("Nitto"), pursuant to which we agreed, contingent upon the execution of a new lease agreement (the "February Lease") for Nitto's space with Landlord and the termination of the Prior Lease, to, among other things, (i) swap buildings with Nitto, and (ii) sell, convey and transfer all right, title and interest in certain furniture, fixtures and equipment to Nitto, as set forth in the Space Swap Agreement. Under the Space Swap Agreement, we paid Nitto (a) a relocation assistance payment in the amount of $0.1 million; (b) $0.2 million representing the difference between the security deposits under the Prior Lease and Nitto’s prior lease, and (c) $1.3 million as reimbursement for the six monthly installments of base monthly rent due pursuant to the new lease between Nitto and Landlord, subject to certain adjustments, which reimbursements are to be paid as rent comes due for Nitto under its new lease.

On February 25, 2019, we and Landlord entered into a second amendment (the “Prior Lease Amendment”) to the Prior Lease. Under the terms of the Prior Lease Amendment, the expiration date of the Prior Lease was accelerated from April 30, 2024 to March 31, 2019 and the Prior Lease terminated on April 1, 2019. The Prior Lease Amendment eliminated all further cash payments due under the Prior Lease, including aggregate base rent over its remaining term of approximately $14.4 million.

On February 25, 2019, we entered into an operating lease agreement with Landlord (the "February Lease"), for the lease of approximately 24,562 square feet of rentable area of the building located at 10628 Science Center Drive, San Diego, California, 92121 (the "Premises"), which Premises were previously occupied by Nitto. The commencement date of the February Lease was April 1, 2019 (the “Commencement Date”). The Premises served as our new principal executive offices and as a laboratory for research and development, manufacturing and other related uses. The term of the February Lease (“Initial Term”) was 51 months, ending June 30, 2023. The aggregate base rent due over the Initial Term was approximately $4.8 million. We were also responsible for the payment of additional rent to cover our share of the annual operating expenses, the annual tax expenses and the annual utilities costs related to the February Lease.

The execution of the February Lease and Prior Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. The leasehold improvements under the Prior Lease were accounted for as non-cash consideration of $5.6 million paid by us upon termination of the Prior Lease to the Landlord. We accounted for a $1.3 million portion of the reduction in the lease liability for the Prior Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.9 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the Lease. The $1.6 million obligation to reimburse Nitto for six monthly installments of base rent of the Prior Lease and certain other costs were accounted for as cost of terminating the Prior Lease in the unaudited condensed statement of operations. The net impact of the modification was a $0.4 million charge in the unaudited condensed statement of operations. Our payment obligations to Nitto under the Space Swap Agreement were fully satisfied as of September 30, 2019 and no assets

or liabilities remained with respect to the Prior Lease as of March 31, 2020. The commencement date of the February Lease did not occur until April 1, 2019 and therefore, as of March 31, 2019, the lease liability for the February Lease was zero. On April 1, 2019, we recorded a $3.8 million lease liability for the February Lease, which was calculated as the present value of future lease payments to be made under the February Lease. A $2.9 million ROU asset was also recorded on April 1, 2019, which represents the difference between the lease liability and the $0.9 million deferred credit for the reduction of the lease liability under the Prior Lease.

On June 19, 2019, we entered into a lease agreement (the “New Lease”) with Landlord for the lease of approximately 8,727 square feet of rentable area of the building located at 10628 Science Center Drive, Suite 225, San Diego, California 92121 (the “New Premises”). The commencement date of the New Lease was July 1, 2019 (the “New Commencement Date”). We are using the New Premises as our new principal executive offices and as a laboratory for research and development and other related uses. The term of the New Lease (the “New Initial Term”) is two years, six months, ending December 31, 2021. The base rent payments due for the New Premises are $0.4 million in 2020 and $0.4 million in 2021, net of certain rent abatement terms. We will also be responsible for the payment of additional rent to cover our share of the annual operating expenses of the building, the annual tax expenses of the building and the annual utilities cost of the building.

On June 19, 2019, we entered into a first amendment to the February Lease with Landlord (the “February Lease Amendment”). Under the terms of the February Lease Amendment, the expiration date of the February Lease was accelerated from June 30, 2023 to June 30, 2019 and the February Lease terminated upon the Commencement Date of the New Lease. The February Lease Amendment eliminated all further rents due under the February Lease, including aggregate base rent over its remaining term of approximately $4.8 million.

The execution of the New Lease and February Lease Amendment resulted in a modification which was not accounted for as a separate contract. Rather, we accounted for the two contracts with Landlord in combination as they were entered into at the same time and negotiated as a package to achieve the same commercial objective. We accounted for a $0.5 million portion of the reduction in the lease liability for the February Lease as a non-cash gain in the unaudited condensed statement of operations due to the reduction in lease term and leased space with Landlord and a $0.2 million portion of the reduction of the lease liability as a deferred credit that is amortized as a reduction to rent expense over the term of the New Lease. No other assets or liabilities remained with respect to the February Lease as of June 30, 2019. The commencement date of the New Lease did not occur until July 1, 2019 and therefore, as of June 30, 2019, the lease liability for the New Lease was zero. On July 1, 2019, we recorded a $0.8 million lease liability for the New Lease, which was calculated as the present value of future lease payments to be made under the New Lease. A $0.6 million ROU asset was also recorded on July 1, 2019, which represents the difference between the lease liability and the remaining $0.2 million deferred credit for the reduction of the lease liability under the February Lease.

Our future lease payments under operating and finance leases at September 30, 2020 are as follows (in thousands):

	Operating Leases		Finance Leases
Remaining 2020	$	109	$	72
2021	442		57
Total lease payments	$	551	$	129
Less: amount representing interest	(38)		(2)
Present value of obligations under leases	513		127
Less: current portion	(403)		(127)
Long-term lease obligations	$	110	$	—

XML

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn October 29, 2020, we were informed by Sanofi that the remaining $5.0 million payment associated with the Enrollment Milestone under our Collaboration and License Agreement with Sanofi for its development of miR-21 programs was triggered upon achievement of an enrollment metric by Sanofi in its Phase 2 clinical study evaluating RG-012 for the treatment of patients with Alport Syndrome. The proceeds from this milestone payment will be used to pay down principal outstanding under our Term Loan. The payment to the Lender will reduce the remaining principal due under the Term Loan to approximately $4.7 million and enable the Company to receive an extension of interest-only payments through 2021, which represents an extension of seven months from the previous terms.

XML

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2019, from which the balance sheet information herein was derived.

Use of Estimates

Use of EstimatesOur condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.

Revenue Recognition

Revenue Recognition

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, milestone payments and payments for other research services under license and collaboration agreements.

We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Collaborative Arrangements

We enter into collaborative arrangements with partners that typically include payment to us of one of more of the following: (i) license fees; (ii) payments related to the achievement of developmental, regulatory, or commercial milestones; and (iii) royalties on net sales of licensed products. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.

As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation(s). The stand-alone selling price may include items such as forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time, or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

License Fees

If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Milestone Payments

At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a milestone event would occur at the inception of an arrangement, the associated milestone value is included in the transaction price. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and therefore not included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any related constraint(s), and if necessary, may adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which could affect license, collaboration or other revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.

Stock-Based Compensation

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. For performance-based awards granted to employees (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.

We account for restricted stock units by determining the fair value of each restricted stock unit based on the closing market price of our common stock on the date of grant. We recognize stock-based compensation expense using the accelerated multiple-option approach over the requisite service periods of the awards.

Clinical Trial and Preclinical Study Accruals

Clinical Trial and Preclinical Study Accruals

We make estimates of our accrued expenses for clinical trial and preclinical study activities as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. These accruals are based upon estimates of costs incurred and fees that may be associated with services provided by clinical trial investigational sites, CROs and for other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.

Prepaid Materials

Prepaid Materials

We capitalize the purchase of certain raw materials and related supplies for use in the manufacturing of drug product in our preclinical and clinical development programs, as we have determined that these materials have alternative future use. We can use these raw materials and related supplies in multiple clinical drug products, and therefore have future use independent of the development status of any particular drug program until it is utilized in the manufacturing process. We expense the cost of materials when used. We periodically review these capitalized materials for continued alternative future use and write down the asset to its net realizable value in the period in which an impairment is identified.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. We are assessing the impact this standard will have on our financial statements and disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which updates and modifies the disclosure requirements on fair value measurements in Topic 820, primarily in relation to Level 3 fair value measurements. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements, which clarifies the interaction between Topic 808, Collaborative Arrangements and Topic 606, including clarification around certain transactions between

collaborative arrangement participants and adding unit-of-account guidance to Topic 808. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. The adoption of this guidance on January 1, 2020 did not have a material impact on our financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes - Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. The adoption of this guidance on January 1, 2020 had no impact on our financial statements.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides guidance around reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation in response to concerns about structural risks of interbank offered rates and the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments in the ASU provide option expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform and apply only if such contracts, hedging relationships and other transactions that reference LIBOR or another reference rate are expected to be discontinued because of reference rate reform. The guidance does not apply to contract modifications made, and hedging relationships entered into or evaluated, after December 31, 2022. We are assessing the impact this standard will have on its financial statements and disclosures.

Fair Value Measurement

Fair Value Measurements

We have certain financial assets recorded at fair value which have been classified as Level 1, 2, or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Accounting standards define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The accounting standards provide an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The accounting standards prioritize the inputs used in measuring the fair value into the following hierarchy:

•Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

•Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

•Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents our fair value hierarchy for assets measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019 (in thousands):

	Fair value as of September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	14,900	$	14,900	$	—	$	—
	$	14,900	$	14,900	$	—	$	—

	Fair value as of December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,909	$	8,909	$	—	$	—
	$	8,909	$	8,909	$	—	$	—

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt Maturities

As of September 30, 2020, future principal payments for the Term Loan due under the Loan Agreement are as follows (in thousands):

2020	$	—
2021	8,419
2022	5,262
	$	13,681

XML

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Common Stock Reserved for Future Issuance

The following shares of common stock were reserved for future issuance as of September 30, 2020 (in thousands):

Class A-1 convertible preferred stock outstanding (as-converted)	2,567
Class A-2 convertible preferred stock outstanding (as-converted)	16,395
Initial Closing warrants	13,890
Milestone Closing warrants	32,884
Common stock options outstanding	6,800
RSUs outstanding	51
Common stock available for future grant under 2019 Equity Incentive Plan	888
Employee Stock Purchase Plan	188
Total common shares reserved for future issuance	73,663

Stock Option Activity

The following table summarizes our stock option and RSU activity (together Stock Awards) under all equity incentive plans for the nine months ended September 30, 2020 (shares in thousands): 

	Number of options	Weighted average exercise price		Number of RSUs	Weighted average grant date fair value
Stock Awards outstanding at December 31, 2019	3,098	$	1.17	129	$	1.50
Granted	3,861	$	1.20	—	$	—
Exercised (options) or Vested (RSUs)	(1)	$	0.95	(59)	$	1.50
Canceled/forfeited/expired	(158)	$	4.82	(19)	$	1.50
Stock Awards outstanding at September 30, 2020	6,800	$	1.10	51	$	1.50

Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan

The following table summarizes the weighted average assumptions used to estimate the fair value of stock options and performance stock awards granted to employees under our 2012 Equity Incentive Plan, 2015 Inducement Plan and 2019 Equity Incentive Plan and the shares purchasable under our Employee Stock Purchase Plan during the periods presented:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Stock options
Risk-free interest rate	0.4	%	1.5	%	1.1	%	2.1	%
Volatility	95.3	%	95.1	%	95.4	%	94.4	%
Dividend yield	—		—		—		—
Expected term (years)	6.1		6.1		6.1		6.1
Performance stock options
Risk-free interest rate	—		—		1.4	%	2.6	%
Volatility	—		—		95.4	%	93.8	%
Dividend yield	—		—		—		—
Expected term (years)	0		0		6.1		6.1
Employee stock purchase plan shares
Risk-free interest rate	0.3	%	2.3	%	0.7	%	2.4	%
Volatility	94.9	%	106.7	%	98.2	%	110.1	%
Dividend yield	—		—		—		—
Expected term (years)	0.5		0.5		0.5		0.5

Stock-Based Compensation

The following table summarizes the allocation of our stock-based compensation expense for all stock awards during the periods presented (in thousands): 

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Research and development	$	255	$	45	$	571	$	240
General and administrative	437		491		1,573		1,576
Total	$	692	$	536	$	2,144	$	1,816

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Operating Lease, Liability, Maturity

Our future lease payments under operating and finance leases at September 30, 2020 are as follows (in thousands):

	Operating Leases		Finance Leases
Remaining 2020	$	109	$	72
2021	442		57
Total lease payments	$	551	$	129
Less: amount representing interest	(38)		(2)
Present value of obligations under leases	513		127
Less: current portion	(403)		(127)
Long-term lease obligations	$	110	$	—

Finance Lease, Liability, Maturity

Our future lease payments under operating and finance leases at September 30, 2020 are as follows (in thousands):

	Operating Leases		Finance Leases
Remaining 2020	$	109	$	72
2021	442		57
Total lease payments	$	551	$	129
Less: amount representing interest	(38)		(2)
Present value of obligations under leases	513		127
Less: current portion	(403)		(127)
Long-term lease obligations	$	110	$	—

XML

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Financing from sale proceeds, debt, and agreement revenues	$ 455,100
Cash and cash equivalents	$ 17,843	$ 34,121

XML

Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Potentially dilutive securities not included in calculation of diluted net loss per share (in shares)	25,813,032	4,908,289	25,813,032	2,973,525

XML

Investments (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Debt Securities, Available-for-sale [Abstract]
Unrealized Gain (Loss) on Investments	$ 0	$ 0

XML

Fair Value Measurements (Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	$ 14,900	$ 8,909
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	14,900	8,909
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	14,900	8,909
Cash equivalents | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	14,900	8,909
Cash equivalents | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	0	0
Cash equivalents | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	$ 0	$ 0

XML

Debt (Details)								1 Months Ended			3 Months Ended		9 Months Ended
	Oct. 29, 2020 USD ($)	Oct. 08, 2020 USD ($)	Aug. 25, 2020	May 03, 2019 USD ($)	Apr. 09, 2019 USD ($)	Jun. 22, 2016 USD ($)	Jun. 17, 2016 number_of_payment	Sep. 30, 2020 USD ($)	Mar. 31, 2019 USD ($)	Nov. 30, 2018 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	May 01, 2020 USD ($)	Apr. 23, 2020 USD ($)	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Upfront payment received									$ 1,800,000	$ 2,500,000
PPP loan															$ 700,000	$ 700,000
Forgiveness threshold amount															$ 500,000
Total revenues											$ 5,000,000	$ 18,000	$ 5,006,000	$ 6,814,000
Subsequent Event
Debt Instrument [Line Items]
Interest-only payment extension	7 months
Revenue under collaborations
Debt Instrument [Line Items]
Total revenues											5,000,000.0	$ 100,000	5,000,000.0	$ 6,800,000
Revenue under collaborations | Sanofi
Debt Instrument [Line Items]
Total revenues								$ 1,000,000.0
Repayments of debt								1,000,000.0
Revenue under collaborations | Sanofi | Subsequent Event
Debt Instrument [Line Items]
Total revenues		$ 4,000,000.0
Repayments of debt		$ 4,000,000.0
Debt Financing Agreement
Debt Instrument [Line Items]
Proceeds from borrowing under term loan						$ 20,000,000.0
Stated interest rate, percentage							8.51%
Number of monthly payments | number_of_payment							24
Long-term debt								13,700,000			13,700,000		13,700,000
Debt fee								1,800,000			1,800,000		1,800,000
Debt issuance costs								$ 100,000			$ 100,000		$ 100,000
Debt instrument effective rate								8.98%			8.98%		8.98%
Debt Financing Agreement | Subsequent Event
Debt Instrument [Line Items]
Long-term debt	$ 4,700,000
Debt Financing Agreement | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate, percentage							0.44%
Fourth Amendment
Debt Instrument [Line Items]
Notice for prepayment										10 days
Prepayment requirement										25.00%
Potential revenue through milestone payments										$ 10,000,000.0
Prepayment requirement of loan from license fees amount									$ 400,000	$ 600,000
Payment fee										5.50%
Seventh Amendment
Debt Instrument [Line Items]
Minimum cash, debt covenant					$ 10,000,000.0
Debt covenant, condition one					10,000,000.0
Debt covenant, condition two					5,000,000.0
Debt covenant, condition three					0
Eight Amendment
Debt Instrument [Line Items]
Minimum cash, debt covenant																	$ 20,000,000.0
Interest only payment fee				$ 100,000
Maturity extension fee				$ 700,000
Eight Amendment - Milestone Payment
Debt Instrument [Line Items]
Minimum cash, debt covenant					10,000,000.0
Tenth Amendment
Debt Instrument [Line Items]
Prepayment requirement								1000000000.00%			1000000000.00%		1000000000.00%
Interest-only payment extension			7 months
Minimum | Seventh Amendment
Debt Instrument [Line Items]
Prepayment requirement of loan from license fees amount					$ 5,000,000
Prepayment requirement of loan from license fees					25.00%
Minimum | Eight Amendment
Debt Instrument [Line Items]
Prepayment requirement of loan from license fees					75.00%
Maximum | Seventh Amendment
Debt Instrument [Line Items]
Prepayment requirement of loan from license fees					75.00%
Maximum | Eight Amendment
Debt Instrument [Line Items]
Prepayment requirement of loan from license fees					100.00%

XML

Debt (Future Principal Payments) (Details) - Debt Financing Agreement Tranche A $ in Thousands	Sep. 30, 2020 USD ($)
Debt Instrument [Line Items]
2020	$ 0
2021	8,419
2022	5,262
Long-term Debt	$ 13,681

XML

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Millions							3 Months Ended				9 Months Ended
	Jan. 22, 2020 shares	Dec. 24, 2019 USD ($) $ / shares shares	May 07, 2019 USD ($) $ / shares shares	May 03, 2019 USD ($) shares	Dec. 12, 2018 USD ($) shares	Oct. 02, 2018	Sep. 30, 2020 shares	Jun. 30, 2020 shares	Mar. 31, 2020 shares	Sep. 30, 2019 shares	Sep. 30, 2020 shares	Sep. 30, 2019 shares
Subsidiary, Sale of Stock [Line Items]
Total common shares reserved for future issuance (in shares)							73,663,000				73,663,000
Reverse stock split ratio						0.0833
Warrants exercised							0			0	0	0
Private Placement
Subsidiary, Sale of Stock [Line Items]
Share sold (in shares)				9,730,534
Warrants callable			9,730,534
Sale of stock price (usd per share) | $ / shares			$ 1.205
Consideration received | $				$ 16.7
Shares issued upon conversion (in shares)			10
Warrants, term			5 years
Warrant exercise price (usd per share) | $ / shares			$ 1.08
Milestone Closing
Subsidiary, Sale of Stock [Line Items]
Consideration received | $		$ 24.6
At The Moment
Subsidiary, Sale of Stock [Line Items]
Share sold (in shares)					1,903,880
Consideration received | $					$ 2.1
Commission fee rate					3.00%
Shares issued (in shares)							0			0	0	0
Commissions paid | $					$ 0.1
Preferred Class A | Private Placement
Subsidiary, Sale of Stock [Line Items]
Warrants callable			4,158,980
Sale of stock price (usd per share) | $ / shares			$ 10.80
Nonvoting convertible preferred stock issued			415,898
Class A-2 Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Reverse stock split ratio		10
Convertible preferred stock converted into common stock (in shares)							321,748				1,648,875
Class A-2 Convertible Preferred Stock | Milestone Closing
Subsidiary, Sale of Stock [Line Items]
Share sold (in shares)		3,288,390
Warrants callable		32,883,900
Consideration received | $		$ 26.0
Warrants, term		5 years
Warrant exercise price (usd per share) | $ / shares		$ 0.666
Class A-1 Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock converted into common stock (in shares)											159,198
Warrant | Preferred Class A | Private Placement
Subsidiary, Sale of Stock [Line Items]
Sale of stock price (usd per share) | $ / shares			$ 0.125
Common stock
Subsidiary, Sale of Stock [Line Items]
Conversions of convertible preferred stock (in shares)							3,217,480	8,296,430	6,566,820
Common stock | Class A-2 Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Conversions of convertible preferred stock (in shares)							3,217,480				16,488,750
Common stock | Class A-1 Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Conversions of convertible preferred stock (in shares)							0				1,591,980
Directors, Executive Officers and Employees | Private Placement
Subsidiary, Sale of Stock [Line Items]
Share sold (in shares)				526,083
Directors, Executive Officers and Employees | Preferred Class A | Private Placement
Subsidiary, Sale of Stock [Line Items]
Warrants callable			526,083
Proceeds from issuance of right to purchase common shares | $			$ 0.6
Certain Directors and Executive Officers | Class A-2 Convertible Preferred Stock | Milestone Closing
Subsidiary, Sale of Stock [Line Items]
Share sold (in shares)		121,581
Warrants callable		1,215,810
Consideration received | $		$ 1.0
2019 Plan
Subsidiary, Sale of Stock [Line Items]
Number of additional shares authorized (in shares)	4,166,860
Number of additional shares authorized yearly increase (in shares)	5.00%
Common stock available for future grant (in shares)							888,432				888,432
Total common shares reserved for future issuance (in shares)							6,850,882				6,850,882

XML

Stockholders' Equity (Common Stock Reserved for Future Issuance) (Detail) shares in Thousands	Sep. 30, 2020 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock options outstanding (in shares)	6,800
Total common shares reserved for future issuance (in shares)	73,663
Common stock available for future grant under 2019 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for future grant (in shares)	888
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for future grant (in shares)	188
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding (in shares)	51
Class A-1 Convertible Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares outstanding (in shares)	2,567
Class A-2 Convertible Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares outstanding (in shares)	16,395
Initial Closing Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding (in shares)	13,890
Milestone Closing Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding (in shares)	32,884

XML

Stockholders' Equity (Stock Option and RSU Activity) (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Number of options
Ending outstanding number (in shares)	6,800
Stock options
Number of options
Beginning outstanding number (in shares)	3,098
Granted (in shares)	3,861
Exercised (in shares)	(1)
Canceled/forfeited/expired (in shares)	(158)
Ending outstanding number (in shares)	6,800
Weighted average exercise price
Weighted average exercise price, beginning balance (in dollars per share) | $ / shares	$ 1.17
Weighted average exercise price, Granted (in dollars per share) | $ / shares	1.20
Weighted average exercise price, Exercised (in dollars per share) | $ / shares	0.95
Weighted average exercise price, Canceled/forfeited/expired (in dollars per share) | $ / shares	4.82
Weighted average exercise price, ending balance (in dollars per share) | $ / shares	$ 1.10
Restricted Stock Units (RSUs)
Number of RSUs
Beginning balance (in shares)	129
Shares granted (in shares)	0
Shares vested (in shares)	(59)
Shares canceled in period (in shares)	(19)
Ending balance (in shares)	51
Weighted average grant date fair value
Beginning balance (usd per share) | $ / shares	$ 1.50
Granted (usd per share) | $ / shares	0
Vested (usd per share) | $ / shares	1.50
Canceled/forfeited/expired (usd per share) | $ / shares	1.50
Ending balance (usd per share) | $ / shares	$ 1.50

XML

Stockholders' Equity (Assumptions Used to Estimate Fair Value of Stock Options and Performance Stock and Employee Stock Purchase Plan) (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee stock purchase plan shares
Weighted average assumptions
Risk-free interest rate	0.30%	2.30%	0.70%	2.40%
Volatility	94.90%	106.70%	98.20%	110.10%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected term (years)	6 months	6 months	6 months	6 months
Stock options
Weighted average assumptions
Risk-free interest rate	0.40%	1.50%	1.10%	2.10%
Volatility	95.30%	95.10%	95.40%	94.40%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected term (years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days
Performance stock options
Weighted average assumptions
Risk-free interest rate	0.00%	0.00%	1.40%	2.60%
Volatility	0.00%	0.00%	95.40%	93.80%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected term (years)	0 months	0 months	6 years 1 month 6 days	6 years 1 month 6 days

XML

Stockholders' Equity (Stock-Based Compensation Expense Allocation) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$ 692	$ 536	$ 2,144	$ 1,816
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	255	45	571	240
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$ 437	$ 491	$ 1,573	$ 1,576

XML

Collaborations (Detail)	1 Months Ended									3 Months Ended			8 Months Ended	9 Months Ended
	Oct. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) shares	Aug. 31, 2020 USD ($)	Apr. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Nov. 30, 2018 USD ($)	Feb. 28, 2014 USD ($) $ / shares shares	Jul. 31, 2013 USD ($)	Jul. 31, 2012 target	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jan. 31, 2014 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Oct. 29, 2020 USD ($)	Dec. 31, 2019 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues (less than in 2019)										$ 5,000,000	$ 18,000			$ 5,006,000	$ 6,814,000
Common stock, shares issued (shares) | shares		39,163,096								39,163,096				39,163,096			21,018,663
Common stock value		$ 39,000								$ 39,000				$ 39,000			$ 21,000
Upfront payment received					$ 1,800,000	$ 2,500,000
Contract with customer, asset		4,000,000.0								4,000,000.0				4,000,000.0
Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments			$ 25,000,000.0
Materials Sold
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments			4,000,000.0
Achievement of Enrollment Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments			5,000,000.0
Achievement of Enrollment Milestone | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments																$ 5,000,000.0
Revenue under collaborations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues (less than in 2019)										5,000,000.0	$ 100,000			5,000,000.0	$ 6,800,000
Sanofi
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of collaborative areas granted | target									4
Initial upfront option payment		1,000,000.0	1,000,000.0
Upfront payment non-creditable portion recognized												$ 2,500,000
Deferred revenue							$ 400,000
Potential revenue through milestone payments						$ 6,800,000
Agreement period						24 months
Upfront payment received				$ 2,500,000	$ 1,800,000	$ 2,500,000
Enrollment Milestone			$ 10,000,000.0
Development milestone not achievable		30,000,000.0								30,000,000.0				$ 30,000,000.0
Sanofi | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial upfront option payment	$ 4,000,000.0
Sanofi | Private Placement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued (shares) | shares							1,303,780
Price per share (in dollars per share) | $ / shares							$ 7.67
Common stock value							$ 10,000,000.0
Restriction period in which Alliances could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock							12 months
Sanofi | Minimum | United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties based on percentage of net sales														10.00%
Sanofi | Minimum | Outside of the United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties based on percentage of net sales														10.00%
Sanofi | Maximum | United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties based on percentage of net sales														20.00%
Sanofi | Maximum | Outside of the United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties based on percentage of net sales														20.00%
Sanofi | Development Commercialization And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial upfront option payment								$ 2,500,000
Deferred revenue creditable against future milestones							$ 1,250,000	$ 1,250,000						$ 1,250,000
Upfront payment non-creditable portion recognized													$ 1,250,000
Sanofi | Proof-of-Concept Trial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments		38,800,000								38,800,000				38,800,000
Sanofi | Regulatory and Commercialization Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments		130,000,000.0								130,000,000.0				130,000,000.0
Sanofi | Clinical
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments		$ 34,000,000.0								$ 34,000,000.0				$ 34,000,000.0
Sanofi | Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments						40,000,000.0
Sanofi | Enrollment Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue through milestone payments						$ 10,000,000.0

XML

Leases (Narrative) (Details)			6 Months Ended
	Jun. 19, 2019 USD ($) ft²	Feb. 19, 2019 USD ($)	Jun. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jul. 01, 2019 USD ($)	Jun. 30, 2019 USD ($)	Apr. 01, 2019 USD ($)	Feb. 25, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	May 31, 2016 USD ($)	Aug. 31, 2015 USD ($)	Jul. 31, 2015 ft²
Lessee, Lease, Description [Line Items]
Net rentable area | ft²														59,248
Term of contract														96 months
Incentive from lessor													$ 1,400,000
Tenant improvement allowance												$ 8,200,000
Lease liability payments eliminated									$ 14,400,000
Operating lease payments due				$ 551,000
Noncash leasehold improvements			$ 5,600,000
Noncash gain due to reduction of lease liability			1,300,000
Deferred cost of liability					$ 900,000
Termination of lease cost			1,600,000
Operating lease liability				513,000				$ 0
Remaining 2020				109,000
Base rent payments due 2021				$ 442,000
Other Noncurrent Liabilities
Lessee, Lease, Description [Line Items]
Deferred rent credit, noncurrent											$ 8,000,000.0
Nitto
Lessee, Lease, Description [Line Items]
Relocation assistance payment		$ 100,000
Security deposit difference payment		200,000
Rent reimbursement		$ 1,300,000
Lease net impact of modification			$ 400,000
Initial direct cost liability									3,800,000
ROU asset									2,900,000
Deferred credit, operating lease liabilities									$ 900,000
February Lease
Lessee, Lease, Description [Line Items]
Net rentable area | ft²										24,562
Term of contract										51 months
Operating lease payments due										$ 4,800,000
New Premises
Lessee, Lease, Description [Line Items]
Net rentable area | ft²	8,727
Term of contract	2 years 6 months
Lease liability payments eliminated	$ 4,800,000
Noncash gain due to reduction of lease liability	500,000
Deferred cost of liability						$ 200,000
Operating lease liability						$ 0
Initial direct cost liability							$ 800,000
ROU asset							600,000
Deferred credit, operating lease liabilities							$ 200,000
Remaining 2020	400,000
Base rent payments due 2021	$ 400,000

XML

Leases (Operating and Finance Maturities) (Details) - USD ($)	Sep. 30, 2020	Jun. 30, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remaining 2020	$ 109,000
2021	442,000
Operating lease payments due	551,000
Less: amount representing interest	(38,000)
Present value of obligations under leases	513,000	$ 0
Less: current portion	(403,000)
Long-term lease obligations	110,000
Finance Lease, Liability, Payment, Due [Abstract]
Remaining 2020	72,000
2021	57,000
Total lease payments	129,000
Less: amount representing interest	(2,000)
Present value of obligations under leases	127,000
Less: current portion	(127,000)
Long-term lease obligations	$ 0

XML

Subsequent Events (Details) - USD ($) $ in Millions	Oct. 29, 2020	Sep. 30, 2020	Aug. 31, 2020
Debt Financing Agreement
Subsequent Event [Line Items]
Long-term Debt		$ 13.7
Achievement of Enrollment Milestone
Subsequent Event [Line Items]
Potential revenue through milestone payments			$ 5.0
Subsequent Event
Subsequent Event [Line Items]
Interest-only payment extension	7 months
Subsequent Event | Debt Financing Agreement
Subsequent Event [Line Items]
Long-term Debt	$ 4.7
Subsequent Event | Achievement of Enrollment Milestone
Subsequent Event [Line Items]
Potential revenue through milestone payments	$ 5.0